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A B S T R A C T
Background
Nicotine receptor partial agonists may help people to stop smoking by a combination of maintaining moderate levels of dopamine to
counteract withdrawal symptoms (acting as an agonist) and reducing smoking satisfaction (acting as an antagonist).
Objectives
To review the efficacy of nicotine receptor partial agonists, including varenicline and cytisine, for smoking cessation.
Search methods
We searched the Cochrane Tobacco Addiction Group’s specialised register for trials, using the terms (’cytisine’ or ’Tabex’ or ’dianicline’
or ’varenicline’ or ’nicotine receptor partial agonist’) in the title or abstract, or as keywords. The register is compiled from searches
of MEDLINE, EMBASE, and PsycINFO using MeSH terms and free text to identify controlled trials of interventions for smoking
cessation and prevention. We contacted authors of trial reports for additional information where necessary. The latest update of the
specialised register was in May 2015, although we have included a few key trials published after this date. We also searched online
clinical trials registers.
Selection criteria
We included randomised controlled trials which compared the treatment drug with placebo. We also included comparisons with
bupropion and nicotine patches where available. We excluded trials which did not report a minimum follow-up period of six months
from start of treatment.
Data collection and analysis
We extracted data on the type of participants, the dose and duration of treatment, the outcome measures, the randomisation procedure,
concealment of allocation, and completeness of follow-up.
The main outcome measured was abstinence from smoking at longest follow-up. We used the most rigorous definition of abstinence,
and preferred biochemically validated rates where they were reported.Where appropriate we pooled risk ratios (RRs), using the Mantel-
Haenszel fixed-effect model.
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Main results
Two trials of cytisine (937 people) found that more participants taking cytisine stopped smoking compared with placebo at longest
follow-up, with a pooled risk ratio (RR) of 3.98 (95% confidence interval (CI) 2.01 to 7.87; low-quality evidence). One recent trial
comparing cytisine with NRT in 1310 people found a benefit for cytisine at six months (RR 1.43, 95% CI 1.13 to 1.80).
One trial of dianicline (602 people) failed to find evidence that it was effective (RR 1.20, 95% CI 0.82 to 1.75). This drug is no longer
in development.
We identified 39 trials that tested varenicline, 27 of which contributed to the primary analysis (varenicline versus placebo). Five of
these trials also included a bupropion treatment arm. Eight trials compared varenicline with nicotine replacement therapy (NRT).
Nine studies tested variations in varenicline dosage, and 13 tested usage in disease-specific subgroups of patients. The included studies
covered 25,290 participants, 11,801 of whom used varenicline.
The pooled RR for continuous or sustained abstinence at six months or longer for varenicline at standard dosage versus placebo was
2.24 (95% CI 2.06 to 2.43; 27 trials, 12,625 people; high-quality evidence). Varenicline at lower or variable doses was also shown
to be effective, with an RR of 2.08 (95% CI 1.56 to 2.78; 4 trials, 1266 people). The pooled RR for varenicline versus bupropion
at six months was 1.39 (95% CI 1.25 to 1.54; 5 trials, 5877 people; high-quality evidence). The RR for varenicline versus NRT for
abstinence at 24 weeks was 1.25 (95% CI 1.14 to 1.37; 8 trials, 6264 people; moderate-quality evidence). Four trials which tested the use
of varenicline beyond the 12-week standard regimen found the drug to be well-tolerated during long-term use. The number needed to
treat with varenicline for an additional beneficial outcome, based on the weighted mean control rate, is 11 (95% CI 9 to 13). The most
commonly reported adverse effect of varenicline was nausea, which was mostly at mild to moderate levels and usually subsided over
time. Our analysis of reported serious adverse events occurring during or after active treatment suggests there may be a 25% increase in
the chance of SAEs among people using varenicline (RR 1.25; 95% CI 1.04 to 1.49; 29 trials, 15,370 people; high-quality evidence).
These events include comorbidities such as infections, cancers and injuries, and most were considered by the trialists to be unrelated
to the treatments. There is also evidence of higher losses to follow-up in the control groups compared with the intervention groups,
leading to a likely underascertainment of the true rate of SAEs among the controls. Early concerns about a possible association between
varenicline and depressed mood, agitation, and suicidal behaviour or ideation led to the addition of a boxed warning to the labelling
in 2008. However, subsequent observational cohort studies and meta-analyses have not confirmed these fears, and the findings of the
EAGLES trial do not support a causal link between varenicline and neuropsychiatric disorders, including suicidal ideation and suicidal
behaviour. The evidence is not conclusive, however, in people with past or current psychiatric disorders. Concerns have also been raised
that varenicline may slightly increase cardiovascular events in people already at increased risk of those illnesses. Current evidence neither
supports nor refutes such an association, but we await the findings of the CATS trial, which should establish whether or not this is a
valid concern.
Authors’ conclusions
Cytisine increases the chances of quitting, although absolute quit rates were modest in two recent trials. Varenicline at standard
dose increased the chances of successful long-term smoking cessation between two- and three-fold compared with pharmacologically
unassisted quit attempts. Lower dose regimens also conferred benefits for cessation, while reducing the incidence of adverse events.
More participants quit successfully with varenicline than with bupropion or with NRT. Limited evidence suggests that varenicline
may have a role to play in relapse prevention. The most frequently recorded adverse effect of varenicline is nausea, but mostly at mild
to moderate levels and tending to subside over time. Early reports of possible links to suicidal ideation and behaviour have not been
confirmed by current research.
Future trials of cytisine may test extended regimens and more intensive behavioural support.
P L A I N L A N G U A G E S U M M A R Y
Can nicotine receptor partial agonists, including cytisine and varenicline, help people to stop smoking?
Background
When people stop smoking they experience cravings to smoke and unpleasant mood changes. Nicotine receptor partial agonists aim to
reduce these withdrawal symptoms and the pleasure people usually experience when they smoke. The most widely-available treatment
in this drug type is varenicline, which is available world-wide as an aid for quitting smoking. Cytisine is a similar medication, but is
only available in Central and Eastern European countries and through internet sales.
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Study characteristics
We searched for randomised controlled trials testing varenicline, cytisine or dianicline. We found 39 studies of varenicline compared
to placebo, bupropion or nicotine patches. We also found four trials of cytisine, one of which compared it to nicotine replacement
therapy. We include one trial of dianicline, which is no longer in development, and so not available to use as a quitting aid. To be
included, trials had to report quit rates at least six months from the start of treatment. We preferred the strictest available definition of
quitting, and results which had been biochemically confirmed by testing blood or bodily fluids.We conducted full searches up to May
2015, although we have also included several key trials published after that date.
Key findings
From the information we found (27 trials, 12,625 people), varenicline at standard dose more than doubled the chances of quitting
compared with placebo. Low-dose varenicline (four trials, 1266 people) roughly doubled the chances of quitting, and reduced the
number and severity of side effects. The number of people stopping smoking with varenicline was higher than with bupropion (five
trials, 5877 people) or with NRT (eight trials, 6264 people). Based on the evidence so far, we can calculate that varenicline delivers one
extra successful quitter for every 11 people treated, compared with smokers trying to quit without varenicline.
The most common side effect of varenicline is nausea, but this is mostly at mild or moderate levels and usually clears over time. People
taking varenicline appear to have about a 25% increased chance of a serious adverse event, although these include many which are
unrelated to the treatment. We also note that more people were lost from the control groups than from the varenicline groups by the
end of the trials, which may mean that the count of events in the control groups is lower than it should be. After varenicline became
available to use, there were concerns that it could be linked with an increase in depressed mood, agitation, or suicidal thinking and
behaviour in some smokers. However, the latest evidence does not support a link between varenicline and these disorders, although
people with past or current psychiatric illness may be at slightly higher risk. There have also been concerns that varenicline may slightly
increase heart and circulatory problems in people already at increased risk of these illnesses. The evidence is currently unclear whether
or not they are caused or made worse by varenicline, but we should have clearer answers to these questions when a further study is
published later this year.
Quality of the evidence
The varenicline studies were generally of high quality, providing evidence that we consider to be reliable and robust. We rate the quality
of the evidence comparing varenicline with NRT as moderate quality (we are reasonably confident of the stability of the evidence),
since in some of them the participants knew which treatment they were receiving (i.e. non-blinded open-label trials). We judge the
evidence from the cytsine trials to be of low quality (we have limited confidence in the evidence), as there are only two trials, with
relatively low numbers included.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Varenicline versus placebo or other f irst-line treatments for smoking cessat ion
Patient or population: Individuals who smoke tobacco
Setting: Varied
Intervention: Varenicline
Comparison: Varied controls
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with control Corresponding risk
with varenicline
Varenicline vs placebo:
cont inuous/ sustained
abst inence at longest
follow-up (24+ weeks)
Study populat ion (where risk refers to quit ters) RR 2.24
(2.06 to 2.43)
12,625
(27 RCTs)
⊕⊕⊕⊕
HIGH 1,2
111 per 1000 250 per 1000
(230 to 271)
Varenicline vs bupro-
pion: cont inuous/ sus-
tained abst inence (24
weeks)
Study populat ion (where risk refers to quit ters) RR 1.39
(1.25 to 1.54)
5877
(5 RCTs)
⊕⊕⊕⊕
HIGH
171 per 1000 238 per 1000
(214 to 264)
Varenicline vs NRT:
point prevalence abst i-
nence (24 weeks)
Study populat ion (where risk refers to quit ters) RR 1.25 (1.14 to 1.37) 6264
(8 RCTs)
⊕⊕⊕©
MODERATE 3
189 per 1000 237 per 1000
(216 to 259)
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Varenicline vs placebo:
number of part icipants
report ing SAEs in dura-
t ion of trials (trials re-
port ing no events in ei-
ther group excluded)
Study populat ion (where risk refers to SAEs) RR 1.25
(1.04 to 1.49)
15,370
(29 RCTs)
⊕⊕⊕⊕
HIGH
30 per 1000 39 per 1000
(32 to 48)
Varenicline vs placebo:
number of part icipants
report ing cardiac SAEs,
including deaths, in du-
rat ion of trials
Study populat ion (where risk refers to SAEs) RR 1.36
(0.91 to 2.04)
8587
(21 studies)
⊕⊕⊕©
MODERATE 4
9 per 1,000 12 per 1,000
(8 to 17)
Varenicline vs placebo:
number of part icipants
report ing nausea in du-
rat ion of trials
Study populat ion (where risk refers to SAEs) RR 3.27
(3.00 to 3.55)
14963
(32 studies)
⊕⊕⊕⊕
HIGH
85 per 1,000 277 per 1,000
(254 to 301)
* The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95% CI).The assumed risk in the comparison group is calculated as the median risk in control groups.
CI: Conf idence interval; RR: Risk rat io; SAEs: Serious adverse events
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1Moderate heterogeneity detected, however all but two studies showed posit ive ef fect of varenicline, so did not downgrade
on this basis.
2Lack of smaller trials with negat ive f indings suggests possible publicat ion bias. However, earliest studies reported 2006.
We are reasonably conf ident that licensing and subsequent trials have been registered online in clinical trials registries. Thus
absence of negat ive studies may be marker of sustained ef f icacy rather than suppression or select ive management of data.
3Downgraded once as three of the eight studies were rated at high risk of bias due to using an open-label design.5
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4Downgraded once due to imprecision; CIs do not rule out an increase in risk
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B A C K G R O U N D
Smoking is the main preventable cause worldwide of morbidity
and premature death. Based on data from 2004, 12% of all deaths
globally among adults aged 30 years and over were attributable to
tobacco, with 5 million adults dying due directly to tobacco use
(WHO 2012). The list of illnesses known to be linked to smok-
ing includes cancers of the cervix, pancreas, kidneys and stomach,
aortic aneurysms, acute myeloid leukaemia, cataracts, pneumonia,
and gum disease. These are in addition to the long-established
links between tobacco use and such illnesses as lung cancer, car-
diovascular diseases, and emphysema, and with prematurity, sud-
den infant death syndrome and low birth weight in the babies of
maternal smokers (Surgeon General 2004).
There is a growing understanding of the neurochemical basis of
nicotine addiction (Fagerström 2006). There is strong evidence
that dependence upon nicotine reflects the effects of the drug at
neuronal nicotinic receptors in the brain (Benowitz 1999; Hogg
2007; Picciotto 1999). More recent studies have explored the po-
tential of neuronal nicotinic acetylcholine receptors (nAChRs) as
targets for a variety of therapeutic interventions (Hogg 2007). It
is thought that the addictive properties of nicotine are mediated
mainly through its action as an agonist at α4β2nAChRs, which
stimulates the release of dopamine (Coe 2005). Pharmacothera-
pies to aid smoking cessation have been developed which exploit
this mechanism, by acting as nicotine receptor partial agonists.
Cytisine
Cytisine was developed as a treatment for tobacco dependence
in Bulgaria in the 1960s, and is available in some eastern and
central European countries and through internet sales, under the
trade name of Tabex (Foulds 2004; Tutka 2005; Tutka 2006). Its
manufacturers, Sopharma Pharmaceuticals, developed their phy-
toproduct from the plant Cytisus Laburnum L. (Golden Rain).
Although cytisine (Tabex) is not licensed for use as a smoking ces-
sation aid across most countries outside Eastern Europe (Walker
2014), studies by Vinnikov 2008 andWest 2011 have highlighted
the potential of this drug, especially in countries with lower av-
erage incomes and where smoking cessation programmes are not
supported by insurance plans or by a national health service. In
many regions, itmay be considerably cheaper to continue smoking
than to embark upon a course of pharmacotherapy for smoking
cessation. West 2011 reports that a pack of cigarettes in China
costs between 15¢ and 73¢, compared with a course of nicotine
replacement therapy (NRT) (USD 230), bupropion (USD 123),
or varenicline (USD 327). Similarly, a pack of 20 cigarettes in In-
dia costs around USD 1.10, or 5¢ for a pack of bidis, compared
with USD 150 for a course of NRT, USD 100 for bupropion and
USD 200 for varenicline. Tabex is currently available in Poland
for the equivalent of USD 15 for a course of treatment, and in
Russia for the equivalent of USD 6 as an over-the-counter medi-
cation. There is also heightened interest and activity in cytisine in
New Zealand, where it is found in the seeds of the native Kowhai
tree, widely used in traditional M ori healing (Thompson-Evans
2011). The current update adds a large single-blind randomised
non-inferiority trial comparing cytisine with NRT, conducted in
New Zealand between 2011 and 2013 (Walker 2014).
Dianicline
In 2006, Sanofi-Aventis registered two trials of dianicline, their
version of a nicotine receptor partial agonist (Tonstad 2011;
Ameridian 2007). However, unfavourable results have led to the
withdrawal of this drug from further development (Kirchhoff
2009). We have been unable to locate results for the AMERID-
IAN trial, and present only the EURODIAN trial report in this
review.
Varenicline
Varenicline was developed by Pfizer Inc to counteract the effects
of nicotine on the nAChRs. The drug was based on the naturally-
occurring alkaloid compound cytisine described above, which had
been shown to be an effective partial agonist for α4β2 receptors
(Papke 1994; Slater 2003).
Varenicline was developed in 1997 (Coe 2005), and is described as
a selective nicotinic receptor partial agonist. It was designed to se-
lectively activate the α4β2nAChR, mimicking the action of nico-
tine and causing a moderate and sustained release of mesolimbic
dopamine (Sands 2005). This, it was suggested, should counter-
act withdrawal symptoms consequent upon low dopamine release
during smoking cessation attempts. However, because it is a par-
tial agonist at these receptors, it elicits some dopamine overflow,
but not the substantial increases evoked by nicotine. Perhaps more
importantly, it blocks the effects of a subsequent nicotine chal-
lenge on dopamine release from the mesolimbic neurones thought
pivotal to the development of nicotine dependence (Coe 2005).
Although varenicline has been shown to be a partial agonist at het-
eromeric neuronal nicotine receptors, there is now evidence that it
may also be a full agonist at the homomeric α7 receptor (Mihalak
2006).
Multicentre trials of varenicline have been conducted or are cur-
rently underway in the USA, Canada, Latin America, Europe,
Australia, the Middle East and the Far East. There have also been
studies in specific patient groups, including the following condi-
tions: cardiovascular disease, chronic obstructive pulmonary dis-
ease, diabetes, drug or alcohol dependence, head and neck can-
cers, HIV infection, bipolar disorders, depression, schizophrenia
or schizoaffective disorders.
Varenicline was approved as a prescription-only aid to smoking
cessation in 2006 by the American Food andDrug Administration
under the trade name Chantix, and by the European Medicines
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Evaluation Agency under the trade nameChampix. In July 2007 it
was approved by theNational Institute forHealth and Clinical Ex-
cellence (NICE) for prescribing by theUKNational Heath Service
(ASH 2006; NICE 2007). Post-marketing surveillance has raised
subsequent concerns about possible links between varenicline and
major health risks, including suicidal ideation and behaviour, de-
pression, and serious adverse cardiovascular events (FDA 2008).
We consider these findings in theDiscussion section of this review,
and in our meta-analyses.
O B J E C T I V E S
To review the efficacy of nicotine receptor partial agonists, includ-
ing varenicline and cytisine, for smoking cessation.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomized controlled trials.
Types of participants
Adult smokers. Trials which target users of smokeless tobacco are
not included in this review, but are listed among the Excluded
Studies. Interventions for smokeless tobacco use cessation are cov-
ered in a companion review (Ebbert 2011).
Types of interventions
Selective nicotine receptor partial agonists, including cytisine, di-
anicline and varenicline, or any other in this class of drug as they
reach Phase 3 trial stage. The efficacy of lobeline is covered in an
earlier Cochrane review (Stead 2003).
For this update, and in anticipation of current ongoing trials reach-
ing publication, we have extended the range of analyses to cover
the following intervention types and subgroups:
I. Varenicline versus other pharmacotherapies:
1. Varenicline versus placebo
2. Varenicline versus bupropion
3. Varenicline versus NRT
4. Varenicline versus mecamylamine
5. Combination treatments (e.g. varenicline + NRT) versus
single-therapy treatment, where the addition of varenicline is the
intervention being tested
6. Varenicline tablets versus other formulations (e.g. patch, in
solution)
II. Variations in usage:
1. Flexible quit dates
2. Variable dosages
3. Preloading (before TQD)
4. Reducing to quit
5. Maintenance therapy (relapse prevention)
6. Harm reduction
III. Specific patient groups:
1. Cardiovascular disease (CVD)
2. Chronic obstructive pulmonary disease (COPD)
3. Asthma
4. Schizophrenia/bipolar/psychiatric disorder
5. Depression
6. Substance use disorder/methadone-maintained
7. Alcohol-dependent smokers
8. HIV
9. Diabetes
10. Head and neck cancer
11. Varenicline in pregnancy
12. Long-term use of NRT
IV. Settings/subgroups:
1. Hospital inpatients/perioperative patients
2. Smokers who have previously failed to quit on varenicline
or NRT or bupropion
3. Light or heavy smokers
4. Varenicline by gender
5. Varenicline in ethnic groups
We have not considered for inclusion any trials of varenicline used
for conditions other than smoking cessation, such as alcoholism,
cocaine dependence, Parkinson’s disease, spinocerebellar degener-
ation, etc.
Types of outcome measures
A minimum of six months abstinence is the primary outcome
measure. We have used sustained cessation rates in preference to
point prevalence, and we have preferred biochemically verified
rates to rates based on self report of quitting. In analysis, we treat
participants lost to follow-up as continuing smokers. We have
recorded any adverse effects of treatment.
8Nicotine receptor partial agonists for smoking cessation (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Search methods for identification of studies
We searched the TobaccoAddictionReviewGroup specialised reg-
ister for trials, using the terms (’cytisine’ or ’Tabex’ or ’dianicline’
or ’varenicline’ or ’nicotine receptor partial agonist’) in the title
or abstract, or as keywords. This register has been developed from
electronic searching of MEDLINE, EMBASE, and PsycINFO,
together with handsearching of specialist journals, conference pro-
ceedings and reference lists of previous trials and overviews. The
most recent search of the Register was in May 2015, and included
reports of trials indexed in the Cochrane Central Register of Con-
trolled trials (CENTRAL), issue 5, 2015; MEDLINE (via OVID)
to update 20150501; EMBASE (via OVID) to week 201519;
PsycINFO (via OVID) to update 20150506. See the Tobacco
Addiction Group Module for details of the search strategies for
these databases.
We also searched UK and US online clinical trials registers for
ongoing and recently completed trials. Trials which may be candi-
dates for inclusion (i.e. RCTs of smoking cessation interventions
using a nicotine receptor partial agonist with a minimum follow-
up of six months), and for which results are not yet available, are
listed in the Characteristics of ongoing studies table.
We contacted the authors of ongoing studies of varenicline and
cytisine where necessary.
We made a strategic decision to delay publication of this update
until we could access the findings of the Pfizer EAGLES 2016 trial
(NCT014569360) in April 2016. Although we did not conduct
full-scale top-up searches during this waiting period, we checked
the status of all ongoing studies known to us, and identified pub-
lished results for six of them: twowere journal articles (Baker 2016;
Eisenberg 2016), now included studies, and four had posted their
results on the ClinicalTrials.gov database; we have added two of
the trials (NCT00828113; NCT01347112) to the included stud-
ies, and the other two (NCT01308736; NCT01806779) to the
excluded studies.
Data collection and analysis
We checked the abstracts of studies generated by the search strat-
egy for relevance, and acquired full reports of any trials that might
be suitable for the review. One author (KC) extracted the data,
and a second author (NLH) checked them. We resolved any dis-
crepancies by mutual consent, or by recourse to a third author
(TL). Studies that did not meet the inclusion criteria are listed in
the Characteristics of excluded studies table, with reasons for their
exclusion.
Studies were evaluated on the basis of the quality of the randomi-
sation procedure and allocation concealment, as described in the
Cochrane Handbook (Higgins 2011). The following information
about each trial, where it is available, is reported in the table
Characteristics of included studies:
• Country and setting (e.g. primary care, community,
hospital outpatient/inpatient)
• Method of selection of participants
• Definition of smoker used
• Methods of randomisation and allocation, and blinding of
trialists, participants and assessors
• Demographic characteristics of participants (e.g. average
age, sex, average cigarettes/day)
• Intervention and control description (dose, provider,
duration, number of visits, etc.)
• Outcomes including definition of abstinence used, and
biochemical validation of cessation
• Proportion of participants with follow-up data
• Any adverse events
• Sources of funding
Studies in the Characteristics of included studies table are grouped
by the type of treatment being tested (cytisine, dianicline, vareni-
cline).
Quit rates are calculated based on the numbers of people ran-
domised to an intervention, and excluding any deaths or untrace-
able moves, in accordance with the Russell Standard (West 2005).
We regard those who drop out or are lost to follow-up as contin-
uing smokers. We have noted any deaths and adverse events in
the results section. Effects are expressed as risk ratios ((number
of events in intervention condition/intervention denominator)/
(number of events in control condition/control denominator)).
For cessation a risk ratio greater than 1 indicates that more peo-
ple are quitting in the intervention condition. For adverse events,
a risk ratio greater than 1 indicates that more people experience
adverse events in the intervention condition.
Where appropriate, we have conducted meta-analyses of the in-
cluded studies, using theMantel-Haenszel fixed-effectmodel, pro-
vided that there was no significant heterogeneity. We assessed sta-
tistical heterogeneity between trials using the I² statistic which
describes the percentage of total variation between studies that is
due to heterogeneity rather than chance (Higgins 2003). Values
over 50% suggest moderate heterogeneity, and values over 75%
substantial heterogeneity.
For studies of disease-specific patients (section III) and for patients
in different settings (section IV), we have conducted and reported
sensitivity analyses, treating them as subgroups of the main anal-
yses and testing for subgroup differences.
For this update, we have produced ’Summary of findings’ tables
covering themain outcomes of smoking abstinence for varenicline
versus placebo, varenicline versus bupropion, varenicline versus
NRT (all in Summary of findings for the main comparison), and
cytisine versus placebo (Summary of findings 2); and incidence
of serious adverse events for the comparison of varenicline ver-
sus placebo. Our grading decisions are based on the five GRADE
considerations: study limitations in design or execution (risks of
bias), inconsistency of results, indirectness of evidence, impreci-
sion of results, and publication bias. Evidence from studies is rated
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as high quality (i.e. we are very confident of the findings), through
moderate, low, and very low quality (i.e. the true effect is likely to
be substantially different from the estimate of effect).
We include in this review the Tobacco Addiction Group glossary
of tobacco-specific terms (Appendix 1).
R E S U L T S
Description of studies
Included studies
Full details of the included studies are given in the Characteristics
of included studies tables.
For this update, we now have 44 trials (previously 24) which met
our inclusion criteria. Four trials (Scharfenberg 1971; Vinnikov
2008; Walker 2014; West 2011) evaluated cytisine (Tabex) for
smoking cessation, covering 3461 participants, 2102 of whom
took cytisine. One trial of 602 smokers, 300 of whom took
the active treatment, tested the Sanofi-Aventis drug dianicline
for smoking cessation (Tonstad 2011). The remaining 39 tri-
als tested varenicline in a variety of populations and settings,
and against various comparators. Two trials, formerly classified
as ’Ongoing studies’ have now posted their findings on the
www.ClinicalTrials.gov website, and we now treat them as in-
cluded studies (NCT00828113;NCT01347112), albeit with lim-
ited information on design and findings. The trials cover more
than 25,200 participants, 11,801 of whom took varenicline (see
Appendix 2).
Nine studies which we originally treated as excluded are now
classified as included studies, so that they can contribute data
to the meta-analyses for neuropsychiatric adverse events. These
studies are flagged with an asterisk in the study ID, indicating
that they do not contribute to the efficacy findings (Brandon
2011*; Ebbert 2011*; Faessel 2009*; Fagerström 2010*; Garza
2011*;Hughes 2011*;McClure 2013* NCT00944554;Meszaros
2013*; Mitchell 2012*). We have not completed Characteristics
of included studies tables or ’Risk of bias’ assessments for these
nine studies, but have recorded our judgements on why they are
not eligible to be included in the efficacy findings.
Cytisine
Cytisine versus placebo was tested as a cessation aid in Ger-
many (Scharfenberg 1971), in Kyrgyzstan (Vinnikov 2008), and
in Poland (West 2011). Scharfenberg 1971 was set in a smoking
cessation clinic in what was then East Germany, Vinnikov 2008
was set in a Kyrgyz mining company, and West 2011 in a War-
saw smoking cessation clinic. A recent New Zealand non-inferi-
ority trial (Walker 2014) compared cytisine to NRT in a popula-
tion of smokers contacting a national smoking quitline. The tri-
als used 1.5 mg Tabex tablets over a 20-day (Scharfenberg 1971)
or 25-day (Vinnikov 2008; Walker 2014; West 2011) treatment
period, with behavioural support kept to a minimum in order
to reduce programme costs. Vinnikov 2008 and Walker 2014 as-
sessed their participants to six months, West 2011 to 12 months,
and Scharfenberg 1971 to two years. Both Vinnikov 2008 and
West 2011 verified claims of abstinence by testing expired carbon
monoxide (CO) levels, while the remaining two trials relied upon
self report without biochemical validation.
Dianicline
The dianicline trial (Tonstad 2011) was set in 22 sites across six
European countries. Dianicline was administered as a 40mg tablet
twice a day for seven weeks, with brief counselling at each contact.
Final follow-up of the participants was at 26 weeks, with claims of
abstinence verified by expiredCO and by plasma cotinine samples.
Varenicline
Study design
Thirty-four studies were double-blinded randomised trials; the re-
maining five were open-label. Three of the open-label trials com-
pared varenicline with NRT (Aubin 2008; Baker 2016; Tsukahara
2010), one compared varenicline with NRT and with placebo
(Heydari 2012), and one compared varenicline plus counselling
with counselling alone (Carson 2014 (formerly Smith 2012)).
Setting
Seventeen studies were set in the USA, two in Japan, two in Den-
mark, one each in Australia, Canada, Iran and the UK, one in
both Taiwan and Korea, one in both China and Singapore, two in
North America (USA and Canada), and ten in multiple countries.
The trials were conducted in smoking cessation clinics, hospitals,
universities and other research centres.
Participants
Participants in themajority of the trials were adult smokers, willing
to make a quit attempt (Aubin 2008; Baker 2016; Bolliger 2011;
Cinciripini 2013; EAGLES 2016; Eisenberg 2016; Gonzales
2006; Gonzales 2014; Heydari 2012; Jorenby 2006; Nakamura
2007; NCT01347112; Niaura 2008; Niaura 2008; Nides 2006;
Oncken 2006; Rennard 2012; Tsai 2007; Tsukahara 2010; Wang
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2009; Williams 2007). Several trials were conducted in clinical
subgroups, including hospital inpatients (Carson 2014; Steinberg
2011; Wong 2012), and disease-specific patient groups (CVD:
Rigotti 2010; acute coronary syndrome Eisenberg 2016; COPD:
Tashkin 2011; asthma: Westergaard 2015; substance use disor-
der: Nahvi 2014a; Stein 2013; alcohol abuse: NCT01347112;
depression: Anthenelli 2013; bipolar/schizophrenia; schizoaffec-
tive disorder: Chengappa 2014; Evins 2014; Williams 2012).
EAGLES 2016 enrolled two cohorts of adult smokers with and
without histories of psychiatric disorders, including primary af-
fective disorders (70%), anxiety disorders (19%), psychotic dis-
orders (9.5%) and personality disorders (0.6%). Two trials tar-
geted subgroups of smokers who were failing to respond to smok-
ing cessation pharmacotherapies, either by increasing the dosage
(Hajek 2015) or by switching to different medications (Rose
2013). Three studies focused on relapse prevention in success-
ful quitters (NCT00828113; Tonstad 2006), or in people with
schizophrenia who had successfully quit (Evins 2014). De Dios
2012 tested varenicline in Latino light smokers, and Ebbert 2015
in adult smokers unwilling to quit abruptly but prepared to reduce
their smoking as a run-up to quitting completely. Tønnesen 2013
tested varenicline as an aid to weaning ex-smokers off extended
use of NRT.
Interventions
Thirty-three of the 39 trials used the standard 12-week regimen
of varenicline, routinely titrating the first week up to the recom-
mended daily dose of 1 mg twice a day. Three trials (Nakamura
2007;Nides 2006;Oncken2006) compared different dosage arms
of varenicline against a placebo arm. One trial in non-responders
regulated dosage up to the target quit date (day 21) to a maximum
of 5 mg a day (Hajek 2015), and another allowed participants to
regulate their own dosage throughout the treatment phase (Niaura
2008). NCT00828113 is a randomised trial comparing extended
(52-week) and standard (12-week) courses of varenicline.
Of the eight trials that used NRT as a comparator condition,
five (Aubin 2008; Baker 2016; De Dios 2012; EAGLES 2016;
Rose 2013) provided a 12-week course, reducing the dosage as a
weaning process, while two trials (Heydari 2012; Tsukahara 2010)
provided an eight-week course, with only the Tsukahara 2010
trial progressively reducing the dosage to the end of treatment.
Stein 2013 gave a 24-week course of NRT, tailored to the level of
nicotine dependency, and matched to the duration of the placebo
and varenicline arms of the trial.
The five trials which used bupropion all supplied the standard reg-
imen of 150 mg twice a day, four of them for 12 weeks (Cinciripini
2013; EAGLES 2016; Gonzales 2006; Jorenby 2006) and Nides
2006 for seven weeks.
Comparisons
Twenty-six RCTs compared varenicline to an identical placebo
regimen (Anthenelli 2013; Bolliger 2011; Chengappa 2014;
EAGLES 2016; Ebbert 2015; Eisenberg 2016; Evins 2014;
Gonzales 2014; Hajek 2015; Nahvi 2014a; Nakamura 2007;
NCT01347112; Niaura 2008; Oncken 2006; Rennard 2012;
Rigotti 2010; Steinberg 2011; Tashkin 2011; Tonstad 2006;
Tonstad 2011; Tsai 2007; Wang 2009; Westergaard 2015;
Williams 2007; Williams 2012; Wong 2012); all these trials used
the standard 12-week course of treatment, apart fromEbbert 2015
(24 weeks, ’reduce to quit’), Evins 2014 (40 weeks, relapse pre-
vention) and Williams 2007 (52 weeks, a safety trial). Four tri-
als (Aubin 2008; Baker 2016; Rose 2013; Tsukahara 2010) used
NRT as the comparator rather than a placebo, while three more
trials (De Dios 2012; Heydari 2012; Stein 2013) used both NRT
and placebo as comparator conditions, in a three-arm study de-
sign. EAGLES 2016 was a four-arm triple-dummy trial, compar-
ing varenicline, bupropion and NRT with a placebo. Four trials
(Cinciripini 2013; Gonzales 2006; Jorenby 2006; Nides 2006)
compared varenicline with bupropion and with placebo. One trial
(Carson 2014) compared varenicline plus quitline counselling to
quitline counselling alone.
Outcomes
As a condition of inclusion, all the trials reported cessation at
least six months from the start of the intervention. Seventeen of
39 studies reported longest follow-up at six months (point preva-
lence or continuous abstinence) (Bolliger 2011; Chengappa 2014;
Cinciripini 2013; DeDios 2012; EAGLES 2016; Eisenberg 2016;
Nahvi 2014a; NCT01347112; Rennard 2012; Rose 2013; Stein
2013; Steinberg 2011; Tsai 2007; Tsukahara 2010; Wang 2009;
Westergaard 2015; Williams 2012), and 20 studies to 12 months.
Hajek 2015, relevant for the exploration of dose variability, re-
ported abstinence only to 12 weeks, and is not included in the
main efficacy findings. Evins 2014 followed its participants until
week 64, as part of a relapse prevention initiative.
All the trials except one (NCT01347112) used biochemical ver-
ification of abstinence by expired CO, at cut-offs ranging from
5 to 10 ppm, at one or more time points. Baker 2016 vali-
dated outcomes at both 9 ppm and 5 ppm cut-off levels. Heydari
2012 and Wong 2012 did not report their cut-offs. Carson 2014
tested “a random sub-set of subjects” (51/103 quitters). Five trials
(Cinciripini 2013; De Dios 2012; Stein 2013; Tønnesen 2013;
Wong 2012) also used salivary or urinary cotinine testing to con-
firm abstinence claims.
Excluded studies
Eight of the excluded studies tested cytisine (Granatowicz 1976;
Kempe 1967; Maliszewski 1972; Metelitsa 1987; Monova 2004;
Ostrovskaia 1994; Paun 1968; Schmidt 1974), and the remaining
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48 tested varenicline, but did not meet our eligibility criteria to
be treated as an included study.
The excluded studies are briefly described, with reasons for ex-
clusion, in the Characteristics of excluded studies tables. Seven
of the excluded studies (Ebbert 2014; Hajek 2013; Hoogsteder
2014; Koegelenberg 2014; NCT01806779; Ramon 2014; Rose
2014) administered varenicline to all participants, and tested the
addition of another pharmacotherapy (nicotine replacement ther-
apy, bupropion, or nicotine vaccine). Since varenicline was not
primarily the intervention being tested, the findings of these trials
are covered in the reviews which address the relevant adjunctive
treatments. Swan 2010, which we had classified as an included
study in the 2012 update, is now an excluded study, as all the par-
ticipants received varenicline, and the intervention being tested
was the addition and relative merits of internet- and telephone-
based counselling. Two trials (NCT01308736; NCT01806779),
formerly treated as ’Ongoing studies’, have now posted their find-
ings on the www.ClinicalTrials.gov website, and we now report
them as excluded studies.
Risk of bias in included studies
Among the cytisine trials, we rated Vinnikov 2008, Walker 2014
and West 2011 as being at low risk of bias in their randomisa-
tion and allocation procedures; Scharfenberg 1971 gave no details
about these, and was therefore rated as unclear. We rated Walker
2014 at high risk of bias for a lack of blinding of participants and
personnel. This study may also have been at risk of bias for pro-
viding cytisine free of charge but NRT at a cost of NZD 3 per
item. Although Vinnikov 2008 invokes the Russell Standard cri-
teria (West 2005) in support of the conduct of their trial, they ex-
cluded 26 participants who took no medication from the denom-
inator; we have reinstated them for our meta-analyses, in order to
present an intention-to-treat estimate, i.e. all people randomised,
excluding only those who died or who moved away.
Of the 39 varenicline trials, 23 reported randomisation and al-
location procedures in sufficient detail to be assessed as being
at minimal risk in their attempts to control selection bias. Fif-
teen trials (Chengappa 2014; Cinciripini 2013; De Dios 2012;
Heydari 2012; NCT00828113; NCT01347112; Oncken 2006;
Rose 2013; Stein 2013; Tashkin 2011; Tsukahara 2010; Wang
2009;Westergaard 2015;Williams 2007;Williams 2012) gave in-
sufficient information for this to be confirmed. A sensitivity anal-
ysis removing these trials made no difference to the findings. None
of the trials reported any assessment of the integrity of the double-
blinding procedure. For the relapse prevention trials (Evins 2014;
NCT00828113; Tonstad 2006), the integrity of the double-blind
phase may be questionable, since all randomised participants had
successfully used varenicline during the open-label phase.
All except eight of the included studies reported prolonged,
sustained or continuous abstinence as their most rigorous esti-
mate of efficacy; De Dios 2012; Heydari 2012; Nahvi 2014a;
NCT00828113; Westergaard 2015; Williams 2007; Williams
2012; and Wong 2012 all reported only point prevalence absti-
nence. Steinberg 2011 used repeated point prevalence at 4, 12
and 24 weeks, which we have treated as sustained abstinence for
the purposes of our meta-analyses. ’Continuous abstinence’ as de-
fined in the remaining trials excluded the first eight weeks of treat-
ment, and couldmore accurately be termed ’prolonged abstinence’
(Hughes 2003).
Aubin 2008 was an unblinded open-label trial, which may have
led to the differential drop-out rates after randomisation, with
nine participants assigned to nicotine patch declining to take part
compared with two in the varenicline group. We rated four open-
label trials of NRT versus varenicline (Aubin 2008; Baker 2016;
Heydari 2012; Tsukahara 2010) at high risk of bias for being un-
blinded. Nakamura 2007 was assessed as being at high risk of se-
lective reporting bias, since they reported continuous abstinence
rates for all participants, but demographic information, craving
andwithdrawalmeasures for the highly nicotine-dependent smok-
ers only. Cinciripini 2013 reported changing interventions (from
nortriptyline to varenicline) three months into their study, but
found no differences between the varenicline and nortriptyline
cohorts and therefore combined them for analysis. Heydari 2012
used an eight-week course of varenicline (presumably to match
the standard NRT regimen), which might be expected to have
compromised its efficacy.
Two trialswhich posted their results on the www.ClinicalTrials.gov
website are rated at high risk of bias for attrition and losses to
follow-up. NCT00828113, comparing long-term and standard
doses of varenicline, lost 60% from each of the groups by twelve-
month follow-up, while NCT01347112, a small study of alcohol-
dependent smokers using varenicline to quit, lost 25% from the
varenicline group and 71% from the placebo group at 24 weeks.
This study also relied upon self report, rather than biochemical
validation of abstinence.
Our judgements on the risks of bias of all the included studies are
summarised in Figure 1.
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Figure 1. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Effects of interventions
See: Summary of findings for the main comparison Nicotine
receptor partial agonists for smoking cessation; Summary of
findings 2Nicotine receptor partial agonists for smoking cessation
1. Cessation
Cytisine
We pooled the findings of two cytisine trials, covering 937 par-
ticipants, 470 of whom took the active drug. Both trials reported
continuous abstinence rates at longest follow-up (24 weeks in
Vinnikov 2008 and 52 weeks in West 2011), delivering an RR of
3.98 (95% CI 2.01 to 7.87; low-quality evidence; Analysis 1.1).
We have not combined these recent trials with Scharfenberg 1971,
as the design and conduct of the latter is of indeterminate quality,
using self-reported point prevalence abstinence and without bio-
chemical verification of its results. A sensitivity analysis combining
the three trials increased the I² statistic from 0% to 68%, indi-
cating substantial heterogeneity between the older study and the
recent ones. The RR for Scharfenberg 1971 at two-year follow-up
was 1.61 (95% CI 1.24 to 2.08; Analysis 1.2), and at six months
1.91 (95% CI 1.53 to 2.37; analysis not shown).
The largest cytisine trial (Walker 2014) compared it with NRT,
and reported non-verified continuous abstinence at six months.
Although this study (in 1360 participants) was designed as a test
of non-inferiority, it demonstrated a significant benefit for cytisine
over NRT, with a RR of 1.43 (95% CI 1.13 to 1.80; Analysis
2.1). The primary endpoint finding (at one month) also favoured
cytisine: RR 1.30 (95% CI 1.12 to 1.51; analysis not shown).
The cytisine trials did not for the most part identify more adverse
events in the intervention than the control arm; Scharfenberg 1971
reported similar rates of mild adverse events (nausea, restlessness,
insomnia, irritability) in the cytisine and placebo groups at four
weeks (23.4% and 20% respectively in abstinent participants),
but did not report long-term rates for the full study population.
Vinnikov 2008 reported 10 events in eight participants (four from
each group), includingdyspepsia, nausea andheadache.West 2011
reported gastrointestinal disorders at higher rates in the cytisine
than in the placebo group (13.8%vs 8.1%, P = 0.02).Walker 2014
reported significantly more adverse events (nausea, vomiting, sleep
disorders) in the cytisine group compared with the NRT group
(4.6% versus 0.03%; P = 0.0002), but similar rates of serious
adverse events in the cytisine (6.9%) and the NRT (6.0%) groups.
Dianicline
The one trial of dianicline that has published its findings (Tonstad
2011) reported continuous abstinence at 26 weeks. The quit rate
among 300 dianicline users was 16.7%, compared with a placebo
quit rate of 13.9% in 302 participants; this yields an RR of 1.20
(95% CI 0.82 to 1.75; Analysis 3.1). Results from the companion
trial (Ameridian 2007) have not been made available to us by the
manufacturers.Development of the drughas nowbeen abandoned
by Sanofi-Aventis.
Varenicline
The evidence base includes 39methodologically sound clinical tri-
als, involving more than 25,290 participants, 11,801 of whom re-
ceived varenicline (see Appendix 2). Where point prevalence mea-
sures were the only ones reported, we have noted this in footnotes
for each analysis.
The Nides 2006 and Nakamura 2007 comparisons chosen for
our primary meta-analysis were between the 1.0 mg twice a day
group and the placebo group, since this matched the regimen now
recommended for clinical practice. For the Oncken 2006 trial we
combined the 1.0 mg twice a day titrated and non-titrated groups
for the meta-analysis, since titration did not affect cessation rates.
I Varenicline versus other pharmacotherapies
1.1. Varenicline versus placebo
The pooled risk ratio (RR) for validated continuous abstinence six
months or more from the start of the intervention (longest follow-
up) is 2.24 (95% CI 2.06 to 2.43; 27 trials, 12,625 participants,
I² = 60%; high-quality evidence; Analysis 4.1; Figure 2). This
finding is consistent with that reported in the previous version of
this review, which included 14 trials and 6166 participants. The
current RR is based on 27 cessation trials of varenicline (26 ver-
sus placebo, and one (Carson 2014) versus counselling only). Al-
though the control group did not receive placebo medication, we
have includedCarson 2014 in themainmeta-analysis; a sensitivity
analysis excluding it made no appreciable difference to the esti-
mate. All the trials in this analysis delivered varenicline at the stan-
dard dosage (1 mg twice a day) for 12 weeks, apart from Heydari
2012 and Nides 2006 (eight weeks). Limiting the analysis to the
15 studies with 12-month follow-up made little difference to the
result (RR 2.29, 95% CI 2.02 to 2.60; 5904 participants). Six-
month abstinence rates for all 25 studies reporting this measure
yielded a virtually identical RR of 2.25 (95% CI 2.08 to 2.44;
12,304 participants, I² = 66%; Analysis 4.2).
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Figure 2. Varenicline (1.0 mg 2/d) vs placebo, outcome: 3.1 Continuous abstinence at longest follow-up (24+
weeks)
The EAGLES 2016 trial presents results separately for the two
constituent cohorts, with and without a history of psychiatric dis-
orders. The groups without a psychiatric history in all cases and at
both time points (12 and 24 weeks) achieved higher quit rates than
the groups in the psychiatric cohort. The RR in the non-psychi-
atric cohort for varenicline versus placebo was 2.42 (95% CI 1.97
to 2.99), with quit rates of 25.5% and 10.5% respectively; the
corresponding measures in the psychiatric cohort were RR 2.20
(95% CI 1.73 to 2.80), and quit rates of 18.3% and 8.3% respec-
tively. Treating the psychiatric cohort as a subgroup of the main
analysis and testing for subgroup differences found no significant
difference between the psychiatric cohort and the remaining trials
(Chi² = 0.02, P = 0.88, I² = 0%; analysis not shown).
We have excluded from the main analysis four trials which tested
extended varenicline treatment. Ebbert 2015 (’Reduce to quit’)
and Stein 2013 (substance-abusing smokers on methadone main-
tenance) both tested 24 weeks of varenicline, and NCT00828113
and Williams 2007 (a safety trial) both prescribed 12 months
of treatment. Pooling these data demonstrated a clear benefit for
varenicline, with a RR of 3.64 (95% CI 2.81 to 4.72; 2170 par-
ticipants, I² = 78%; Analysis 4.3). A sensitivity analysis removing
NCT00828113, which is at high risk of attrition bias, increased
the RR to 4.15 (95% CI 3.14 to 5.49) and dropped the I² to 0%.
1.2. Varenicline versus bupropion
Five trials (Cinciripini 2013; EAGLES 2016; Gonzales 2006;
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Jorenby 2006; Nides 2006) compared varenicline to bupropion.
Although the Nides 2006 trial tested three dosing variants of
varenicline, we have used the ’1 mg twice a day’ arm for our analy-
sis, since this matches the regimen now recommended for clinical
practice. The pooled RR for the five trials at six months was RR
1.39 (95%CI 1.25 to 1.54; 5877 participants, I² = 0%; moderate-
quality evidence; Analysis 5.1), in favour of varenicline. We con-
ducted a sensitivity analysis to test the effect of excluding Nides
2006, which had included previous users of bupropion, but the
RR remained steady, at 1.37 (95% CI 1.23 to 1.52). The three-
month and 12-month results were in line with the main finding
(Analysis 5.2; Analysis 5.3).
The EAGLES 2016 trial demonstrated higher quit rates for this
comparison in the non-psychiatric than in the psychiatric cohort,
with a RR of 1.36 (95% CI 1.15 to 1.60; non-psychiatric), com-
pared with RR 1.28 (95% CI 1.05 to 1.57; psychiatric). Quit
rates were 25.5% for varenicline and 18.8% for bupropion in the
non-psychiatric cohort, and 18.3% for varenicline and 13.7% for
bupropion in the psychiatric cohort.
1.3 Varenicline versus NRT
Eight trials tested varenicline against nicotine replacement therapy.
Three trials were open-label (Aubin 2008; Baker 2016; Tsukahara
2010), and one trial was an open-label comparison of varenicline,
NRT and no pharmacotherapy. Baker 2016 compared nicotine
patch (the reference treatment) against varenicline and against
combination NRT (patch plus lozenge). Three trials were placebo-
controlled three-arm studies, with De Dios 2012 and Stein 2013
testing varenicline against a placebo tablet and against NRT, and
Rose 2013 comparing varenicline, bupropion and NRT, with all
participants receiving an active treatment plus two dummy treat-
ments. EAGLES 2016 was a double-blind four-arm trial, compar-
ing varenicline, bupropion and NRT against placebo. The pooled
analysis indicates a benefit for varenicline over NRT. The RR at
24 weeks was 1.25 (95% CI 1.14 to 1.37; 6264 participants, I²
= 39%; moderate-quality evidence; Analysis 6.1). Removing the
three open-label trials (all at high risk of bias for blinding) from the
analysis slightly strengthened the effect estimate (RR 1.34, 95%
CI 1.19 to 1.50), and increased the I² value to 47%. Stein 2013
treated its participants for 24 weeks rather than the standard 12;
removing it from the analysis made little difference to the result or
to the I² value. For Baker 2016, Analysis 6.1 uses the varenicline/
patch comparison; substituting the combination NRT arm for the
nicotine patch armmade minimal difference to the study or meta-
analysis findings.
The EAGLES 2016 trial again demonstrated higher quit rates
for this comparison in the non-psychiatric than in the psychiatric
cohort, with a RR of 1.38 (95%CI 1.17 to 1.63; non-psychiatric),
compared with RR 1.41 (95% CI 1.15 to 1.74; psychiatric). Quit
rates were 25.5% for varenicline and 18.5% for NRT in the non-
psychiatric cohort, and 18.3% for varenicline and 13.0% for NRT
in the psychiatric cohort.
1.4 Varenicline versus mecamylamine
No trials currently report on this comparison.
1.5 Combination varenicline treatment versus single-therapy
treatment
No trials currently report on this comparison.
1.6 Varenicline tablets versus other formulations
No trials currently report on this comparison.
II Variations in usage
2.1 Flexible quit date
One large multicentre study (Rennard 2012) allowed participants
to select their own quit date anywhere between 8 and 35 days after
joining the study. The trial found a clear benefit for varenicline
over placebo, with an RR of 2.74 (95% CI 1.81 to 4.16; 659
participants; Analysis 7.1). By the end of the four-week ’quit win-
dow’ (day 35), 80.5% of the varenicline group had made a quit
attempt, compared with 73.3% of the placebo group. Varenicline
participants were also found to have made an earlier quit attempt
(median day 17) than the placebo participants (median day 24)
(P = 0.0074).
2.2 Variable dosages
Low-dose varenicline versus placebo
Four trials investigated this comparison (Nakamura 2007; Niaura
2008; Nides 2006; Oncken 2006). For this review, we have com-
bined the titrated and non-titrated arms of the Oncken 2006 trial,
as there were no detectable differences between the arms for any
outcomes. Three of the trials prescribed half the recommended
daily dosage, either as a single 1 mg tablet or as two 0.5 mg
doses, while Niaura 2008 allowed participants to regulate their
own dosage at anywhere between 0.5 mg and 2.0 mg a day. The
regimen favoured varenicline over placebo, with a RR at 52 weeks
of 2.08 (95% CI 1.56 to 2.78; 1266 participants; Analysis 7.2).
The Niaura 2008 trial found that those on varenicline settled on
a mean modal dose of 1.35 mg a day, compared with 1.63 mg a
day for the placebo group.
Variable dosing at the participant’s or physician’s discretion
Six studies (Anthenelli 2013; Chengappa 2014; Cinciripini 2013;
Gonzales 2014; Hajek 2015; Niaura 2008) explored the option of
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reducing the dosage to moderate side effects, either at the physi-
cian’s behest or within the participant’s own control. While this
may have made the treatment more tolerable, it appeared not to
have compromised efficacy, yielding a RR against placebo of 2.29
(95% CI 1.81 to 2.89; 1789 participants; I² = 70%; Analysis 7.2),
which is very close to the point estimate for the main analysis, but
with a wider confidence interval.
Standard-dose versus low-dose varenicline
Three trials (Nakamura 2007; Nides 2006; Oncken 2006) tested
the standard regimen (1 mg twice a day) against half the recom-
mended daily dose, either as a single 1 mg tablet or as two 0.5 mg
doses, and found a modest advantage for the standard dosage: RR
1.25 (95% CI 1.00 to 1.55; 1079 participants; Analysis 7.3).
Standard dose versus high-dose varenicline
In one recent trial (Hajek 2015; not included in the main analy-
ses), 200 smokers who were judged not to be responding to the
standard dose of varenicline (no strong nausea, no clear reduction
in smoking enjoyment, and less than 50% smoking reduction af-
ter 10 days) were allocated to additional treatment (varenicline or
placebo) up to the target quit date (day 21). Participants main-
tained that dosage for three weeks, but could reduce it if side ef-
fects became intolerable. Participants could take up to 3 mg a day
in addition to the standard daily dose of 2 mg. The trial found a
marginal but non-significant benefit for quit rates with the higher
dosing schedule, with an RR at 12 weeks of 0.88 (95% CI 0.54
to 1.44; Analysis 7.4), but noted a trend in the varenicline group
for more fatigue and decreased appetite, and significantly higher
levels of nausea and vomiting.
2.3 Preloading (before the TQD)
No trials currently report on this comparison.
2.4 Reducing to quit
One recent trial (Ebbert 2015) tested varenicline against placebo
in 1510 smokers disinclined to quit abruptly, but willing to reduce
their smoking gradually as a gateway to quitting. Treatment was
given in this trial for 24 weeks rather than the standard regimen
of 12 weeks, with participants asked to reduce their smoking rate
by 50% by week 4, by at least 75% by week 8, and by 100% by
week 12. After 12 months, the RR for quitting was 3.99 (95% CI
2.93 to 5.44; Analysis 7.5) in favour of varenicline.
2.5 Maintenance therapy (relapse prevention)
Two trials have tested varenicline as an aid to relapse prevention
in smokers who had successfully quit on varenicline. Tonstad
2006 randomised 1208 quitters to a further 12 weeks of either
varenicline or placebo, while Evins 2014 randomised 87 quitters
with schizophrenia, schizoaffective or bipolar disorder to a further
40 weeks of either varenicline or placebo treatment. We note that
the integrity of the blinding in these trials may be questionable,
as all the participants had already used open-label varenicline to
achieve abstinence. At 12 months, the RR in favour of varenicline
was 1.24 (95% CI 1.08 to 1.42; Analysis 7.6). Heterogenity was
high, at 82%, possibly reflecting the relatively extended treatment
period in the smaller trial. A random-effects analysis eliminated
the significant difference (RR 1.75, 95% CI 0.71 to 4.33).
2.6 Harm reduction
No trials currently report on this comparison.
III Specific patient groups
3.1 Cardiovascular disease (CVD)
Rigotti 2010 compared varenicline to placebo in a trial of 714 peo-
ple with stable cardiovascular disease. Eisenberg 2016 randomised
302 smokers admitted for acute coronary syndrome to 12 weeks
of treatment plus 12 weeks follow-up. At longest follow-up (52
weeks and 24 weeks respectively), the RR was 1.88 (95% CI 1.4
to 2.47; 1006 participants; I² = 81%; Analysis 8.1) in favour of
varenicline. Treating the trials as a subgroup of the main analysis
(Analysis 4.1) and testing for subgroup differences demonstrated
no significant difference between them (Chi² = 1.70, P = 0.19, I²
= 41.1%; analysis not shown).
3.2 COPD
Tashkin 2011 compared varenicline to placebo in 504 adult smok-
ers with mild to moderate COPD. At 52 weeks, the RR was 3.35
(95% CI 1.89 to 5.94; Analysis 8.2) in favour of varenicline.
3.3 Asthma
Westergaard 2015 compared varenicline to placebo in 52 young
adults (aged 19 to 40) with asthma. At six months, there was no
difference in quit rates between the intervention and control arms
(RR 1.25, 95% CI 0.38 to 4.14; Analysis 8.3).
3.4 Schizophrenia/bipolar/psychiatric disorder
Four trials tested varenicline against placebo in smokers diagnosed
with bipolar disorder (Chengappa 2014), with a history of var-
ious psychiatric disorders (and at least one-third of the cohort
stably taking psychotropic medications (EAGLES 2016), with
schizophrenia, schizoaffective or bipolar disorders (Evins 2014),
and with schizophrenia or schizoaffective disorder (Williams
2012). The pooled analysis found a benefit for varenicline at six
months, with a RR of 2.28 (95% CI 1.82 to 2.87; 2332 partici-
pants, I² = 0%; Analysis 8.4). Treating the trials as a subgroup of
17Nicotine receptor partial agonists for smoking cessation (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
the main analysis (Analysis 4.1) and testing for subgroup differ-
ences demonstrated no significant difference between them (Chi²
= 0.10, P = 0.76, I² = 0%; analysis not shown).
3.5 Depression
Anthenelli 2013 compared varenicline to placebo in 523 adult
smokers with current or past depression. At 52 weeks, the RR was
1.97 (95% CI 1.28 to 3.01; Analysis 8.5) in favour of varenicline.
3.6 Substance use disorder/methadone-maintained
Two trials tested varenicline against placebo in smokers on meth-
adone treatment for substance use disorder. Nahvi 2014a covered
112 outpatients in New York, and Stein 2013 315 outpatients in
New England. The latter study included a combination NRT arm
(patch + ad lib nicotine gum), which is included in Analysis 6.1.
The pooled analysis did not find an effect of varenicline: RR 3.72
(95% CI 0.50 to 27.59; I² = 0%: Analysis 8.6). Treating the trials
as a subgroup of the main analysis (Analysis 4.1) and testing for
subgroup differences demonstrated no significant difference be-
tween them (Chi² = 0.25, P = 0.62, I² = 0%; analysis not shown).
3.7 Alcohol-dependent smokers
NCT01347112, which posted its
results on the www.ClinicalTrials.gov website, reported cessation
rates of 25% (4/16) for the varenicline group, and 0% (0/17) for
the placebo group. These findings were not biochemically verified,
and the study sustained high losses, putting it at high risk of bias.
3.8 HIV
No trials currently report on this comparison, although
NCT00918307 includes a conference abstract giving pre-
liminary findings. No results have been posted on the
www.ClinicalTrials.gov trials registry database.
3.9 Diabetes
No trials currently report on this comparison.
3.10 Head and neck cancer
No trials currently report on this comparison.
3.11 Varenicline in pregnancy
No trials currently report on this comparison.
3.12 Varenicline for long-term use of NRT
Tønnesen 2013 aimed to wean 139 ex-smokers off long-term use
of NRT. All had been consuming an average of 16 NRT units a
day for approximately six years. Participants were randomly allo-
cated to varenicline or placebo for the standard 12-week treatment
phase, and were followed up to 52 weeks. The trial did not find
a difference between the varenicline and placebo arms for partic-
ipants, either for having smoked (10% in the varenicline group
and 11.6% in the placebo group between weeks 36 and 52) or for
not using NRT, with a RR of 1.31 (95% CI 0.83 to 2.08; Analysis
8.8).
IV Different settings and subgroups
4.1 Hospital inpatients/perioperative patients
Three trials currently address this population of smokers. Carson
2014 targeted adult smokers admitted to hospital for smoking-re-
lated acute illnesses, Steinberg 2011 adult smokers admitted with
any diagnosis, and Wong 2012 adult smokers admitted for non-
cardiac elective surgery. The pooled analysis at longest follow-up
favoured varenicline treatment, with a RR of 1.39 (95% CI 1.09
to 1.77; 744 participants, I² = 36%; Analysis 9.1). Treating the
trials as a subgroup of the main analysis (Analysis 4.1) and testing
for subgroup differences demonstrated a significant difference be-
tween the hospital group and the remaining trials (Chi² = 15.87,
P < 0.0001, I² = 93.7%; analysis not shown). This may be linked
to the negative findings of the Steinberg 2011 trial.
4.2 Smokers who have previously failed to quit on
varenicline or NRT or bupropion
Gonzales 2014 tested varenicline versus placebo in a group of
smokers who had previously used varenicline for two weeks or
more, at least three months prior to admission to the study, and
had failed to quit but were motivated to try again. The trial found
a clear benefit for varenicline, with a RR at 52 weeks of 6.15 (95%
CI 2.98 to 12.70; 494 participants; Analysis 9.2).
4.3 Light or heavy smokers
De Dios 2012 is a small pilot study conducted in 32 Latino light
smokers (smoking 10 or fewer cigarettes a day), randomising to
varenicline, NRT or placebo tablets. The six-month result, al-
though favouring the varenicline arm, did not achieve statistical
significance: RR 7.64 (95% CI 0.44 to 131.75; Analysis 9.3)
4.4 Varenicline by gender
No trials currently address this comparison, although a recent
meta-analysis (McKee 2015) presents abstinence data stratified
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by gender from 16 RCTs (supplied by Pfizer). Their meta-anal-
ysis demonstrates, compared with other smoking cessation treat-
ments, greater efficacy for short- and immediate-term outcomes
in women smokers versus men, and equal efficacy for abstinence
at one year.
4.5 Varenicline in ethnic groups
No trials currently report on this comparison.
2. Craving and withdrawal
The results of the trials included in our review lend support to
the theoretical basis for the development of varenicline. Its prop-
erties as a partial agonist, causing moderate activation of the
α4β2nAChR,may be expected tomitigate craving andwithdrawal
symptoms, while its antagonist properties in blocking nicotine
binding may lead to reduced smoking satisfaction and reduced
psychological reward in those who continue to smoke while tak-
ing the drug. The varenicline trials which tested withdrawal and
craving all reported its superiority over placebo in reducing with-
drawal symptoms, as measured on the Minnesota Nicotine With-
drawal Scale or the Wisconsin Smoking Withdrawal Scale; crav-
ing, as measured on the Brief Questionnaire of Smoking urges;
and enjoyment of concurrent smoking, as measured on the modi-
fied Cigarette Evaluation Questionnaire.Those trials (Nides 2006;
Oncken 2006; Nakamura 2007; Niaura 2008) which measured
the effects of varying dosage detected greater reductions in crav-
ing and withdrawal symptoms in the standard dose groups (1.0
mg twice a day) than in the reduced dose groups. Hajek 2015
noted similar disparities in enjoyment of smoking when partici-
pants moderated their own dosage up to the TQD. Full details of
the comparative incidence of craving and withdrawal symptoms
are shown in Appendix 3.
3. Adverse events (AEs)
The predominant adverse event for varenicline wasmild tomoder-
ate nausea, subsiding over time, at rates between 6% (Stein 2013)
and 51% (Nahvi 2014a), but with almost half the studies report-
ing levels between 24% and 29%. The trials testing non-standard
regimens found a dose-response relationship for the incidence of
nausea: rates ranged from 17.5% (0.3 mg daily) to 52% (1.0 mg
twice daily) inNides 2006, and from7.2%(0.25mg twice daily) to
24.4% (1.0 mg twice daily) in Nakamura 2007. Self regulation of
treatment in Niaura 2008 appeared to reduce rates of nausea, with
13.4% of varenicline users reporting it compared with 5.2% of the
placebo group. Both titration and dosage levels affected the inci-
dence and severity of nausea in Oncken 2006, with the lower dose
resulting in rates of 16.3% (titrated) and 22.6% (non-titrated),
compared with 34.9% (titrated) and 41.9% (non-titrated) in the
standard dosage groups. Hajek 2015 allowed participants to in-
crease their dosage up to 5 mg a day by the TQD, and reported
nausea rates of 80% in the varenicline group compared with 18%
among the placebo participants. In Gonzales 2006 and Jorenby
2006, an average of 9.5% in the varenicline groups discontinued
treatment but remained in the trial for follow-up, compared with
an average of 14% in the bupropion groups and 8% in the placebo
groups. Discontinuation rates for any adverse event were highest
inWilliams 2007, where participants took the trial medication for
a year, at 28.3% in the varenicline group and 10.3% in the control
group. In the 12-week open-label phase of Evins 2014, 31.8% of
participants taking varenicline discontinued the study because of
adverse events, or for non-adherence to the protocol, or because
they no longer wished to stop smoking. In Phase 1 of Rose 2013,
62 of 112 (55%) non-responders to NRT assigned to varenicline
withdrew or were lost to follow-up, but this was a comparable
attrition rate to those lost from the NRT group (60%) and from
the bupropion group (58%), and appeared not to be associated
with adverse events. The study also noted that 25% of participants
across all three conditions reduced their dosage at some point dur-
ing treatment.
Adverse events were monitored weekly during treatment from
weeks one to seven (Gonzales 2006; Jorenby 2006; Nides
2006; Oncken 2006), weekly throughout 12 weeks of treatment
(Anthenelli 2013; Aubin 2008; Bolliger 2011; Carson 2014;
Cinciripini 2013; EAGLES 2016; Ebbert 2015; Evins 2014;
Gonzales 2014; Nakamura 2007; Niaura 2008; Rennard 2012;
Rigotti 2010; Tashkin 2011; Tsai 2007; Wang 2009), or fort-
nightly throughout 12 weeks of treatment (Rose 2013; Tønnesen
2013). Stein 2013 monitored participants at weeks two and four,
for adherence and adverse events. Tonstad 2006monitored atweek
13 (end of open-label phase) and at week 25 (end of double-blind
phase), and Williams 2007 monitored weekly from weeks one to
eight and thenmonthly toweek 52. Baker 2016monitored adverse
events and delivered counselling at weeks 1, 4, 8 and 12. Steinberg
2011 collected adverse event data through self report at weeks 2, 4,
12 and 24, and Nahvi 2014a in four visits over 12 weeks of treat-
ment. Hajek 2015 followed the UK’s NHS Stop Smoking Service
protocol andmonitoredweekly for the firstmonth post-TQD, and
again at 12-week end of treatment. The trials reported only those
adverse events occurring in at least 5% of the varenicline groups,
and at higher rates than in the placebo groups, with the excep-
tion of Bolliger 2011, Nahvi 2014a, Nakamura 2007, Stein 2013,
Steinberg 2011, and Tønnesen 2013 (any occurrence), Anthenelli
2013 (occurring in 1%of either group), Ebbert 2015 (occurring in
at least 2% of either group), Chengappa 2014, Cinciripini 2013,
Gonzales 2014, and Hajek 2015 (at least 5% in either group),
Evins 2014 (occurring in 10% of either group), and Rennard 2012
(any event occurring in at least 5% of either group, and psychiatric
events in at least 1% of either group).
Meta-analyses of the four main adverse events in the varenicline
versus placebo groups yielded RRs of 3.27 (95% CI 3.00 to 3.55;
32 studies; 14,963 participants; I² = 22%) for nausea (Analysis
10.1); 1.49 (95%CI 1.35 to 1.65; 29 studies; 14,447 participants;
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I² = 0%) for insomnia (Analysis 10.2); 2.12 (95% CI 1.88 to
2.38; 26 studies; 13,682 participants; I² = 62%) for abnormal
dreams (Analysis 10.3); and1.17 (95%CI1.07 to 1.29; 25 studies;
13,835 participants; I² = 27%) for headache (Analysis 10.4). All
differences were statistically significant.
4. Serious Adverse Events (SAEs)
A serious adverse event (SAE) may be defined as any untoward
medical occurrence that resulted in death; was life-threatening; re-
quired inpatient hospitalisation or prolongation of existing hospi-
talisation; resulted in persistent or significant disability or incapac-
ity; or resulted in a congenital anomaly or birth defect (Nakamura
2007).
Vinnikov 2008 reported no SAEs in their cytisine trial, whileWest
2011 reported seven, none of which was deemed to be related
to the medication, and Scharfenberg 1971 gave no information
about the incidence of SAEs in either group. Walker 2014, com-
paring cytisine with NRT (no placebo group), reported 56 SAEs
in 45 participants taking cytisine (eight of the SAEs occurring in
one person), and 45 SAEs in 39 participants taking NRT. One
person died in each group, but neither death (one alcohol-related
asphyxiation and one heart attack) was deemed to be treatment-
related.
Among the varenicline studies, there were no treatment-related
deaths in any of the intervention groups during treatment or fol-
low-up phases. However, Carson 2014 reported 13 fatalities dur-
ing the first 12 months of the study period, in a population of in-
patients admitted for acute episodes of smoking-related illnesses.
All the deaths (six in the varenicline + counselling group and seven
in the counselling-only group) were in people with known under-
lying comorbidities, including COPD, bradycardia, arrhythmia,
lung cancer, stroke and non-ST-elevation myocardial infarction.
The authors do not attribute any of the deaths to studymedication
(Carson 2011).
Non-fatal SAEs occurred in 29 of the varenicline trials. We dis-
counted from this analysis four trials which did not report any
SAEs (De Dios 2012; Heydari 2012; Westergaard 2015; Wong
2012) and a further four which had no placebo group (Aubin
2008; Baker 2016; Rose 2013; Tsukahara 2010). Event counts for
Analysis 11.1 and Analysis 11.2 are of individuals reporting one
or more SAEs. Analysis 11.1 demonstrates an RR of 1.25 (95%
CI 1.04 to 1.49; 15,370 participants, I² = 0%; high-quality ev-
idence), indicating an increased risk of SAEs in the varenicline
groups compared with the placebo groups. A secondary analysis
restricted to SAEs occurring within or immediately after the treat-
ment phase demonstrated a similar effect (RR 1.25, 95% CI 1.02
to 1.52; 15,000 participants, I² = 0%). A sensitivity analysis using
a Peto odds ratio (appropriate for the analysis of rare events) made
no difference to the findings. Details of the SAEs among 32 of the
included studies are given in Appendix 4.
We also include a meta-analysis of cardiac SAEs including deaths
(Analysis 11.4). There were 92 events in 8587 participants from21
studies. There were more events in the varenicline groups and the
confidence intervals are wide and do not rule out an increase (RR
1.36, 95% CI 0.91 to 2.04; I² = 0%; moderate-quality evidence).
For this update. we have conducted new meta-analyses of neu-
ropsychiatric adverse events, using any study included in the ef-
ficacy findings which reported the incidence of these events, plus
nine studies (flagged with an asterisk in the study ID) excluded
from the efficacy analyses, but offering data on safety. The RR
for depression is 0.94 (95% CI 0.77 to 1.14; 36 studies; 16,189
participants, I² = 0%; Analysis 10.5), with non-significantly lower
rates in the varenicline groups. The RR for suicidal ideation is
0.68 (95% CI 0.43 to 1.07; 24 studies; 11,193 participants, I² =
0; Analysis 10.6), with border-line non-significantly lower rates in
the varenicline groups. It should be noted that all five events in the
varenicline group for suicidal ideation occurred in the psychiatric
cohort, with none reported in the non-psychiatric group.
The EAGLES Study
EAGLES 2016, a double-blind triple-dummy RCT, is the largest
trial to have been conducted with varenicline, and was stratified by
the presence (n = 4074) or absence (n = 3984) of a history of psy-
chiatric disorders. The authors estimate that at least one-third of
the psychiatric cohort participants were stably taking psychotropic
medications throughout the course of the study. The primary sa-
fety endpoint was a composite measure of 16 neuropsychiatric ad-
verse events, including anxiety, depression, feeling abnormal, and
hostility (all rated as severe), and agitation, aggression, delusions,
hallucinations, homicidal ideation, mania, panic, paranoia, psy-
chosis, suicidal ideation, suicidal behaviour, and completed suicide
(all rated as moderate or severe). Outcomes were assessed using
the Columbia Suicide Severity Rating Scale (C-SSRS), the Sui-
cide Behavior Questionnaire - Revised (SBQ-R), and the Hospital
Anxiety and Depression Scale (HADS) at visits throughout the
treatment and follow-up phases of the study.
Rates of neuropsychiatric AEs were similar across all four treat-
ment groups, with more AEs in the psychiatric than in the non-
psychiatric cohort. Event rates in the psychiatric cohort during
treatment and up to 30 days after were varenicline 6.5%, bupro-
pion 6.7%,NRT5.2% and placebo 4.9%; the corresponding rates
in the non-psychiatric cohort were 1.3%, 2.2%, 2.5% and 2.4%
respectively. The risk difference between groups was significantly
lower for the varenicline group compared with placebo in the non-
psychiatric cohort (RD -1.28, 95% CI -2.40 to -0.15); all other
differences in the remaining comparisons (varenicline, bupropion,
NRT, all versus placebo) in both cohorts were statistically non-sig-
nificant. The study authors interpret this as indicating that none of
the first-line smoking cessation treatments compared with placebo
significantly increases the risk of neuropsychiatric adverse events
in smokers with or without psychiatric disorders.
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An analysis by treatment group in the psychiatric cohort, assessing
the incidence of AEs categorised by severity (severe or serious),
discontinuation and corrective intervention (including medica-
tion, psychotherapy, counselling and hospitalisation), found few
differences between the groups: counts of severe AEs were iden-
tical across the active treatment groups (14 in each), with the
placebo group reporting 13. Serious AEs were similar: varenicline
six, bupropion five, NRT and placebo three each. AEs leading to
permanent treatment discontinuation were varenicline 16, bupro-
pion and placebo 15 each, and NRT 12, while AEs requiring in-
tervention were varenicline and NRT seven each, bupropion 12,
and placebo 11. Based on the upper limits of the confidence inter-
vals, the authors conclude that it is highly unlikely that varenicline
and buporpion contribute to neuropsychiatric adverse events of
moderate to severe intensity at a rate above 1.5% in smokers with-
out a psychiatric disorder, and above 4% in smokers with such
disorders. These estimates are also consistent with no increase in
neuropsychiatric event rates in either population of smokers.
The authors report the limitations of their findings, confirming
that the results may not be generalisable to smokers with untreated
or unstable psychiatric disorders. For the psychiatric cohort, they
confined recruitment to smokers with any of four major disease
categories (mood, anxiety, psychosis and borderline personality
disorder), and did not include smokers with current substance use
disorders or imminent risk of suicide. They also point out that
light smokers (fewer than 10 cigarettes a day) were excluded from
the study population, and that the trial has low power to detect
rare neuropsychiatric events.
The evidence currently presented demonstrates an inconsistent
pattern between the two cohorts inAE event rates, with the psychi-
atric cohort reporting higher rates in the active treatment groups
compared with placebo, and the reverse pattern in the non-psychi-
atric cohort. This difference is in line with current SPC warnings
that care should be taken in people with a history of psychiatric
illness, and with the FDA 2015 Drug Safety Communication ad-
vising that they were unable to draw reliable conclusions on these
issues. The reliance in this study on a composite safety endpoint,
covering a mix of adverse and serious adverse events, also pre-
cludes firm conclusions about the risk levels for individual disor-
ders, which may be elevated for some components and reduced
for others. We await further details of the findings to explore the
robustness of the risk profile.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Cytisine versus placebo for smoking cessat ion
Patient or population: Individuals who smoke tobacco
Setting: Varied
Intervention: Cytisine
Comparison: Placebo
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with placebo Corresponding risk
with Cytisine
Cytisine vs placebo:
cont inuous abst inence
at longest follow-up
(24+ weeks)
Study populat ion (where risk refers to quit ters) RR 3.98
(2.01 to 7.87)
937
(2 RCTs)
⊕⊕©©
LOW 1
21 per 1000 85 per 1000
(43 to 169)
* The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95% CI).The assumed risk in the comparison group is calculated as the median risk in control groups.
CI: Conf idence interval; RR: Risk rat io
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1Imprecision rated ’very serious’ (downgraded two levels on this basis) as only two studies, and fewer than 300 events in each
arm.
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D I S C U S S I O N
This update now covers four trials of cytisine, and 39 trials of
varenicline. Full searches were conducted to May 2015, although
we have included key trials which we obtained after this date.
Summary of main results
Cytisine
Two studies (Vinnikov 2008; West 2011) have demonstrated a
benefit for cytisine over placebo. However, absolute quit rates were
relatively low, with Vinnikov 2008 reporting 9% for cytisine and
1% for placebo at 24 weeks, and West 2011 8.4% and 2.4% re-
spectively at 52weeks. The authors note that their deliberately par-
simonious intervention for the Polish trial, with a 25-day regimen
(in accordance with the manufacturer’s guidelines; Tabex 2011)
and minimal behavioural support, may have limited the achiev-
able cessation rates. Further trials with modified regimens may
need to be conducted to explore the balance between the positives
of affordability and availability within lower- and middle-income
economies and themodest efficacy demonstrated to date. A recent
non-inferiority trial comparing cytisine with NRT (Walker 2014)
demonstrated a benefit for cytisine at six months, with continuous
abstinence rates of 21.8% and 15.3% respectively.
Varenicline
The evidence from 27 trials in 12,625 participants indicates that
varenicline increases the chances of successful smoking cessation
between two- and three-fold compared with placebo. This esti-
mate has remained stable, despite the growing inclusion of prag-
matic trials in real-world settings and in particular groups of smok-
ers normally excluded from clinical trials, e.g. in lower- and mid-
dle-income countries, and in disease-specific populations. Long-
term use of varenicline (two trials of 24 weeks, two trials of 52
weeks) delivered an unequivocal advantage for varenicline over
placebo, without a concomitant increase in adverse or serious ad-
verse events.
In five trials (5877 participants), varenicline was shown to in-
crease the probability of quitting more than bupropion. Eight tri-
als (three of them open-label) in 6264 people compared vareni-
cline with nicotine patches, and found a modest but clear benefit
for varenicline. One trial found no differences between any of the
three tested treatments (varenicline, nicotine patch, and nicotine
patch plus lozenge).
More smokers quit successfully with varenicline than with a
placebo or an alternative intervention in all the populations and
subgroups that we reviewed, including variations in usage (flexible
versus fixed quit dates, different dosages, reducing to quit, relapse
prevention therapy), in disease-specific groups of patients (cardio-
vascular, COPD, schizophrenia and psychiatric disorders, depres-
sion), and in various subgroups or settings (hospital inpatients,
smokers who failed to quit on other therapies). The exceptions
to these findings were standard versus high-dose varenicline, and
varenicline versus placebo in young adults with asthma, in Latino
light smokers, in methadone-maintained substance abusers, and
in long-term users of NRT. In these instances the results favoured
varenicline, but did not reach statistical significance.
The number needed to treat for an additional beneficial out-
come (NNTB) can be derived from the pooled difference between
placebo and treatment quit rates.However, absolute quit rates vary
considerably between trials, according to the definition of cessa-
tion, length of follow-up, the population treated and the extent of
the counselling and follow-up support given. The risk ratio should
be independent of these factors and can be used to derive NNTBs
for the assumed placebo rates that will apply in each local setting.
We estimated a control quit rate with behavioural support at six
months of 7.5%, derived from the weighted mean of the control
event rates in the first few varenicline trials conducted in the USA.
Based on this rate, the NNTB for varenicline is 11 (95% CI 9 to
13). For comparison we can estimate NNTBs from recent meta-
analyses of nicotine replacement therapy (NRT) (RR 1.60, 95%
CI 1.53 to 1.68, Stead 2012) and bupropion (RR 1.62, 95% CI
1.49 to 1.76, Hughes 2014). Assuming the same 7.5% rate in the
behavioural support-only conditions, the NNTB for all types of
NRT is 23 (95% CI 20 to 25), and the NNTB for bupropion is
22 (95% CI 18 to 28).
Adverse events
The main adverse effect of varenicline was nausea, which was gen-
erally mild to moderate, diminished over time, and was associated
with low discontinuation rates. Those trials which tested levels of
dosage and the presence or absence of titration found an increase
in adverse events (apart from headache) with increasing dosage,
and also found that titration appeared to reduce the incidence of
nausea. The transitory nature of this adverse eventmay find further
support in the relapse prevention study (Tonstad 2006), which
reported nausea in 33.5% of varenicline users in the open-label
phase; once the successful quitters were randomised to varenicline
or placebo, rates of nausea fell to 1.2% in the varenicline group
and 0.7% in the placebo group. This virtual elimination of nausea
as an adverse event may suggest that habituation over 12 weeks of
treatment had resolved the condition. However, it is also plausi-
ble that those who suffered most with adverse events during the
open-label phase may not have successfully completed treatment
or, having quit, would be less likely to accept the invitation to take
part during the double-blind phase. It would therefore be unwise
to draw too strong an inference from the difference in rates be-
tween the two phases of the study.
New for this update are analyses of neuropsychiatric events (de-
pression and suicidal ideation). In both cases, the event rates were
higher in the placebo groups than in the varenicline groups, al-
though neither point estimate reached statistical significance.
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Serious adverse events
Our meta-analysis of serious adverse event (SAE) data from 29
trials suggests there may be a 25% increased risk of such events
among the varenicline groups compared with the controls. While
this finding (RR 1.25, 95% CI 1.04 to 1.49; 15,370 participants;
I² = 0%) reaches statistical significance, it must be noted that it is
based on simple counts across the trials of participants reporting
one or more such events, and does not distinguish between events
attributed and those unrelated to treatment. A sensitivity analysis
removing events known to have occurred after the treatment phase
made a negligible difference to the point estimate (see Analysis
11.2). This finding should also be considered in the light of the
higher losses to follow-up in the control arm (mean of 28.4%) of
most of the studies (25/29) compared with the varenicline arm
(meanof 23.8%) (seeAnalysis 12.1),making it likely that the event
rate in the intervention groups was consistently underestimated.
A calculation of the number needed to treat for an additional
harmful outcome (NNTH), based on a typical control rate of 2%,
returned a figure of 143 (95% CI 74 to 556), i.e. one additional
SAE for every 143 people treated with varenicline.
Neuropsychiatric SAEs
Post-marketing surveillance has raised continuing safety issues
concerning varenicline. In February 2008 the US Food and
Drug Administration (FDA 2008) issued a public health advi-
sory, reporting that an association between varenicline and an in-
creased risk of behaviour change, agitation, depressed mood, sui-
cidal ideation and behaviour “appears increasingly likely”. Three
months later, the FDA approved changes to the product labelling,
including a boxed warning, and a Medication Guide produced by
Pfizer Inc.
Tonstad 2010a points out the complexities of separating treat-
ment-related events during the cessation process from those associ-
ated with nicotine withdrawal, with normalisation of monoamine
oxidase levels, and possibly with increased caffeine levels. Any
causal relationship between varenicline and serious neuropsychi-
atric events must be convincingly disentangled from possible con-
founding factors. A review of the ten trials completed up to the end
of 2008 (Tonstad 2010b) found no significant excess incidence of
disorders in varenicline users compared with control groups (RR
1.02, 95% CI 0.86 to 1.22), apart from sleep disorders (RR 1.70,
95% CI 1.50 to 1.92). However, although the absolute risk of de-
pressedmood disorders and disturbances appears to be low in these
study populations (varenicline 2.8% vs placebo 1.9%), the RR
of 1.42 (95% CI 0.96 to 2.08), while not statistically significant,
suggests an increased likelihood of such disorders for varenicline
users. It must also be noted that these trials excluded participants
with current or recent depression, panic disorder, psychosis, bipo-
lar disorder or alcohol/drug abuse or dependence, and represent
an atypically ’healthy’ population of smokers. The findings may
not be readily generalisable to a mixed real-world population of
smokers.
Recent studies have explored possible links between varenicline
use and suicidal ideation and behaviour. Any such evaluation is
complicated by the fact that people who smoke have a two- to
three-fold increased risk of suicide (Hemmingsson 2003; Miller
2000). A UK cohort study (Gunnell 2009) evaluating rates of fa-
tal and non-fatal self harm, suicidal thoughts and depression in
users of varenicline compared with NRT and bupropion found
no clear evidence of an association. The hazard ratio for self harm
among people using varenicline compared with NRT was 1.12
(95% CI 0.67 to 1.88), and compared with bupropion was 1.17
(95% CI 0.59 to 2.32). Similarly, current evidence did not detect
an effect for an increase in risks of depression or suicidal thoughts
associated with varenicline compared with the other two medica-
tions. Although the upper level of the confidence interval for the
self-harm estimate does not preclude the possibility of a two-fold
increase for varenicline users, the data broadly confirm that the
absolute incidence was low. The Gunnell 2009 analysis has subse-
quently been updated byThomas 2013, using validated outcomes,
and deploying instrumental variable analysis to counter residual
confounding. The updated analyses confirmed that people taking
varenicline were no more likely than those taking NRT to suffer
fatal or non-fatal self harm (HR 0.88, 95% CI 0.52 to 1.49) or
treated depression (HR 0.75, 95% CI 0.65 to 0.87). The interim
report by the UK-based Drug Safety Research Unit of their cohort
study of prescription event monitoring (Kasliwal 2009) has found
no evidence of an excess of suicidal thoughts or behaviours; both
of the reported suicide attempts in the cohort of 2682 patients
occurred in people with a previous history of psychiatric illness
and with precipitating factors for the event. A similar study con-
ducted in New Zealand by the Intensive Medicines Monitoring
Programme identified one suicide (0.03%, 95% CI 0.007% to
0.16%) in a cohort of 3415 recipients of dispensed varenicline
prescriptions (Harrison-Woolrych 2011).
Thomas 2014 used MHRA yellow card data to review the in-
cidence of depression and suicidal behaviour spontaneously re-
ported for 110 different drugs, including varenicline. Varenicline
was ranked first for the number of reports per million prescrip-
tions for depression (248, 95% CI 233 to 264), second behind
paroxetine for non-fatal suicidal behaviour (172 per million, 95%
CI 159 to 185), and sixth for completed suicide behind clozapine,
citalopram, fluoxetine, paroxetine and venlafaxine (10 permillion,
95% CI 8 to 14).
Three recent retrospective cohort studies have reported on the in-
cidence of psychiatric events, criminal offending and traffic ac-
cidents and offences (Molero 2015), on cardiovascular and neu-
ropsychiatric events in users of varenicline (Kotz 2015), and on
neuropsychiatric events in varenicline compared with NRT users
in the Military Health System (Meyer 2013). The Swedish study
(Molero 2015) reviewed a cohort of 7,917,436 adults, of whom
69,757 had been treated with varenicline between 2006 and 2009.
They found that varenicline use was not associated with suici-
dal behaviour, with criminal offending, with traffic accidents or
offences, or with psychoses. There were, however, marginally in-
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creased risks of anxiety (hazard ratio (HR) 1.23, 95% CI 1.01 to
1.51) and of mood conditions (HR 1.31, 95% CI 1.06 to 1.63) in
people with a pre-existing psychiatric disorder. In those without
an existing psychiatric disorder, the risks were elevated but not sta-
tistically significantly different. In the English study (Kotz 2015),
data from 753 NHS general practices were reviewed to compare
recipients of NRT (106,759; the reference group) with users of
varenicline (51,450) and bupropion (6557), for the incidence of
neuropsychiatric and cardiovascular events. Varenicline was not
associated with an increased risk for any neuropsychiatric condi-
tions, compared with NRT users. The hazard ratio for depression
was 0.66 (95% CI 0.63 to 0.69), and for self harm 0.56 (95% CI
0.46 to 0.68), compared with rates in NRT users. However, note
comments below on this study and the Thomas 2013 data. Meyer
2013 compared propensity-matched cohorts of people prescribed
varenicline or NRT (10,814 in each group) within the American
military system for rates of hospitalisation for neuropsychiatric
events within 30 days of prescription. The adjusted HR at 30 days
was 1.14 (95% CI 0.56 to 2.34), and at 60 days 1.11 (0.59 to
2.10), indicating no evidence for an elevated risk of hospitalisa-
tion among varenicline users compared with those taking NRT
(reference group).
In contrast with these broadly reassuring findings, Moore 2011
used the FDA’s Adverse Events Reporting System (AERS) to assess
the occurence of suicidal behaviour or depression in 9575 case re-
ports of varenicline use, and in 1751 case reports of bupropion use
for smoking cessation. They concluded that varenicline was linked
to a steep increase in depression or self-injurious behaviours (OR
8.4, 95% CI 6.8 to 10.4) compared with NRT. While this report
highlights continuing concerns about safety, it must be noted that
inferences drawn from spontaneous reporting systems should be
treated with caution. Because of heightened media coverage and
FDA warnings, suicidal ideation or behaviour during varenicline
use may be more likely to be reported to the AERS than if the
patient exhibited the same features while on NRT, for example.
The FDA caution against ascribing a causal connection between
a drug and the event, pointing out that there is often insufficient
information on the report forms to evaluate the event, and that
not all adverse events will be reported to them: “Therefore, AERS
cannot be used to calculate the incidence of an adverse event in
the U.S. population” (FDA 2012). The limitations of this class of
data include potential confounding by indication (i.e. the patient’s
condition may predispose to higher rates of adverse event); under-
reporting; double-counting frommultiple sources; the use of con-
comitant medications; and lack of representativeness which limits
generalisability (Gibbons 2011). The Institute for SafeMedication
Practice (ISMP) has questioned whether a spike in routine reports
of serious adverse events for varenicline submitted to the AERS
in the third quarter of 2010 is associated with a delay in pass-
ing the information from Pfizer to the FDA, and with classifying
such events as “expected” rather than fast-tracking them (ISMP
2011). In light of the constraints of spontaneous reporting sys-
tems, Moore and colleagues compared reports submitted for NRT
use (to estimate baseline risks for smokers) with those submitted
for antibiotic use (as a proxy for population-based risks), which
indicated that smokers may already be at a fourfold-increased risk
of suicidal behaviour or depression, regardless of which cessation
aids they use. The authors recommended that varenicline should
not be offered as a first-line treatment for smoking cessation, and
noted that theVeteransAffairsCenter forMedicationSafety shared
this precautionary approach (VA 2011). It is notable, however,
that a matched observational study of more than 28,000 partici-
pants commissioned by the FDA and conducted by the VA Cen-
ter found no difference in rates of hospitalisation for psychiatric
events between users of NRT and users of varenicline; the hazard
ratio for varenicline versus NRT was 0.76; 95% CI 0.40 to 1.46
(FDA 2011a). A recent FDA Drug Safety Communication (FDA
2011a, October 2011) concludes that “Based on FDA’s assessment
of currently available data, the Agency continues to believe that
the drug’s benefits outweigh the risks and the current warnings in
the Chantix drug label are appropriate”.
Cardiovascular SAEs
Following the publication of Rigotti 2010 (testing varenicline in
people with stable cardiovascular disease (CVD)), the FDA issued
aDrug SafetyCommunication (FDA 2011b) advising that vareni-
cline may be associated with a small increased risk of certain car-
diovascular adverse events in people with CVD. A systematic re-
view of 14 trials (Singh 2011) claims that varenicline may increase
the risk of serious cardiovascular events among tobacco users, with
a meta-analysis yielding a Peto odds ratio of 1.72 (95% CI 1.09 to
2.71). While the authors describe this as “a 72% increased risk”,
it should be noted that the incidence of such events was low, at
1.06% in varenicline users and 0.82% in the placebo group, re-
turning an absolute difference of 0.24%, i.e. about 1 in 400. The
review has some acknowledged limitations, including the validity
of the classification of the cardiac events (unadjudicated, other
than those derived from the Rigotti trial); higher losses to follow-
up in the placebo groups, which may underestimate the true rate
of control events; and the choice of a Peto rather than a Mantel-
Haenszel odds ratio (the latter just missing statistical significance
[M-H OR 1.56, 95% CI 0.99 to 2.44]). The choice of a random-
effects rather than a fixed-effect model would also lower the point
estimate (OR 1.47, 95% CI 0.92 to 2.34). The assumption of
a baseline risk rate of 5.57% for cardiac adverse events in their
calculation of a number needed to treat for an additional harmful
outcome (NNTH) may also be questionable, since it is based on
the Rigotti study population of smokers with established cardiac
disease, while the event counts used to derive the odds ratio come
from trials which were mostly in unusually ’healthy’ trial partici-
pants.
These concerns were echoed by an observational prospective co-
hort study of dispensed prescriptions for varenicline in New
Zealand between April 2007 and November 2010 (Harrison-
Woolrych 2012). The study, conducted by the IntensiveMedicines
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Monitoring Programme, covered all patients who received vareni-
cline, and has so far identified 172 cardiovascular adverse events
within that cohort. Forty-eight of these were classified as myocar-
dial ischaemia (including 12 reports of myocardial infarction and
eight of angina), and 50 were classified as hypotensive events.
Within each of these two subgroups, the investigators considered
that two key cases may have been triggered by the use of vareni-
cline. Twenty-seven episodes of dysrythmia were also reported,
two of which culminated in sudden death; one was attributed to
pre-existing heart disease, while the other displayed no definitive
underlying cause. Although this cohort was subject to raised base-
line risks because of their smoking and to multiple confounding
factors, the authors speculate on possible mechanisms of dysreg-
ulation of blood pressure, which could have contributed to the
events.
A Danish cohort study (Svanström 2012) compared propensity-
matched cohorts of people prescribed varenicline or bupropion
(17,926 in each group) from 2007 to 2010 for rates of acute
coronary syndrome, ischaemic stroke, and cardiovascular death six
months from the start of treatment. The study found no excess of
events in the varenicline group (6.9 cases per 1000 person-years)
compared with the bupropion group (7.1 cases per 1000 person-
years). The hazard ratio (varenicline versus bupropion) for acute
coronary syndrome was 1.20 (95%CI 0.75 to 1.91), for ischaemic
stroke 0.77 (95% CI 0.40 to 1.48), and for cardiovascular death
0.51 (95% CI 0.13 to 2.02). The presence or absence of a history
of cardiovascular disease did not affect the overall findings.
The Kotz 2015 cohort study, briefly reported above, found signif-
icantly reduced risks of ischaemic heart disease (HR 0.80, 95%
CI 0.72 to 0.87), of cerebral infarction (HR 0.62, 95% CI 0.52
to 0.73), of heart failure (HR 0.61, 95% CI 0.45 to 0.83) and of
arrhythmia (HR 0.73, 95% CI 0.60 to 0.88) in varenicline users
compared to NRT users.
A recent systematic review and meta-analysis (Sterling 2016) of
varenicline and cardiovascular serious adverse events included 38
RCTs (12,706 participants) published up to 2015, and found no
evidence of an association, in people with (RR 1.04, 95% CI 0.57
to 1.89) or without (RR1.03, 95%CI 0.64 to 1.64) cardiovascular
illness. This study also analysed all-cause mortality, and found no
difference between the varenicline and placebo groups (RR 0.88,
95% CI 0.50 to 1.52).
We await results from the CATS study (NCT01574703), con-
ducted among participants in the EAGLES 2016 study, and de-
signed to monitor the incidence of major cardiovascular events
(MACEs) for 28 weeks after the completion of the EAGLES 2016
trial. The CATS study was completed in July 2015, and is expected
to report later this year.
Overall completeness and applicability of
evidence
We have followed standard Cochrane methodology to perform
this update. Figure 3 (a funnel plot of the main analysis) appears
to identify a lack of smaller trials with negative findings. However,
the earliest studies in this review were reported in 2006, and we
are reasonably confident that the licensing and subsequent trials
have been routinely registered online in clinical trials registries.
The absence of negative studies may be more a marker of sustained
efficacy than of the suppression or selective management of data.
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Figure 3. Funnel plot of comparison: 4 Varenicline (1.0 mg 2/d) vs placebo, outcome: 4.1 Continuous or
sustained abstinence at longest follow-up (24+ weeks).
Varenicline’s efficacy for smoking cessation is nowwell established,
with the point estimate remaining unchanged as more studies (in-
cluding non-Pfizer trials) accumulate. Trials are now being con-
ducted and reported in patient groups originally excluded from the
earlier studies, and more flexible regimens appear not to compro-
mise levels of efficacy. However, concerns about possible adverse
events in vulnerable individuals mean that varenicline is unlikely
to be made available as an over-the-counter option, or outside the
supervision of a health professional. The costs of treatment have
hitherto restricted usage to high-income countries, although trials
are increasingly being conducted in low- andmiddle-income coun-
tries. Cytisine, an unlicensed treatment in the European Union
and the USA, is an affordable alternative available in parts of East-
ern Europe and Russia, and for online purchase worldwide, and
may have the potential to meet the needs of smokers wishing to
quit in areas of economic constraint.
Quality of the evidence
We judge the current evidence from the cytsine trials to be of low
quality, meaning that we have limited confidence in the evidence;
only two trials contribute to themeta-analysis, with relatively small
numbers taking part. We rated the evidence from studies com-
paring varenicline with placebo and bupropion as comparators as
being of high quality, i.e. reliable and robust. We rate the evidence
from studies that compared varenicline with NRT as moderate
quality (i.e. we are reasonably confident of the stability of the evi-
dence), since three of them were non-blinded open-label trials.
Potential biases in the review process
We have delayed publication of this update in order to be able to
report on the EAGLES 2016 trial. Our information on that trial
has been drawn from the trial registry summary (NCT01456936)
with results posted on May 3rd 2016, from Society for Research
on Nicotine and Tobacco (SRNT) conference abstracts, from a
presentationmade at the SRNTconference inChicago (March 3rd
2016), from correspondence with the Pfizer Medical Information
Department, and from the in-press release of the initial findings in
The Lancet. Further results as they become available may moderate
our findings in this update.
The comprehensive searches for this update are current to May
2015. Since May 2015 we have checked the status of all on-
going studies, and have generated monthly routine searches of
PubMed (keywords ’varenicline’ and ’cytisine’) to identify any ad-
ditional relevant research. Studies collected in this way include
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Baker 2016; EAGLES 2016; Ebbert 2015; Eisenberg 2016; Hajek
2015; Westergaard 2015. However, we cannot vouch for the com-
pleteness of the evidence base beyond the May 2015 search date,
and may have missed some relevant reports or developments.
All the varenicline trials reported in this review apart from seven
(Carson 2014; De Dios 2012; Heydari 2012; Nahvi 2014a; Rose
2013; Stein 2013; Tsukahara 2010)were funded and/or supported
by Pfizer Inc, the manufacturers of varenicline. Evidence from
systematic reviews suggests that industry-funded trials, although
conducted to a high standard, are more likely to have outcomes
favourable to the product sponsor than studies with other spon-
sors (Etter 2007; Walsh 2011). However, a sensitivity analysis re-
moving them from the main analysis made no difference to the
result. Future updates of this review are increasingly likely to cover
findings from community-based independently-conducted trials.
Although we have reported information from studies other than
RCTs for the incidence and likelihood of adverse events and se-
rious adverse events, it is important to acknowledge the risks of
relying upon evidence from cohort studies, surveys, and prescrip-
tion event-monitoring data. There is, for example, evidence from
observational studies (Kotz 2015; Thomas 2013) of residual con-
founding contributing to the observed reductions in the hazard
ratios for depression and death. The lower rates in the varenicline
users are attributable not to a protective effect conferred by the
treatment but to baseline differences between the varenicline and
NRT cohorts; the former were healthier, wealthier and younger
(Davies 2015). The Thomas 2015 study (see below), based on 39
RCTs, found no significant reductions in depression, self harm or
death rates, compared with placebo.
Agreements and disagreements with other
studies or reviews
Reviews of controlled studies of cytisine (Etter 2006; Etter 2008;
Tutka 2005; Tutka 2006; Tutka 2008) have focused upon its po-
tential as an established and affordable aid to smoking cessation.
Many of the early cytisine studies excluded from this review are
discussed and evaluated in Etter 2006. A recent systematic review
and network meta-analysis (Leaviss 2014) has compared the effi-
cacy and cost effectiveness of cytisine (two trials: Vinnikov 2008;
West 2011) versus varenicline (21 trials). While the analysis found
both treatments to be effective for smoking cessation, cytisine de-
liveredmore quality-adjusted life-years at a lower cost than vareni-
cline. Cytisine was also associated with lower rates of headache
and nausea than varenicline.
A Cochrane overview and network meta-analysis of a number
of pharmacological interventions for smoking cessation (Cahill
2013) assessed 12Cochrane reviews published toNovember 2012,
and therefore drew on the previous version of this review. Compar-
isons between varenicline, bupropion and single-treatment NRT
found varenicline to be superior to both treatments (OR 1.59;
95% credible interval 1.29 to 1.96, and OR 1.57, 95% credi-
ble interval 1.29 to 1.91 respectively). Varenicline demonstrated
comparable efficacy to combination NRT (OR 1.06, 95% credi-
ble interval 0.75 to 1.48), but the number of NRT trials inform-
ing this comparison was low (nine trials). The direct comparisons
between varenicline and placebo, varenicline and bupropion and
varenicline and NRT reported in the EAGLES 2016 trial con-
firmed in all cases the network results of the same comparisons in
Cahill 2013. A 2012 network meta-analysis (Mills 2012), com-
paring high-dose and combination NRT versus varenicline and
versus bupropion across 146 RCTs, found varenicline (11 trials)
to be superior to placebo and to bupropion at all time points, and
similar in efficacy to standard and to high-dose NRT.
Attention in recent years has tended to shift from efficacy (now
clearly established) to adverse and serious adverse events. A meta-
analysis of gastrointestinal adverse events associated with vareni-
cline use in 12 RCTs (Leung 2011) found that the drug produced
higher rates of nausea (NNTH of 5), constipation (NNTH of
24), and flatulence (NNTH of 35). Another meta-analysis in 12
RCTs of adverse effects during varenicline use (Drovandi 2015)
found elevated rates of discontinuation attributable to adverse ef-
fects (OR 1.47, 95% CI 1.19 to 1.81) among the varenicline users
compared to placebo, and higher rates of nausea, insomnia and
headache. Since publication of the Singh 2011 systematic review, a
number of other meta-analyses and commentaries have addressed
the risks of cardiovascular adverse events associated with vareni-
cline usage. Two reviews which covered largely the same research
as the Singh review did not demonstrate a statistically significantly
raised event rate for cardiovascular disorders (Prochaska 2012, 22
studies; Ware 2013, 15 studies); the discrepancies were attributed
by the Singh team to differences in interpretation of the outcomes
and to modifications to the statistical computations. Mills 2013, a
networkmeta-analysis of 63 RCTs of NRT, bupropion and vareni-
cline, found no elevated risk of serious cardiovascular events asso-
ciated with any of the treatments, although trials of NRT demon-
strated an increased risk for less serious events. The RR for major
adverse cardiovascular events (MACEs) in varenicline compared
with placebo was 1.34 (95% credible interval 0.66 to 2.66; 18
trials).
Thomas 2015 is a systematic review and meta-analysis of 39 RCTs
(10,761 participants), assessing the risk of neuropsychiatric ad-
verse events among users of varenicline. The authors found no
evidence of an increased risk of suicide or attempted suicide (Peto
odds ratio (OR) 1.67, 95% CI 0.33 to 8.57), suicidal ideation
(Peto OR 0.58, 95% CI 0.28 to 1.20), depression (Peto OR 0.96,
95% CI 0.75 to 1.22) or death (Peto OR 1.05, 95% CI 0.47 to
2.38) associated with varenicline. There was no evidence that the
risk of depression and suicidal ideation differed by age, sex, ethnic-
ity, smoking status, the presence or absence of psychiatric illness,
or study sponsorship. This analysis included varenicline prescribed
for any indication; our own analyses of depression (Analysis 10.5)
and suicidal ideation (Analysis 10.6) use most of the same studies
(including nine trials which did not contribute to our efficacy anal-
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yses), but we have dropped six trials which did not target smoking
cessation, and have included four studies not then available to the
Thomas team (Carson 2014; Ebbert 2015; Hajek 2015; Nahvi
2014a).
Because they are relatively rare, the incidence of serious neuropsy-
chiatric events associated with varenicline has tended to be exam-
ined through retrospective cohort studies and prescription event
monitoring studies, rather than through randomised trials, and
has been considered in the Discussion section above. Gibbons
2013 is a re-analysis of SAE neuropsychiatric data from 17 RCTs
of varenicline, stratifying by the presence or absence of psychi-
atric disorders. The analysis found no excess of suicidal thoughts
or behaviour in the varenicline group without psychiatric disor-
ders (0.47 events per 1000, compared with 1.46 per 1000 in the
placebo group), nor in the varenicline group with a history of psy-
chiatric disorders (14.57 events per 1000, compared with 15.39
per 1000 in the placebo group). No suicides were reported in any
of the groups. The same study also analysed a Department of De-
fence data set comparing events in a varenicline cohort (19,933
people) versus a cohort of NRT users (15,867 people) between
August 2006 and August 2007 (i.e. before the FDA issued a black-
box warning). Rates of neuropsychiatric events in this cohort were
2.28% for varenicline and 3.1% for nicotine patch.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
• Varenicline at standard dosage (1.0 mg twice a day)
increased the chances of successful long-term smoking cessation
by more than two-fold compared with pharmacologically
unassisted quit attempts.
• Varenicline at reduced dosage remained an effective aid to
smoking cessation, delivering success rates similar to those
achieved with nicotine replacement and bupropion, and
appearing to reduce the impact of adverse events in the early
weeks of treatment.
• More people quit successfully with varenicline than with
bupropion.
• Eight trials of varenicline versus nicotine replacement
therapy indicate a modest but unequivocal benefit for varenicline.
• Limited evidence suggests that varenicline may have a role
to play in relapse prevention.
• The most commonly reported adverse effect of varenicline
is nausea, but mostly at mild to moderate levels and tending to
subside over time.
• Users of varenicline may have an elevated risk of any serious
adverse event, with rates about 25% higher than in those not
using the drug.
• Evidence from randomised controlled studies does not
confirm a causal link between varenicline and psychiatric adverse
events in people without a history of psychiatric disorders.
• The evidence is less clearcut for the relationship between
varenicline and neuropsychiatric events in people with past or
current psychiatric disorders. The largest RCT suggests there
may be up to a 4% increased risk of moderate-to-severe
neuropsychiatric events in smokers with psychiatric disorders
taking varenicline, compared with a 1.5% increased risk in
smokers without these disorders. These estimates are also
consistent with no increased risk in either cohort.
• The imminent publication of data from a large recent trial
should provide more definitive data on how varenicline may
impact on major cardiovascular events.
• Cytisine was shown to be effective and affordable, although
absolute quit rates were modest.
• Dianicline was no more effective than placebo in helping
smokers to quit. Development of the drug has been suspended
by the manufacturers.
Implications for research
• Further varenicline trials may be useful in disorder-specific
groups of patients, excluded from the earlier trials.
• Future trials should continue to investigate the long-term
success of extended treatment compared with standard 12-week
treatment.
• The incidence of serious adverse events should continue to
be monitored through controlled trials, and described with
greater precision than is currently reported.
• Further exploration of safety issues in people with past or
current psychiatric disorders may still be warranted.
• Additional trials of cytisine are needed to explore variations
in the drug regimen and in the level of behavioural support
needed to boost quit rates.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [author-defined order]
Scharfenberg 1971
Methods Country: East Germany
Aim: To test the efficacy of cytisine for smoking cessation
Setting: smoking cessation clinic, Magdeburg, July-December 1967
Study Design: double-blind placebo-controlled randomised trial
Analysis: Chi squared test (P < 0.1)
Participants 1214 smokers recruited from 1452 applicants through smoking clinics and via initial
press releases. 88.2% M. 2.5% of participants smoked < 10 CPD, 42.4% 10 - 20 CPD,
48.9% 21 - 30 CPD, 5.2% > 30 CPD 40.4% had smoked > 20yrs. 40.6% had tried to
quit at least once before.
Randomised to cytisine (607) or placebo (607)
Exclusion criteria not stated (214 volunteers excluded at initial screening)
Interventions 1. 20-day course of cytisine. 1.5 mg tabs: Days 1 - 3 6/day; days 4 - 12 5/day; days 13 -
16 4/day; days 17 - 20 3/day.
2. Placebo tablets, same regimen
Behavioural support: None
Outcomes Self-reported abstinence at 4 wks, 6m and 2 yrs
ITT analysis. Attrition rate 34% by longest follow-up
Treatment type Medication: CYTISINE [TABEX]
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk not stated
Allocation concealment (selection bias) Unclear risk “a numbered pouch”
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk not stated
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk not stated
Selective reporting (reporting bias) Unclear risk not stated
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Vinnikov 2008
Methods Country: Kyrgyzstan
Setting: Mining company (Kumtor Operating Company)
Aim: To test the efficacy and safety of cytisine for smoking cessation in a workplace
setting
Study Design: Double-blind placebo-controlled parallel-group RCT
Analysis: Logistic regression used to assess influence of cytisine use, age, weight, CPD,
smoking duration, previous quit attempts, FTND score and exhaled CO levels
Participants 197 adult smokers, aged 20+, smoking at least 15 CPD, no prior use of cytisine, and
motivated to quit Randomised to cytisine (100) or placebo (97). 26 (15 cytisine, 11
placebo) who took no medication were excluded from trial report
97% men, mean age 39, mean CPD 22, mean FTND 5.3, 86% had tried to quit
previously; mean previous quit attempts 3.3
Exclusion criteria: Standard pharmacotherapy trial criteria
Interventions Tabex tablets (1.5 mg cytisine):
1. First 3 days: 6 tabs per day; reduce smoking by half
2. Days 4 - 12: 5 tabs per day; stop smoking completely
3. Days 13 - 16: 4 tabs per day
4. Days 17 - 20: 3 tabs per day
5. Days 21 - 22: 2 tabs per day
6. Days 23 - 25: 1 tab per day
Placebo tablets, same regimen
Treatment period was 25 days, with TQD Day 5. All participants received “behavior
counselling” (no further detail)
Outcomes Primary outcome: CO-validated CAR from Day 5 to wk 8
Secondary outcome: CO-validated CAR from Day 5 to wk 26
Validation was by expired CO ≤ 8ppm
Other outcomes: Change in health-related QoL measures, changes in body weight,
adverse events, SAEs
Attrition to 8 wks was 6 in cytisine group and 7 in placebo group; to 26 wks 10 in
cytisine group and 16 in placebo group
Treatment type Medication: CYTISINE [TABEX]
Notes New for 2012 update
Additional information supplied by the author
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Randomization was done by independent
statistician in an Excel programme and the
randomization keywas kept by an indepen-
dent person”
Allocation concealment (selection bias) Low risk See above
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Vinnikov 2008 (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Low risk “Nor patients neither investigators did not
know where Tabex and where placebo
were”; “follow-up was blind”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 26 participants who did not take a single
treatment dosewere excluded fromdenom-
inators by authors (restored to our MAs)
Selective reporting (reporting bias) Low risk Expected and predicted outcomes reported
West 2011
Methods Country: Poland
Setting: Smoking cessation clinic in Warsaw
Aim: To test the efficacy and safety of cytisine for smoking cessation with minimal
counselling and support
Dates conducted: December 2007 - September 2010
Study Design: Single-centre, double-blind placebo-controlled parallel-group RCT
Analysis: Power calculation (80%, alpha = 0.05, to detect a between-group difference of
6 percentage points for primary outcome)
Participants 740 healthy adults, smoking 10+ CPD, motivated to quit. Randomised to cytisine (370)
or placebo (370)
46.5% men, mean age 48, mean CPD 23, prior quit attempts 82%, mean FTND 6.2
Exclusions were current psychiatric disorder or any medical condition contraindicated
on cytisine label
Interventions Tabex tablets (1.5 mg cytisine):
1. First 3 days: 6 tabs per day
2. Days 4 - 12: 5 tabs per day
3. Days 13 - 16: 4 tabs per day
4. Days 17 - 20: 3 tabs per day
5. Days 21 - 22: 2 tabs per day
6. Days 23 - 25: 1 tab per day
Placebo tablets, same regimen
Treatment period was 25 days. Quitting advice, randomisation and drugs dispensed at
baseline visit; phone calls at TQD + 1 wk later (+ optional clinic visit). Clinic visit 4 wks
post-TQD, then phone calls at 6m and 12m, with visit to confirm abstinence if claimed.
Behavioural support was minimal, to simulate likelihood of real-world conditions in
countries where Tabex is available
Outcomes Primary: CO-validated abstinence 12m after end of treatment. Abstinence defined as
smoking < 5 cigs during preceding 6m, and none in week before visit
Secondary outcomes: sustained CO-validated abstinence at 6m follow-up; 2-wk PPA at
4 wks; 7-day PPA at 12m
Validation was expired CO < 10ppm
Attrition: 79 (cytisine) and 89 (placebo) participants were lost to follow-up over 12m.
Drug discontinuation or reduction rates similar in both groups: 6.2% for cytisine and
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West 2011 (Continued)
4.6% for placebo
Other outcomes: Adverse events, SAEs
Treatment type Medication: CYTISINE [TABEX]
Notes New for 2012 update
The trial was funded by theUKNational PreventionResearch Initiative, Cancer Research
UK, and the National Institute for Health Research
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “performed by a statistician at Sopharma,
who generated a list of study-group assign-
ments for 740 participants with nQuery
Advisor software. Assignments were made
in variable block sizes of either 20 (10 cyti-
sine, 10 placebo) or 10 (5 and 5)”
Allocation concealment (selection bias) Low risk See above
Blinding (performance bias and detection
bias)
All outcomes
Low risk “Trial staff and participants were unaware
of the group assignments and the random-
ization scheme”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Dropouts and attrition fully reported
Selective reporting (reporting bias) Low risk All expected and predicted outcomes re-
ported
Walker 2014
Methods Country: New Zealand
Setting: National Quitline
Aim: “a non-inferiority trial to investigate whether cytisine was at least as effective as
nicotine-replacement-therapy”
Study Design: parallel-group non-inferiority RCT
Dates conducted: March 2011 - February 2013
Analysis: Power calculation (90%, 1-tailed, alpha = 0.05) and assuming a 20% loss to
follow-up, to detect a 5% difference in 1-month quit rates; cytisine 1-month quit rate
was assumed to be 55%, with a non-inferiority margin of 5%
Participants 1310 daily smokers, callers to the NZ National Quitline, aged 18+, motivated to quit.
Allocated to cytisine (655) or to open-label NRT (655). Mean age 38, 57% women,
33% NZ Maori, mean CPD 19, mean FTND 5.4
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Walker 2014 (Continued)
Interventions All participants received standard Quitline support, i.e. average 3 x 10 - 15-minute calls
over 8 wks
1. 25-day course of cytisine (Tabex) tablets, + NRT vouchers in case they needed them
AFTER completing the cytisine course
2. Usual care, i.e. 8-week course of NRT (patch, gum or lozenge), tailored to dependence
level, supplied by vouchers
Outcomes Self-reported CAR (5 cigarettes or fewer) at 1m
CAR and 7-day PPA (no smoking) at 1 wk, 1m, 2m and 6m. Adverse events
Validation: None used
Treatment type Medication: CYTISINE [TABEX] / NRT OPEN-LABEL
Notes Funding by Health Research Council of New Zealand; cytisine supplied at no cost by
Sopharma
New for 2016 update
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “randomly allocated, by computer ... in a
1:1 ratio”
Allocation concealment (selection bias) Low risk “Randomization was stratified with the use
of minimization according to sex, ethnic-
ity (Maori, Pacific Islander, or non-Maori
and non-Pacific Islander), and cigarette de-
pendence, which was determined bymeans
of the Fagerström Test of Cigarette Depen-
dence, in which smokers were assigned to
one of two groups: those with scores of 5
or lower, indicating lower dependence, and
those with scores greater than 5, indicating
greater dependence”
Blinding (performance bias and detection
bias)
All outcomes
High risk “Participants and researchers collecting
outcome data were aware of treatment al-
location”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Losses fully reported. By 6m, 182 cyti-
sine participants (28%) lost to follow-up,
and 16 withdrawals; 173 NRT participants
(26%) lost to follow-up, and 14 with-
drawals. 19 cytisine users crossed over to
NRT, and 1 NRT user crossed over to cyti-
sine. ITT analyses conducted
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Walker 2014 (Continued)
Selective reporting (reporting bias) Low risk None noted
Other bias Unclear risk Cytisine was supplied free, while NRT
users had to pay a nominal charge (NZD 3
for an 8-wk course of each NRT item);
Duration of treatment differed (25 days vs
8 wks), but 1º outcome set to 1m to coun-
teract this
Tonstad 2011
Methods Countries: France, Spain, Belgium, Sweden, Denmark, Norway
Setting: 22 research centres
Aim: To test the efficacy and safety of dianicline for smoking cessation
Dates conducted: June 2006 - June 2007
Study Design: Double-blind placebo-controlled parallel group RCT
Study name: EURODIAN study
Analysis: Power calculation (72% - 99%, alpha = 0.05, for an OR of 2 - 2.4, given a
placebo quit rate of 7.5% - 15%); ITT denominators used
Participants 602 healthy adult volunteers, smoking 10+CPDwithin previous 2m, aged 18+; allocated
to dianicline (300), or placebo (302). 42% men, mean age 45, mean CPD 21, mean
previous quit attempts 3.4, mean FTND score 5.75. Treatment groups were comparable
at baseline
Exclusion criteria: Standard pharmacotherapy trial criteria, plus any quit attempt in
previous 3m, any use of bupropion, NRT, tobacco other than cigarettes 3+ times in
previous 3m
Interventions 1. Dianicline 40 mg bid for 7 wks (not titrated).
2. Placebo inactive tablets, same regimen
TQD was set for days 3 - 7 following baseline visit
All participants received standardised brief counselling (≤ 10 mins, based on Smoke-Free
and Living It) at each visit
Weekly visits throughout wks 1 - 7, then (for treatment completers) at wks 8, 10, 14,
18, 22 and 26 Smoking status and brief advice at each visit
Participants completed smoking diaries
Outcomes Primary outcome: CO-confirmed CAR for wks 4 - 7
Secondary outcomes: CO-confirmed CAR at 26 wks. PPA wks 4 - 7
Validation by expired CO < 10 ppm (all visits) and plasma cotinine ≤ 8µg/L (wks 4
and 7)
Other outcomes: adverse events, SAEs; craving and withdrawal symptoms
Dropouts and losses to follow-up were included in the analyses as continuing smokers
(ITT analysis)
25.2% dianicline and 23% placebo participants did not complete the study. AE-related
dropouts were 4.3% dianicline and 7.6% placebo
Treatment type Medication: DIANICLINE
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Tonstad 2011 (Continued)
Notes New for 2012 update
The trial was funded by Sanofi-Aventis. “The sponsor did not play a role in writing of
the manuscript”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “a predefined, central, and computer-gen-
erated randomization accessed through an
InteractiveVoiceResponse Systemassigned
participants on a 1:1 ratio”
Allocation concealment (selection bias) Low risk See above
Blinding (performance bias and detection
bias)
All outcomes
Low risk “Participants and investigators were
blinded to drug treatment assignments”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Dropouts fully reported
Selective reporting (reporting bias) Low risk All expected and predicted outcomes cov-
ered
Anthenelli 2013
Methods Country: USA (9 centres) and international (24 centres, across Bosnia & Herzogovina,
Croatia, Germany, Hungary, Romania, Russian Federation, Spain)
Setting: Academic clinical trial centres and smoking cessation clinics
Aim: To assess the efficacy and safety of 12 weeks of varenicline treatment or placebo for
smoking cessation, with 40 weeks of non-treatment follow-up, in adults with current or
past depression (MDD)
Study Design: Double-blind placebo-controlled RCT
Dates conducted: March 2010 - June 2012
Analysis: Power calculation of 250 in each arm (80%, alpha = 0.05) to detect an OR of
2.35, assuming a placebo efficacy rate of 7%
Participants 525 adult smokers, aged 18 - 75, smoking at least 10 CPD, motivated to quit, diagnosed
with unipolar MDD without psychotic features. 37% male, mean age 46, av CPD at
baseline 22, mean FTND 5.9. Allocated to varenicline (256) or placebo (269)
Exclusion criteria: Current or past diagnosis of dementia, schizophrenia, schizoaffective
disorder, or other psychotic disorder, bipolar I disorder, bipolar II disorder. People with
antisocial, schizotypal, or any other personality disorder severe enough to compromise
their ability to comply with the study requirements
Current use of either bupropion or nortryptiline
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Anthenelli 2013 (Continued)
Interventions 1. Varenicline 1 mg x 2/day, titrated for first wk
2. Placebo inactive tablets, same regimen
All participants received manual-guided SC support, telephone support and one-to-one
10-minute counselling by the same person where possible. Participants in both groups
could reduce the dosage if they wished
TQD was set for wk 1 visit
Treatment period was 12 wks. Visits at screening, baseline, weekly for wks 1 - 12, and
then at wks 13, 16, 24, 32, 40, 52 (or early termination); phone calls at wks 14, 20, 28,
36, 44 and 48. Weekly pill counts to assess adherence
Safety data were reviewed regularly by an external independent data safety monitoring
committee
Outcomes Primary: CO-confirmed CAR for wks 9 - 12
Secondary: CO-confirmed CAR for wks 9 - 24, 9 - 52; 7-day PPA at wks 12, 24, 52;
AEs and SAEs
Verification: CO < 10 ppm
Treatment type Medication: VARENICLINE
Notes New for 2016 update
Funding by Pfizer; Dept of VA merit review award; NIAAA grant
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Eligible participants were randomly as-
signed to varenicline or placebo in a 1:1 ra-
tio by using a computer generated, 4-block
randomization scheme at each site.”
Allocation concealment (selection bias) Low risk “Randomization was stratified by antide-
pressant medication use at baseline (any vs.
none) and baseline Montgomery-Åsberg
Depression Rating Scale (MADRS) score
(11 vs. 11) (32). Investigators obtained par-
ticipant identification numbers and ran-
domized study drug assignments by using
a Web-based or telephone call-in comput-
erized drug management system.”
Blinding (performance bias and detection
bias)
All outcomes
Low risk “The study drug was supplied in blinded
bottles by the sponsor to the study sites,
where they were dispensed according to
computerized instructions.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk 68.4% of varenicline group completed
study (lost 15.6% in treatment and 16% in
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Anthenelli 2013 (Continued)
follow-up); 66.6% of placebo group com-
pleted study (lost 21.9% in treatment and
11.5% in follow-up)
Selective reporting (reporting bias) Low risk None noted
Other bias Low risk None noted
Aubin 2008
Methods Country: Belgium, France, Netherlands, UK, USA
Setting: 24 research centres
Aim: To compare the efficacy of varenicline with nicotine patch, both open-label
Dates conducted: January 2005 - June 2006
Study design: Open-label randomised trial
Analysis: Power calculation (90%, alpha = 0.05) based on expected OR of 1.75 at wk
12; logistic regression model including terms for treatment, centre and country
Participants Healthy adults, recruited from smoking cessation clinics or by local advertising, aged 18
- 75, weight > 45.5 kg, BMI 15 - 38, smoking ≥ 15 CPD. Varenicline arm 378, NRT
arm 379. Mean age 42.9, 49.2% men, 93% white. Mean CPD 22.7. Previous use of
nicotine patch 47.4%, previous use of bupropion 20%. Mean FTND 5.5.
Exclusion criteria: Standard pharmacotherapy trial criteria, + participants must not have
been in a varenicline trial in previous year, or used NRT in previous 6m
Interventions 1. Varenicline 1mg x 2/day for 12 wks, titrated 1st wk
2. Nicotine patch (21 mg wks 2 - 6, 14 mg wks 7 - 9, 7 mg wks 10 - 11)
No placebo control group
All participants received Clearing the Air S-H booklet at baseline, and brief counselling
(≤ 10 mins) at each clinic visit or by phone. TQD was at wk 1 visit. Weekly visits
throughout treatment phase, plus a phone call 3 days post-TQD
In follow-up phase, clinic visits at wks 13, 16, 24, 32, 40, 48 and 52, plus brief phone
calls at wks 14, 20, 28, 36 and 44
Outcomes CO-confirmed CAR for last 4 wks treatment (varenicline wks 9 - 12, NRT wks 8 - 11)
CO-confirmed CAR at wks 9 - 24 and 9 - 52 (varenicline) and 8 - 24 and 8 - 52 (NRT)
7-day PPA at EoT and at wks 24 and 52
Other outcomes: Weight change, withdrawal symptoms (using MNWS and mCEQ),
adverse events
Validation was by expired CO ≤ 10 ppm
Dropouts and losses to follow-up were included in the analyses as continuing smokers
(ITTanalysis) Attrition in treatment phasewas 17.3%varenicline, 20.3%NRT.Losses to
follow-up 17% in each group 65.7%of varenicline and 62.2%ofNRTgroups completed
study
Treatment type Medication: VARENICLINE / NRT OPEN-LABEL
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Aubin 2008 (Continued)
Notes The trial was funded by Pfizer Inc
New for 2008 update
Denominator used in trial report is all treated (V 376, Pl 370). We have used all ran-
domised [378/379], which tips the RR into statistical significance
Not included in main MA, as no placebo group
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Using a central computer-generated se-
quence”
Allocation concealment (selection bias) Low risk Central allocation
Blinding (performance bias and detection
bias)
All outcomes
High risk “Using an open-label design”
Incomplete outcome data (attrition bias)
All outcomes
Low risk “Missing CO data were assumed to be <
10 ppm provided other conditions were
met”, i.e. no NRT other than prescribed
patches. Missing = negative assumption re-
duced successes by 1 in each group
Selective reporting (reporting bias) Low risk All predicted outcomes fully reported, +
analysis by country and treatment centre
Other bias Unclear risk Different duration of regimens, but effect
sizes similar in last 4 wks of each course
Baker 2016
Methods Country: USA
Setting: 2 University sites in Wisconsin (Madison, Milwaukee)
Aim: To compare the efficacy of varenicline with nicotine patch, and with combination
NRT (C-NRT)
Dates conducted: May 2012 - November 2015
Study design: Open-label randomised trial (no placebo)
Analysis: Logistic regression, comparing varenicline and C-NRT arms against nicotine
patch (reference) arm. Power calculations based on detecting a 10% difference, with >
80% power; numbers required: patch 227, varenicline and C-NRT 387
Participants Healthy adults, recruited from participants in the ongoing Wisconsin Smokers Health
Study or by media and community outreach, aged 17+, smoking ≥ 5 CPD, motivated
to quit.
Varenicline arm 424, nicotine patch arm 241, combination NRT arm 421
Mean age 48.1, 47.9% men, 67% white. Mean CPD 17. Mean FTND 4.8
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Baker 2016 (Continued)
Exclusion criteria: Standard pharmacotherapy trial criteria, CO < 4 ppm, no suicide
attempts in previous 5 years, or current suicidal ideation,diagnosis or treatment of psy-
choses in previous 10 years
Interventions 1. Varenicline 1mg x 2/day for 12 wks, titrated 1st wk
2. Nicotine patch: 11+ CPD on 21 mg wks 1 - 8, 14 mg wks 9 - 10, 7 mg wks 11 - 12;
5 - 10 CPD on 14 mg wks 1 - 10, 7 mg wks 11 - 12
3. Nicotine patch as for (2), plus nicotine lozenge (2 mg or 4 mg), at least 5 times a day
for 12 wks
No placebo control group.
All participants received counselling (20 mins at visits 1, 2 and 3, and 10 mins by phone
and at visits 4, 5) at 1 week pre-TQD and at TQD, wks 1, 4, 12 post-TQD, plus phone
call at wk 8
In follow-up phase, participants were contacted at wks 26 and 52 by phone
Outcomes All comparisons were based on varenicline and C-NRT versus patch (reference arm),
and on varenicline versus C-NRT
CO-confirmed PPA at wk 26
CO-confirmed PA from day 7 post-TQD to day 181
CO-confirmed PPA at wks 4, 12, 52
Other outcomes: Adherence, withdrawals, adverse events
Validation was by expired CO ≤ 9 ppm and ≤ 5 ppm
Dropouts and losses to follow-up were included in the analyses as continuing smokers
(ITT analysis) Withdrawal rates were 8.3% varenicline, 6.2% nicotine patch, 3.1% C-
NRT
Treatment type Medication: VARENICLINE / NRT OPEN-LABEL
Notes The trial was funded by grant 5R01HL109031 from National Heart, Lung, and Blood
Institute, and by grant K05CA139871 from the National Cancer Insitute
New for 2016 update
Not included in the main MA, as no placebo group
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “computer-based randomisation”
Allocation concealment (selection bias) High risk “Treatment assignment was unblinded”
[open-label]
Blinding (performance bias and detection
bias)
All outcomes
High risk “Treatment assignment was unblinded”
[open-label].
“The follow-up telephone assessmentswere
intended to be blinded, but a database
search by interviewers could have revealed
treatment assignment”
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Baker 2016 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low rates of attrition, ITT analysis used
Selective reporting (reporting bias) Low risk All predicted outcomes reported, protocol
available
Other bias Low risk None noted
Bolliger 2011
Methods Countries: Brazil, Colombia, Costa Rica, Egypt, Jordan, Lebanon,Mexico, Saudi Arabia,
South Africa, United Arab Emirates, Venezuela
Setting: 42 research centres (51.2% Latin America, 30.6% Africa, 18.2% Middle East)
Aim: To test the efficacy and tolerability of varenicline in regions not previously exposed
to smoking cessation RCTs of varenicline
Dates conducted: April 2008 - August 2009
Study Design: Double-blind placebo-controlled RCT
Analysis: Power calculation (90%, alpha = 0.05); ITT denominators and logistic regres-
sion analysis (step-down procedure)
Participants 593 adults, recruited from smoking cessation clinics, aged 18 - 75, weight > 45.5 kg,
BMI 15 - 38, smoking ≥ 10 CPD, motivated to quit. Randomised to varenicline 394
(390 got medication), or placebo 199 (198 got medication). Mean age 43.5, 63.6%
men, mean CPD 23.8, mean FTND 6.0. 55% had no prior quit attempt
Exclusion criteria: Standard pharmacotherapy trial criteria, + participants must not have
used NRT, bupropion, clonidine or nortriptyline in previous 6m
Interventions 1. Varenicline 1mg x 2/day, titrated during wk 1
2. Placebo inactive tablets, same regimen
Treatment period was 12 wks. All participants received You can quit smoking self-help
booklet (available in English, Spanish, Portugese and Arabic) at baseline, and brief coun-
selling (≤ 10 mins) at each clinic or telephone contact. TQD set for wk 1. Clinic visits
at wks 2, 3, 4, 6, 8, 10 and 12 throughout treatment phase, plus a phone call 3 days
post-TQD
In follow-up phase, clinic visits at wks 13, 16, 20 and 24, plus brief phone calls at wks
14, 18 and 22
Outcomes Primary outcome: CO-validated CAR at 9 -12 wks
Secondary outcomes: CO-validated CAR at 9 - 24 wks; 7-day PPA at wks 12 and 24
Other outcomes: Adverse events, clinically significant changes in vital signs, SAEs.
Abstinence was assessed using the Nicotine-Use Inventory (NUI); validation was by
expired CO ≤ 10 ppm
Dropouts and losses to follow-up were included in the analyses as continuing smokers
(ITT analysis). [4 (V) 1 (P) who did not receive allocated intervention reincluded in
denominators in this analysis.] Attrition in treatment phase was 11.2% (V) and 20.6%
(P); in follow-up phase 2.5% (V) and 0.5% (P)
Treatment type Medication: VARENICLINE
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Bolliger 2011 (Continued)
Notes New for 2012 update
The study was funded and managed by Pfizer Inc
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Using a block randomization within each
site, eligible participants were randomly as-
signed in a 2:1 ratio to receive varenicline
or placebo”
Allocation concealment (selection bias) Low risk “a web-based or telephone call-in drug
management system directed by the spon-
sor”
Blinding (performance bias and detection
bias)
All outcomes
Low risk “All of the study personnel and participants
were blinded to treatment assignment un-
til the end of the nontreatment follow-up
phase”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Dropouts and attrition fully reported
Selective reporting (reporting bias) Low risk All predicted and expected outcomes re-
ported
Carson 2014
Methods Country: Australia
Setting: Respiratory, cardiology, neurology, vascular and general medicine wards of 3
Adelaide (South Australia) hospitals
Aim: To evaluate efficacy and safety of varenicline + quitline counselling vs quitline
counselling alone in people admitted with smoking-related acute illnesses
Study Design: Phase II/III open-label single-blind RCT
Dates conducted: August 2008 - December 2011
Power calculation: 196 participants per arm, based on a 15% difference (45% vs 30%)
at 52 wks, giving 80% power, 0.05 2-sided significance
Study name: Smoking Termination Opportunity for inPatients (STOP)
Participants 392 adult smokers, aged 18 - 75, smoking 10 CPD+, willing to quit, admitted with acute
smoking-related illnesses; randomised to varenicline + counselling (196) or counselling
alone (196)
Mean age 53, 32% women, 96%white, mean CPD 25, mean FTND 5.6, mean baseline
LoS 6.5 days
Exclusion criteria: Standard pharmacotherapy criteria, acute or pre-existing psychiatric
illness, history of psychosis or suicidal ideation, use of varenicline in past 12m
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Carson 2014 (Continued)
Interventions 1. Varenicline 1.0 mg x 2/d for 12 wks, including wk 1 at titrated dose (described as
standard MIMS dosing schedule), + counselling
2. Counselling only
Both groups received Quit SA 5A behavioural counselling, i.e. maximum of 8 calls over
3m. Also booklet Quit because you can, + stickers and fridge magnets. Participants had
to set a TQD within 1st 2 wks
Contacts were attempted with all participants at days 3 and 5, wks 1, 2, 3, 4, 12 (EoT).
Additional contacts at wks 26 and 52
Outcomes Primary outcome: Self-reported CAR (< 5 cigs in total) (2 wks - 12m)
Secondary outcomes: CAR at 4, 12 and 26 wks. 7-day PPA each week for 1st 4 wks; crav-
ing; prevalence of I/P smoking; Reduced hospital bed utilisation; Reduction in health-
care costs
CO validation ≤ 10 ppm used only in “a random sub-set of subjects”
Treatment type Medication: VARENICLINE
Notes Partially funded by theDepartment of Respiratory Medicine, Queen Elizabeth Hospital,
Adelaide, SA; information based on unpublished data supplied by authors, + published
2014 study report
New for 2012 update (study ID was Smith 2012; changed for 2015 update)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “A pre-defined, central, computer-gener-
ated randomization sequence was used to
assign subjects in a 1:1 ratio to either 12
weeks of treatment with varenicline plus
Quitline-counseling or 12 weeks of Quit-
line-counseling alone.”
Allocation concealment (selection bias) Low risk “using opaque, sealed envelopes with con-
secutive numbers”
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Open-label design. Attempt at single-
blinding (statistical investigator). “Partici-
pants and investigators were not blinded to
treatment assignment”
“Randomization and allocation conceal-
ment were performed by respiratory staff
independent of the study”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk “Missing data from questionnaire (e.g., a
question missed when administering fol-
low-up) were randomly imputed via a com-
puter programme”
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84% varenicline completed the study at 52
wks, vs 82% in the placebo group
Selective reporting (reporting bias) Unclear risk None noted
Other bias Unclear risk None noted
Chengappa 2014
Methods Country: Pittsburgh, USA
Setting: 2 outpatient clinics, Western Psychiatric Institute and Clinic; and Dubois Med-
ical Regional Center, Pennsylvania
Aim: To assess the efficacy and safety of varenicline to assist in smoking cessation among
patients with bipolar disorder who were euthymic and motivated to quit smoking
Study Design: Double-blind placebo-controlled RCT
Dates conducted: February 2010 - March 2013
Analysis: Power calculation of 60 in each arm
Randomised placebo-controlled quadruple-blind trial
Participants 60 outpatient smokers with DSMIV-diagnosed bipolar disorder, aged 18 - 65, stable
state or on medication, willing to quit in the next 30 days, 10+ CPD; randomised to
varenicline (31) or placebo (29)
Mean age 46, 69% women, 66% white, mean CPD 18.1, mean FTND 6.2
Exclusions: Bupropion use (for SC); usual pharmacological criteria
Interventions 1. Varenicline 1 mg x 2/day, titrated for first wk
2. Placebo inactive tablets, same regimen
All participants received 15-minute SC counselling at each visit. CO tested and pill
counts at each visit. Participants in both groups could reduce the dosage if they wished.
TQD was set for wk 2 onwards (i.e. full dosage reached)
Treatment period was 12 wks. Weekly pill counts to assess adherence
Safety data were reviewed blind monthly by an external independent data safety and
monitoring board (DSMB)
Outcomes Primary: 7-day PPA, CO-verified, at 12 wks
Secondary outcomes: 7-day PPA at 24 wks; CA at 12, 24 wks
Validation: CO < 10 ppm
Treatment type Medication: VARENICLINE
Notes New for 2016 update
Funding from the National Insitute of Mental Health, and Pfizer
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Unclear risk Method not stated, other than “stratified
by gender”
Allocation concealment (selection bias) Unclear risk Not stated
Blinding (performance bias and detection
bias)
All outcomes
Low risk “The treatment assignment was blinded to
participating subjects, raters, investigators
and statisticians”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 24 participants in each group completed
treatment phase, and 24 (77%) and 20
(69%) completed full study in varenicline
and placebo groups respectively
Data were analysed using ITT with LOCF
Selective reporting (reporting bias) Unclear risk None noted
Other bias Unclear risk 8 participants (4 in each arm) were on
bupropion for depression; 3/15 varenicline
quitters and 1/3 placebo quitters were on
long-term bupropion
Cinciripini 2013
Methods Country: Houston, TX, USA
Setting: University of Texas MD Anderson Cancer Center
Aim: To assess the relative efficacy of varenicline and bupropion SR plus intensive coun-
selling on smoking cessation and emotional functioning
Study Design: Double-blind placebo-controlled RCT
Dates conducted: August 2006 - October 2007
Analysis: “our sample size provided adequate power for assessing our primary outcome
of prolonged abstinence at EOT (ie, ß= 0.99 for differences relative to placebo for
varenicline and ß = 0.84 for differences relative to placebo for bupropion SR) but modest
power for detecting drug group differences ( ß = 0.74).”
Participants 294 volunteer smokers, aged 18 - 65, 5+CPD, fluent in English, no uncontrolled chronic
illness, baseline CO > 6 ppm. Mean age 44, 39% women, 66% white, mean CPD 20,
mean FTND4.5, mean baseline CO 24.5 ppm. Allocated to varenicline (86), bupropion
(102) or placebo (106)
Exclusions: Usual pharma exclusions, current or history of psychotic disorder, moderate
or high risk of suicidality, contra-indications to varenicline or bupropion
Interventions 1. Varenicline: 12-week course (1 mg x 2/day) + non-active bupropion course (placebo)
2. Bupropion: 12-week course (150mg x 2/day) + non-active varenicline course (placebo)
3. Placebo: 12-week course (placebo pill x 2/day)
Blinded study physician could adjust dosages to reduce side effects if required throughout
study
All participants got intensive counselling, i.e. 6 x in-person 30-minute individual coun-
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selling sessions and 4 x 15-minute phone calls during treatment phase, based on MI
techniques. During follow-up, each participant got a 15-minute in-person visit at 3m
and 6m, and a 15-minute phone call at 4m
Outcomes Primary: PA at EoT
Secondary: PA at 3m post-quit, 6m post-quit; CA at 3m post-quit, 6m post-quit; 7-day
PPA at EoT, 3m post-quit, 6m post-quit
Validation: CO < 10 ppm. Self-reported abstainers were asked to send a salivary cotinine
sample (< 15 ng/mL) by post
Treatment type Medication: VARENICLINE and BUPROPION
Notes New for 2016 update
Funding: NIDA grant DA017073, NCI grant P50CA70907; varenicline supplied by
Pfizer
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Adaptive randomization (minimization)
was used to stratify the groups for sex, race/
ethnicity, history of depression, and base-
line smoking rate.”
Allocation concealment (selection bias) Unclear risk Not stated
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Study physician was blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Losses to treatment and follow-up re-
ported, and key variables with significant
differences (FTND, years of education)
identified between those who stayed in and
those who left. ITT analysis conducted.
By 6m, 21/86 for varenicline (24.4%), 29/
102 for bupropion (28.4%) and 30/106 for
placebo (28.3%) had been lost to follow-
up
Selective reporting (reporting bias) Unclear risk None noted
Other bias Unclear risk Study began as nortriptyline vs bupropion;
3 months later, 19 people had been re-
cruited to bupropion and 18 to placebo;
nortriptyline was replaced as the target
treatment by varenicline. The nortriptyline
phase group (cohort 1) had 19 days ofmed-
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ication and 3 counselling sessions before
TQD,whereas varenicline phase group (co-
hort 2) had 12 days of medication and 2
counselling sessions before TQD. No dif-
ferences were found between the 2 cohorts,
nor between overall findings and cohort 2
findings. Authors therefore combined both
groups into a single study cohort for anal-
ysis
De Dios 2012
Methods Country: Rhode Island and Massachussetts, USA
Setting: Butler Hospital, RI
Aim: To assess the relative efficacy of varenicline and NRT on smoking cessation in
Latino light smokers (< 10 CPD)
Study Design: Feasibility double-blind placebo-controlled 3-arm RCT
Dates conducted: April 2010 - July 2010
Analysis: No power calculation, as this was a pilot study with small sample size
Participants 32 Latino volunteer light smokers (≤ 10 CPD), aged 18+, willing to set a quit date.
Mean age 42, 53.1% women, mean CPD 7.6, mean FTND 2.9. Allocated to varenicline
(10), NRT (11), placebo (11)
Exclusions: Usual pharmacological conditions, on NRT or smokeless tobacco, history
of suicide attempts, chronic or acute psychiatric disorder, employed as a pilot, driver or
heavy machinery operator
Interventions 1. Varenicline 12-wk treatment course, titrated 1st wk
2. NRT 24-hour patch: 12 wks: 4 wks @ 14 mg, 8 wks @ 7 mg
3. Varenicline-placebo, i.e. identical tablet, same regimen
All participants received a 30-minute face-to-face “culturally informed” smoking cessa-
tion behavioural intervention, + a non-tailored self-help brochure, all available in both
English and Spanish. All participants were compensated for attendance, and could re-
ceive travel vouchers if necessary
Outcomes Primary: 7-day PPA at 6m
Secondary: 7-day PPA at wks 1, 2, 1m, 2m, 3m, 4m; adherence
Validation: CO < 5 ppm; salivary cotinine (not for the NRT group) > 10 mg/nL
Adverse events not reported in detail, although study reports that “There was no pattern
that suggested a higher side-effect profile for those in the varenicline group”
Treatment type Medication: VARENICLINE / NRT
Notes New for 2016 update
Funding: NCI grant R01CA0129226-S1 (De Dios); NIDA grant K24-DA000512
(Stein); NIDA grant R01-DA1234, NCI grant K07-CA95623 (Stanton)
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Unclear risk Not stated
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk “Study personnel and participants in the
two-pill groups (varenicline and vareni-
cline-placebo) were blinded to treatment
condition. The research pharmacy main-
tained the study blind.”
NRT group could not be blinded to treat-
ment; outcome assessment blinding not re-
ported
Incomplete outcome data (attrition bias)
All outcomes
Low risk Losses to follow-up were fully reported; per
protocol and ITT analyses conducted
Selective reporting (reporting bias) Unclear risk None noted
Other bias Unclear risk None noted
EAGLES 2016
Methods Countries: Argentina, Australia, Brazil, Bulgaria, Canada, Chile, Denmark, Finland,
Germany, Mexico, New Zealand, Russian Federation, Slovakiam South Africa, Spain,
USA
Setting: multiple research centres
Aim:To evaluate the efficacy of varenicline, bupropionSR, nicotine patch andplacebo for
smoking cessation, and to assess how far this is moderated by the presence of psychiatric
disorders
Dates conducted: November 2011 - January 2015
Study Design: Phase 4 triple-dummy, double-blind placebo-controlled parallel-group
RCT
Study name: EAGLES (Evaluating Global Events in a Global Smoking Cessation Study)
Participants Treatment-seeking adult smokers, aged 18 - 75, smoking at least 10 CPD, with exhaled
CO > 10 ppm at screening. Participants in the psychiatric disorder cohort had to have a
current or lifetime stable psychiatric diagnosis, confirmed by Structured Clinical Inter-
view for DSM IV disorders (SCID), i.e. no acute exacerbation in the previous 6 months,
no changes to treatment for 3 months, not imminently likely to change treatment, and
not at risk of self harm. Allocation for the pyshiatric cohort was balanced across four
diagnostic group disorders, i.e. mood, anxiety, psychotic, personality
44% men, mean age 46, mean CPD 20.7, mean FTND 5.8
Exclusions: Past or current diagnosis of schizophreniform or delusional disorders, all
delirium, dementia, and other cognitive disorders, and all substance-induced disorders
(other than nicotine)
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In the psychiatric disorders group, 70% had primary affective disorders, 19% anxiety
disorders, 9.5% psychotic disorders, 0.6% personality disorders, and at least were
taking psychotropic medications
Participants were grouped by the presence (4116) or absence (4028) of a history of
psychiatric disorders
Psychiatric disorders: varenicline 1032; bupropion 1033, NRT patch 1025, placebo
1026
No psychiatric disorders: varenicline 1005; bupropion 1001, NRT patch 1013, placebo
1009
Safety analyses were conducted in cohorts of 4074 (psychiatric) and 3984 (non-psychi-
atric)
Interventions 1. Varenicline, 1 mg x 2/day (1 wk titrated, then 11 weeks full dose)
2. Bupropion SR, 150 mg x 2/day (titrated for 3 days, then full dose for 11 weeks)
3. Nicotine patch, 21 mg x 7 weeks, 14 mg x 2 wks, 7 mg x 2 weeks (11 weeks)
4. Triple-dummy placebo for each arm of the trial (12 weeks)
All participants received counselling (up to 10mins) at all contacts, and were encouraged
to complete all visits even if treatment was discontinued
Participants were monitored at weeks 1 - 6, 8, 12, 13, 16, 20, 24; contacts were up to
15 face-to-face visits and 11 telephone visits
Outcomes At least 1 SAE of anxiety depression, feeling abnormal, or hostility, and/or moderate or
severe AE of agitation, aggression, delusions, hallucinations, homicidal ideation, mania,
panic paranoia, psychosis, suicidal ideation/behaviour/completed
4-week abstinence confirmed by CO < 10 ppm at wks 9 - 12, and 15-wk abstinence at
weeks 9 - 24
In the non-psychiatric cohort, 78.9% completed treatment, and 78.4% completed the
study
In the psychiatric cohort, 74.2% completed treatment, and 77.8% completed the study
Treatment type VARENICLINE / BUPROPION / NRT
Notes Trial was funded by Pfizer and GlaxoSmithKline
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “computer-
generated randomisation schedule ... using
a block size of 8 (1:1:1:1 ratio) for each of
the 20 diagnosis by region combinations”
Allocation concealment (selection bias) Low risk “Investigators obtained participant identi-
fication numbers via a web-based or tele-
phone call-in drug management system”
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Blinding (performance bias and detection
bias)
All outcomes
Low risk “Study product kit codes did not allow
deciphering of randomised treatment or
block size. As such, participants, investiga-
tors, and research personnel were masked
to treatment assignment”
“The triple dummy design feature re-
quired participants to take study medica-
tion as masked tablets dispensed in separate
varenicline and bupropion pill bottles each
with matching placebo along with with ei-
ther applying active or placebo patches on
a daily basis”
Incomplete outcome data (attrition bias)
All outcomes
Low risk All losses fully accounted for; ITT analysis
conducted throughout
Selective reporting (reporting bias) Low risk All protocol-reported outcomes were ad-
dressed
Other bias Low risk None noted
Ebbert 2015
Methods Country: 65 centres in 10 countries: USA (14), Australia (4), Canada (6), CzechRepublic
(7), Egypt (3), Germany (7), Japan (6), Mexico (4), Taiwan (7), UK (7)
Setting: Clinics, hospitals, academic research centres
Aim:Todetermine the efficacy and safety of varenicline for increasing smoking abstinence
rates through smoking reduction
Study Design: Double-blind placebo-controlled multinational RCT
Study name: Reduce to Quit
Dates conducted: July 2011 - July 2013
Analysis: “A sample size of 1404 randomized participants in a 1:1 ratio (702 in each
group) was estimated to provide 90% or more power to detect a difference between
varenicline and placebo of 10.3% in the primary end point of CAR during weeks 15
through 24, assuming a CAR of 17.2% for varenicline and 6.9% for placebo using a
2-group, continuity-corrected, 2-sided χ² test. A P value of .05 or less was considered
significant”
Participants 1510 adult smokers, unwilling to quit abruptly (within the next month), aged 18+,
smoking mean 10+ CPD, interested in trying to quit within 3 months. Mean age 44.
5, 43.7% women, mean CPD 20.7, mean FTND 5.5. Allocated to varenicline (760) or
placebo (750)
Exclusions: suicidal behaviour in previous 2 years or history of suicide attempts; major
depression, anxiety; diagnosis of psychosis, panic disorder, PTSD, schizophrenia
Interventions 1. Varenicline 24 wks, titrated 1st wk (12 wks to quit + 12 wks post-quit)
2. Placebo 24 wks, titrated 1st wk (12 wks to quit + 12 wks post-quit)
All participants asked to reduce their smoking rate by 50% by wk 4, by 75%+ by wk 8,
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and 100% by wk 12. Individual 10-minute counselling at each visit (18 face-to-face and
10 phone calls), + a copy of Clearing the air: quit smoking today.
Outcomes Primary: CAR at wks 15 - 24
Secondary: CAR at wks 21 - 24, 15 - 52, 21 - 52; 7-day PPA at wks 24, 52
Validation: CO < 10 ppm
Treatment type Medication: VARENICLINE
Notes New for 2016 update
Funding: Pfizer
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Participants were randomized to receive
varenicline or placebo for 24 weeks of treat-
ment in a 1:1 ratio using a computer gener-
ated block randomization schedule within
site”
Allocation concealment (selection bias) Low risk “Investigators obtained participant identi-
fication numbers and treatment group as-
signments through a web-based or tele-
phone call-in drug management system”
Blinding (performance bias and detection
bias)
All outcomes
Low risk “Participants, investigators, and research
personnel were blinded to randomization
until after the database was locked”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Losses fully reported. ITT analyses con-
ducted for efficacy (760 varenicline, 750
placebo), and treated denominators for
safety outcomes (751 varenicline, 742
placebo)
Selective reporting (reporting bias) Low risk None noted
Other bias Low risk None noted
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Methods Country: 40 centres in USA and Canada
Setting: Hospitals
Aim:Todetermine the efficacy and safety of varenicline for increasing smoking abstinence
rates through smoking reduction
Study Design: Double-blind placebo-controlled multicentre RCT
Study name: Evaluation of varenicline in smoking cessation for patients post-acute coro-
nary syndrome (EVITA)
Dates conducted: not stated
Analysis: “The sample size was estimated assuming a 7 day point prevalence abstinence
rate of 24% at 24 weeks in patients receiving placebo.With this assumption, 150 patients
per study arm would achieve a >80% power to identify a >15% absolute increase in
abstinence rates (24% to 39%) using a two-tailed α of 0.05”
Participants 302 adult smokers, aged 18+, smoking 10+CPD, interested in trying to quit, hospitalised
in USA or Canada for acute coronary syndrome (MI or unstable angina). Mean age 55,
25% women, mean CPD 21.5
Allocated to varenicline (151) or placebo (151)
Exclusions: Excessive alcohol, history of panic disorder, psychosis, bipolar disease, de-
mentia, renal or hepatic impairment, current or recent drug use, history of suicidal
ideation/attempt or family history of suicide
Interventions 1. Varenicline 12 wks, titrated 1st wk
2. Placebo 12 wks, titrated 1st wk
Medication was begun in hospital. All participants received low-intensity counselling
Follow-up at wks 1, 2 and 8 by phone, and clinic visits at wks 4, 12 and 24
Outcomes Primary: 7-day PPA at wk 24
Secondary: CAR at all follow-up visits, 7-day PPA at other follow-up visits, ≥ 50%
reduction in CPD
Measures of side effects and SAEs
Validation: CO ≤ 10 ppm
Treatment type Medication: VARENICLINE
Notes New for 2016 update
Funded by Pfizer
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Patients were randomized to either vareni-
cline or matching placebo... Randomiza-
tionwas performed by enrolling center per-
sonnel and stratified by center using a com-
puter-generated list of permuted blocks of
2 and 4”
Allocation concealment (selection bias) Unclear risk Not stated
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Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Described as “double-blind”, but no fur-
ther detail
Incomplete outcome data (attrition bias)
All outcomes
Low risk Losses fully reported; ITT analyses con-
ducted
Selective reporting (reporting bias) Low risk None noted
Other bias Low risk None noted
Evins 2014
Methods Country: USA
Setting: Massachussetts General Hospital and 9 other community mental health centres
in Massachussetts, Michigan, New Hampshire, Indiana, Alabama, Minnesota
Aim: To determine whether smokers diagnosed with schizophrenia and bipolar disease
have higher rates of prolonged tobacco abstinence with maintenance pharmacotherapy
than with standard treatment
Study Design: Double-blind placebo-controlled RCT
Dates conducted: March 2008 - April 2012
Analysis: “The study was powered to show differences between varenicline and placebo
for point-prevalence abstinence at week 52. Assuming a 35% to 40% relapse in the
varenicline group and a 75%to80%relapse in the placebo group, estimates based on trials
of bupropion involving smokers with schizophrenia, we estimated that 48 participants
per study group would provide 91% to 99% power and 40
patients per study group would provide 85% to 98% power to detect a treatment effect
using a 2-group Fisher exact test with a .05, 2-sided significance level”
Participants 247 outpatient smokers with schizophrenia, schizoaffective or bipolar disorder, aged 18
- 70, CPD 10+, 87 of whom met the abstinence criteria after 12 wks of open-label
varenicline to enter this relapse prevention trial. Randomised to varenicline (40) or
control (47). Mean age 48, 37% women, 74% white, mean FTND 5.9, mean CPD 23.
2
Interventions All participants had received 12wks open-label varenicline, andwere confirmed abstinent
at wks 11 and 12
1. Varenicline 1 mg x 2/day for a further 40 wks, + tapered CBT relapse prevention
counselling
2. Placebo, same regimen, i.e. CBT alone
Outcomes Primary: 7-day PPA at wk 52 (12 wks cessation treatment + 40 weeks relapse prevention
treatment);
Secondary: PPA and CAR at wk 64 (52 wks after achieving abstinence); effect of vareni-
cline on psychiatric symptoms (Calgary Depression Scale for Schizophrenia, Brief Psy-
chiatric Rating Scale, Schedule for Assessment of Negative Symptoms), nicotine with-
drawal symptoms (Wisconsin SmokingWithdrawal Scale), health-related quality of life
(SF-12), body mass index, and adverse events
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Validation: CO < 9 ppm
Treatment type Medication: VARENICLINE
Notes New for 2016 update
Funding: NIDA grant R01 DA021245, DHHS grant 05B1MACMHS, Pfizer
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Randomization was conducted via cen-
tralized computer-generated random se-
quence performed by Massachusetts Gen-
eralHospital research pharmacy staffmem-
bers, who were not otherwise involved in
the trial, in double-blind fashion, in blocks
of 4, stratified by study site and by a sin-
gle categorical predictor that was a combi-
nation of psychiatric disorder and type of
antipsychotic medication (eMethods 1 in
the Supplement), using a permuted block
design with 1:1 ratio”
Allocation concealment (selection bias) Low risk See above
Blinding (performance bias and detection
bias)
All outcomes
Low risk See above. “participants were followed up
for biochemically verified abstinence and
safety outcomes under double-blind con-
ditions through week 64”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Losses fully reported; by wk 52, 33/40
varenicline participants completed study,
and 28/42 placebo participants. ITT anal-
yses conducted
Selective reporting (reporting bias) Low risk None noted
Other bias Low risk “Telephone follow-up at week 76 for self
report of smoking behavior from those who
had achieved continuous abstinence from
weeks 12 through 64 was added to the
protocol after trial commencement to bet-
ter evaluate the duration of continuous ab-
stinence after discontinuation of mainte-
nance treatment.”
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Methods Country: USA
Setting: 19 research centres
Aim: To test the efficacy and safety of varenicline for smoking cessation
Dates conducted: June 2003 - April 2005
Study Design: Double-blind placebo-controlled parallel-group RCT
Analysis: Power calculation (90%, alpha = 0.05); ITT denominators and logistic regres-
sion analysis (step-down procedure)
Participants 1025 healthy adult volunteers, recruited through media advertising. Allocated to vareni-
cline (352), bupropion (329) or placebo (344). 54% men, 79% white, mean age 42.
4, mean CPD 21, mean FTND score 5.3. No significant differences between groups at
baseline
Exclusion criteria: Standard pharmacotherapy trial criteria, + use of tobacco products
other than cigarettes; use of NRT, clonidine, nortriptyline within last month; BMI < 15
or > 38 or weight < 45.5 kg; any prior use of bupropion or varenicline
Interventions 1. Varenicline 1 mg x 2/day
2. Bupropion 150 mg x 2/day
3. Placebo inactive tablets, same regimen
Treatment period was 12 wks. All participants received Clearing the Air self-help booklet
at baseline, andbrief counselling (≤ 10mins) at each clinic visit.Weekly visits throughout
treatment phase, plus a phone call 3 days post-TQD
In follow-up phase, clinic visits at wks 13, 24, 36, 44 and 52, plus brief phone calls at
wks 16, 20, 28, 32, 40 and 48
Outcomes Primary outcome: CO-validated CAR at 9 - 12 wks
Secondary outcomes: CO-validated CAR at 9 - 24 wks and 9 - 52 weeks; 7-day PPA at
wks 12, 24 and 52
Other outcomes: Weight change, withdrawal symptoms (using MNWS, QSU-brief and
mCEQ), adverse events
Validation was by expired CO ≤ 10 ppm
Dropouts and losses to follow-up were included in the analyses as continuing smokers
(ITT analysis) Attrition in treatment phase was 31.5%, losses to follow-up 16% of
treatment completers
Treatment type Medication: VARENICLINE / BUPROPION
Notes This trial had the same aims and study design as Jorenby 2006 The trial was funded by
Pfizer Inc.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “predefined ... computer-generated ran-
domization sequence”, 1:1:1, using block
size of 6, stratified by centre
Allocation concealment (selection bias) Low risk Central allocation
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Blinding (performance bias and detection
bias)
All outcomes
Low risk “Participants and in-
vestigators were blinded to drug treatment
assignments[, and] ... were not encouraged
to guess their treatment assignment”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Considered abstinent if, at next non-missed
visit, they reported no smoking... Missing
CO but otherwise OK considered absti-
nent, except at end of study, where all cri-
teria had to be present
Selective reporting (reporting bias) Low risk All expected and predicted outcomes cov-
ered
Other bias Unclear risk None noted
Gonzales 2014
Methods Country: 37 centres in 8 countries: USA (8), Australia (4), Belgium (4), Canada (4),
Czech Republic (4), France (3), Germany (5), UK (5)
Setting: Clinics, hospitals, academic research centres
Aim: To evaluate the efficacy and safety of retreatment with varenicline in smokers who
had taken varenicline for ≥ 2 weeks in a previous smoking cessation attempt
Study Design: Double-blind placebo-controlled multinational RCT
Dates conducted: December 2010 - November 2012
Analysis: “A sample size of 490 participants randomized to varenicline or placebo in a 1:
1 ratio was estimated to provide≥90% power for a comparison of varenicline vs. placebo
using a two-group continuity corrected two-sided χ² test at the 0.05 significance level
for the primary end point (CAR for weeks 9-12), assuming anOR of 3.36 with a placebo
CAR of 12% and a varenicline CAR of 31%. It was also estimated to provide 80% power
for the treatment comparison in the key secondary end point (CAR for weeks 9-52) for
an OR of at least 2.55 with a 6% CAR in the placebo group and 14% in the varenicline
group.”
Participants 498 adult smokers (varenicline 251, placebo 247) with previous use of 2+ wks of vareni-
cline at least 3m prior to screening, aged 18+, CPD 10+, motivated to quit. Mean age
47.5, 50.4% women, 93% white, mean CPD 20.5, mean FTND 5.5
Interventions 1. Varenicline 12 wks, titrated in 1st wk, 1 mg x 2/day
2. Placebo, identical regimen
Brief (< 10 mins) counselling at each contact. TQD set for wk 1 visit. Clinic visits at
wks 1, 2, 3, 4, 6, 8, 9, 10, 11, 12; 13, 16, 24, 32, 40, 48, 52. Brief phone calls at wks 5,
7, 14, 20, 36, 44. Dosage could be halved if intolerable
Outcomes Primary: CAR at wks 9 - 12, 9 - 52
Secondary: CAR at wks 9 - 24; 7-day PPA at wks 12, 24, 52
Validation: CO < 10 ppm
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Gonzales 2014 (Continued)
Treatment type Medication: VARENICLINE
Notes New for 2016 update
Funding: Pfizer
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Eligible participants were randomly as-
signed to receive either varenicline or
placebo at a 1:1 ratio for 12 weeks of drug
treatment using computer-generated block
randomization within each site”
Allocation concealment (selection bias) Unclear risk Not stated
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Not stated
Incomplete outcome data (attrition bias)
All outcomes
Low risk Losses to follow-up fully reported. ITT
analyses conducted
Selective reporting (reporting bias) Low risk None noted
Other bias Low risk None noted
Hajek 2015
Methods Country: UK
Setting: Specialist stop-smoking clinic in London
Aim: To determine whether increasing varenicline dose in people who show no response
to the drug improves treatment efficacy in terms of tobacco withdrawal relief and absti-
nence rates
Study Design: Double-blind placebo-controlled RCT
Dates conducted: July 2011 - February 2013
Analysis: ANOVA for continuous end points and X² for categorical end points. Sample
size of 200 for 80% power to detect a difference in 4-wk abstinence between 60% placebo
and 80% varenicline. 2-tailed P < 0.05
Participants 200 non-responders to varenicline at day 12, from an initial cohort of 503 given vareni-
cline while still smoking, randomised to varenicline (100) or placebo (100) add-on treat-
ment. Treatment-seeking smokers, aged 18+; 28% women, 65% white, mean age 45.8
yrs, 20.5 cigs in previous wk, mean FTND 5.5
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Hajek 2015 (Continued)
Interventions 503 eligible consented volunteers began taking varenicline at standard dosage; at day 12,
204were rated as non-responders (no strong nausea, no reduction in smoking enjoyment,
< 50% reduction in baseline smoking), and 200 were then randomised to additional
varenicline or placebo. All participants received phone calls on days 15 and 18, with
TQD at day 21 + phone call 24 hours later, and 4 x weekly supportive visits (as per
standard NHS stop-smoking treatment protocol). participants were invited to a 12-week
final visit for assessment
1. Varenicline: standard dose + initial increase of 0.5mg x 2/day which could be increased
by 0.5 twice daily up to a total of 5 mg/day. Dosage used at TQD was maintained for 3
wks, with an option to reduce it if necessary. From 4 wks, only standard dose was used
2. Placebo: same regimen, but with identical placebo pills
Outcomes Smoking enjoyment and withdrawal symptoms weekly for 1st 4 wks; CAR at wks 1, 4,
12 after TQD
Validation: CO < 9 ppm
Treatment type Medication: VARENICLINE
Notes Funding: Pfizer
Although this study did not assess abstinence beyond 3m, we have included it for assess-
ment of variation in dosing, and for safety data. We have not pooled the efficacy findings
with the other included studies, apart from sensitivity analysis 13.2 (CAR at 9 - 12 wks)
New for 2016 update
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Participants were randomized to treat-
ment arms using sequentially numbered
prepackaged medication containers boxed
according to a computer-generated ran-
domization list prepared by an indepen-
dent statistician”
Allocation concealment (selection bias) Low risk See above
Blinding (performance bias and detection
bias)
All outcomes
Low risk “The authors were unblinded only after the
data analysis was completed”
Incomplete outcome data (attrition bias)
All outcomes
Low risk All losses during treatment and follow-up
reported; ITT analyses conducted
Selective reporting (reporting bias) Low risk None noted
Other bias Low risk None noted
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Heydari 2012
Methods Country: Tehran, Iran
Setting: Smoking cessation clinics in the Tobacco Prevention and Control Research
Centre, Shahid Beheshti University of Medical Sciences
Aim: To evaluate the effectiveness of varenicline in the Iranian community of tobacco
quitters and compare it with other treatment methods
Study Design: 3-arm randomised parallel clinical study
Dates conducted: 2009 - 2010
Analysis: 91 participants per group were required
Participants 272 treatment-seeking participants: Brief advice (91), NRT (92), varenicline (89). 41.
2% women, mean age 42.5 yrs, mean FTND 5.5
Interventions All participantsweremanagedby the same physician. All received brief (5mins) education
and counselling at 4 x weekly sessions. TQD was day 14
1. Control group: no pharmacotherapy
2. NRT: 8 wks of 15 mg NRT patches
3. 8 wks of 1 mg x 2/day varenicline (titrated 1st wk)
Outcomes Abstinence at 6m and 12m, in person or by phone, verified by expired CO (cut-off value
not given)
Treatment type Medication: VARENICLINE / NRT
Notes Funding: Masih Daneshvari Hospital Research Institute, Tehran
New for 2016 update
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Smokers who attended the clinic for help
in quitting were divided randomly”
Allocation concealment (selection bias) Unclear risk Not stated
Blinding (performance bias and detection
bias)
All outcomes
High risk Open-label; blinding of outcome assessors
not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk No attrition: “Participants entered the
study of their own accord and none left the
study”
Selective reporting (reporting bias) High risk No information on potential differences
between phone- and in-person reporting of
abstinence at 6m and 12m, nor of whether
all such claims of abstinence were biochem-
ically verified
No information on SAEs, if any
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Heydari 2012 (Continued)
Other bias Unclear risk Participants were all previous quit-at-
tempters
Varenicline was given for 8 wks, i.e. of
the normal regimen, presumably to align it
with the NRT dosage pattern
Abstinence-by-gender data (Table 2) ap-
pears to contain an error for women on
NRT at 12m; we have ignored this finding
in favour of the combined-genders data
Jorenby 2006
Methods Country: USA
Setting: 14 research centres
Aim: To test the efficacy and safety of varenicline for smoking cessation
Dates conducted: June 2003 - March 2005
Study Design: Double-blind placebo-controlled RCT.
Analysis: Power calculation (90%, alpha = 0.05); ITT denominators and logistic regres-
sion analysis (step-down procedure)
Participants 1027 healthy adult volunteers. Allocated to varenicline (344), bupropion (342) or
placebo (341). 58%men, 84%white, mean age 43.3, mean CPD 22, mean FTND score
5.3. No significant differences between groups at baseline
Exclusion criteria: Standard pharmacotherapy trial criteria, + use of tobacco products
other than cigarettes; use of NRT, clonidine, nortriptyline within last month; BMI < 15
or > 38 or weight < 45.5 kg; any prior use of bupropion or varenicline
Interventions 1. Varenicline 1 mg x2/day
2. Bupropion 150 mg x2/day
3. Placebo inactive tablets, same regimen
Treatment period was 12 wks. All participants received brief counselling (≤ 10 mins) at
each clinic visit Weekly visits throughout treatment phase, plus a phone call 3 days post-
TQD
In follow-up phase, clinic visits at wks 13, 24, 36, 44 and 52, plus brief phone calls at
wks 16, 20, 28, 32, 40 and 48
Outcomes Primary outcome: CO-validated CAR at 9 - 12 wks
Secondary outcomes: CO-validated CAR at 9 - 24 wks and 9 - 52 wks; 7-day PPA at
wks 12, 24 and 52
Other outcomes: Weight change, withdrawal symptoms (using MNWS, QSU-brief and
mCEQ), adverse events
Validation was by expired CO ≤ 10 ppm
Dropouts and losses to follow-up were included in the analyses as continuing smokers
(ITT analysis) Attrition in treatment phase was 29.3%, losses to follow-up 8% of treat-
ment completers
Treatment type Medication: VARENICLINE / BUPROPION
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Jorenby 2006 (Continued)
Notes This trial had the same aims and study design as Gonzales 2006. The trial was funded
by Pfizer Inc
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “computer-generated list”
Allocation concealment (selection bias) Low risk “completed centrally ... and sites used an
electronic system to assign participants to
treatment”
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk “in a double-blind manner”
Incomplete outcome data (attrition bias)
All outcomes
Low risk CA for missed visits: if self-reported absti-
nent at next visit, assumed abstinent, ex-
cept at wk 52 visit when all criteria had to
be met
Selective reporting (reporting bias) Low risk All expected and predicted outcomes cov-
ered
Other bias Unclear risk None noted
Nahvi 2014a
Methods Country: USA
Setting: 3 urban outpatient clinics for substance use disorder (SUD) in the Bronx, NY
Aim: to test the efficacy and safety of varenicline for smoking cessation among opioid-
dependent people on a maintenance regimen
Study Design: Randomised quadruple-blind controlled trial
Dates conducted: August 2009 - September 2011
Analysis: 50 participants in each arm would give 80% power to detect a 22% abstinence
rate in the varenicline users (½ the expected rate in non-MM participants)
Participants 112 smokers in methadone treatment for substance abuse, aged 18+, CPD 5+, moti-
vated to quit within next 6m. Allocated 57 varenicline, 55 placebo. 52% women, 54%
Hispanic, mean CPD 15, mean FTND 4
Interventions All participants set a TQD 1 wk after treatment began. All were offered structured, brief
(≤ 10 mins) individual in-person counselling by a physician or tobacco specialist at
baseline and at 2-, 4-, 8- and 12-wk visits. All participants were also offered free quitline
support
1. Varenicline: 12-wk standard regimen, titrated for 1st wk
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Nahvi 2014a (Continued)
2. Control: Identical placebo tablets and regimen
Outcomes 7-day PPA at 12 and 24 wks
Validation: Expired CO < 8 ppm
Treatment type Medication: VARENICLINE
Notes Funding: National Center for Research Resources grant UL1 RR025750 to SN, and the
National Institute on Drug Abuse grants K23 DA025736 to SN and R25 DA023021
to SN and JHA
New for 2016 update
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Treatment group allocation was com-
puter-generated, and stratified by the three
clinic sites in blocks of six within each stra-
tum”
Allocation concealment (selection bias) Low risk “a central data manager concealed the al-
location sequence using a password-pro-
tected file, assigned subjects to treatment
groups and faxed pre-printed medication
orders to the study pharmacist. The phar-
macist prepared the research medication
by compounding varenicline tablets or
placebo lactose powder to create iden-
tical-appearing capsules. The pharmacist
marked medication bottles with subjects’
study identification numbers, and deliv-
ered medications for individual study sub-
jects to clinical sites, where they were dis-
tributed to each subject by the research as-
sistant”
Blinding (performance bias and detection
bias)
All outcomes
Low risk “The pharmacist prepared the research
medication by compounding varenicline
tablets or placebo lactose powder to create
identical-appearing capsules. The pharma-
cist marked
medication bottles with subjects’ study
identification numbers, and deliveredmed-
ications for individual study subjects to
clinical sites, where they were distributed
to each subject by the research assistant”
“All subjects, research assistants, counsel-
lors and physicians were blinded to treat-
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Nahvi 2014a (Continued)
ment assignment”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Losses during treatment (varenicline 6,
placebo 9) and during follow-up (vareni-
cline 2, placebo 3) fully reported; ITT anal-
yses conducted
Selective reporting (reporting bias) Low risk None noted
Other bias Low risk None noted
Nakamura 2007
Methods Country: Japan
Setting: 19 study sites
Aim: To test efficacy, safety and tolerability of 3 doses of varenicline over 12 wks
Dates conducted: not stated
Study Design: Double-blind, placebo-controlled, parallel group RCT
Analysis: Power calculation (90%, alpha = 0.05) for 0.5 or 1.0 mg vs placebo; ITT de-
nominators; also logistic regression (step-down) with dose and study centre as categorical
variables
Participants 619 healthy Japanese adult volunteers, aged 20 - 75, smoking ≥ 10 CPD. Allocated
to varenicline 0.25 mg x 2/day (153), 0.5 mg x 2/day (156), 1.0 mg x 2/day (156) or
placebo x 2/day (154). 1 participant withdrew before treatment, and is excluded from
ITT denominator. 1 RTA death removed from varenicline group at 52 wks
Participants stratified by level of nicotine dependence,measured byTobaccoDependence
Screener scale (≥ 5) and by FTND. 515 (83.3%) classified as nicotine dependent
Demographic data only supplied for nicotine-dependent group (515/618): 75% men,
mean age 39.8, mean CPD 24, mean FTND score 5.6
Exclusion criteria: Standard pharmacotherapy trial criteria, + use of NRT within last
30 days, use of pipe tobacco, snuff, chewing tobacco, cigars within last 30 days and
throughout trial
Interventions 1. Varenicline 0.25 mg x 2/day
2. Varenicline 0.50 mg x 2/day
3. Varenicline 1.00 mg x 2/day
4. Placebo tablet x 2/day
Treatment period 12 wks, 1st wk titrated dosage. All participants received a smoking
cessation booklet Clearing the Air at baseline, + brief counselling (≤ 10 mins) at each
clinic visit. Weekly visits throughout treatment phase, plus a 5-min phone call at TQD
and +3 days post-TQD
In follow-up phase, clinic visits at wks 13, 16, 24, 36, 44 and 52, plus brief phone calls
at wks 20, 28, 32, 40 and 48
Outcomes Primary outcome: CO-validated CAR at 9 - 12 wks
Secondary outcomes: CO-validated CAR at 9 - 24 wks and 9 - 52 wks; 7-day PPA at
wks 2, 12, 24 and 52
Validation was by expired CO ≤ 10 ppm
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Nakamura 2007 (Continued)
Other outcomes: Withdrawal symptoms (using MNWS, QSU-brief and mCEQ), ad-
verse events
Dropouts and losses to follow-up were included in the analyses as continuing smokers
(ITT analysis)
Attrition in treatment phasewas 6.4%, losses to follow-up11.4%of treatment completers
(excluding 1 death)
Treatment type Medication: VARENICLINE
Notes Trial was funded by Pfizer Inc
New for 2008 update
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “computer-generated list of random num-
bers”
Allocation concealment (selection bias) Low risk “randomized to 1 of the 4 treatment groups
in a 1:1:1:1 ratio using a central procedure”
Blinding (performance bias and detection
bias)
All outcomes
Low risk “double-blinding of subjects and investiga-
tors was maintained throughout the study”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No comment on level or handling of miss-
ing data
Selective reporting (reporting bias) High risk CARs for all participants reported, but de-
mographics, withdrawal and craving mea-
sures, and PPA for nicotine-dependent
group only
Other bias Unclear risk None noted
NCT00828113
Methods Randomised quadruple-blind placebo-controlled trial
Participants 101 adult smokers
Interventions All get 13 weeks varenicline, then half continue and half switch to placebo, until week
52
Outcomes Biochemically confirmed abstinence (at 52 weeks)
CO-confirmed at ≤ 10 ppm
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NCT00828113 (Continued)
Treatment type VARENICLINE
Notes Study results posted on clinicaltrials.gov June 2012, updated October 2015
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Unclear risk Not stated
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Stated to be quadruple-blind
Incomplete outcome data (attrition bias)
All outcomes
High risk High attrition rates: varenicline 30/50 (27
withdrawals, 3 lost), placebo 31/51 (26
withdrawals, 5 lost)
Selective reporting (reporting bias) High risk Results unpublished; available only on
www.ClinicalTrials.gov
NCT01347112
Methods Phase II/III randomised quadruple-blind placebo-controlled trial
Participants 33 adult alcohol-dependent smokers
Interventions Varenicline 1 mg bid for 12 weeks vs placebo
Outcomes Prolonged abstinence at 12 weeks (end of treatment), and at 6m
Abstinence self-reported, not biochemically confirmed
Treatment type VARENICLINE
Notes Study results posted on www.clinicaltrials.gov May 2014
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Unclear risk Not stated
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NCT01347112 (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Described as “double-blind”
Incomplete outcome data (attrition bias)
All outcomes
High risk High attrition rates: 4/16 varenicline group
(1withdrawal, 3 lost), 12/17 placebo group
(7 withdrawals, 5 lost)
Selective reporting (reporting bias) High risk Results unpublished; available only on
www.ClinicalTrials.gov
Other bias High risk Trial planned to include 70 participants,
but recruited only 33
Niaura 2008
Methods Country: USA
Setting: 5 research centres
Aim: To test the efficacy and safety of varenicline in smokers allowed to modify their
own dosage regimen
Dates conducted: December 2001 - June 2003
Study Design: Double-blind placebo-controlled RCT
Analysis: Power calculation (90%, alpha = 0.05); ITT denominators and logistic regres-
sion analysis (step-down procedure)
Participants 320 healthy adult volunteers, aged 18 - 65, smoking≥ 10 CPD. Allocated to varenicline
(160), or placebo (160)
52% men, 91% white, mean age 42, mean CPD 22, mean FTND score 5.4
Exclusion criteria: Standard pharmacotherapy trial criteria, + use of NRTwithin last 3m
Interventions 1. 0.5 mg varenicline ad lib, from 1 to 4 per day as wished
2. Placebo tablets ad lib, from 1 to 4 per day as wished
Treatment period 12 wks, 1st wk titrated dosage up to 0.5 mg x 2/day. All participants
received a smoking cessation booklet Clearing the Air at baseline, + brief counselling (≤
10 mins) at each clinic visit. Weekly visits throughout treatment phase
In follow-up phase, clinic visits at wks 13, 24, and 52 wks, plus monthly phone calls
between visits
Outcomes Primary outcome: CAR at 4 - 7, 9 - 12 and 9 - 52 wks
Validation was by expired CO ≤ 10 ppm
Secondary outcomes: CO-confirmed CAR at 9 - 24 wks; CO-confirmed 7-day PPA
Other outcomes: Meanmodal dosage; withdrawal symptoms (usingMNWS,QSU-brief
and mCEQ), adverse events
Dropouts and losses to follow-up were included in the analyses as continuing smokers
(ITT analysis)
Attrition in treatment phase was 22% in varenicline group and 29% in placebo group;
losses to follow-up by wk 52 were 36% from varenicline group and 43% from placebo
group
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Niaura 2008 (Continued)
Treatment type Medication: VARENICLINE
Notes The trial was funded by Pfizer Inc
New for 2010 update.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “randomly permuted blocks and a pseudo-
random number generator”
Allocation concealment (selection bias) Low risk “participants were assigned in a 1:1 ratio
to varenicline treatment or placebo in the
numerical order that they were accepted to
the study”
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk “double-blind” but no further information
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing data imputed if prior and subse-
quent abstinence confirmed, otherwise as-
sumed still smoking
Selective reporting (reporting bias) Low risk All expected and predicted outcomes cov-
ered
Other bias Unclear risk None noted
Nides 2006
Methods Country: USA
Setting: 7 research centres
Aim: To test efficacy, tolerability and safety of 3 doses of varenicline over 6 wks
Dates conducted: February 2000 - January 2003
Study Design: Phase 2 double-blind placebo-controlled RCT
Analysis: Power calculation (80%, 2-tailed, alpha = 0.05); Dunnett adjustment for mul-
tiple comparisons used for primary endpoint (CQR within treatment phase). ORs and
CIs least squares mean estimates. Not powered for varenicline/bupropion comparison
Participants 638 healthy volunteer smokers, aged 18 - 65, smoking at least 10 CPD on average. 48%
men, 87% white, av age 42, av CPD 20, mean FTND 5.5. Allocated to varenicline
group 1 (128), group 2 (128), group 3 (127), bupropion (128), placebo≤ (127)
Exclusion criteria: Standard pharmacotherapy trial criteria, + use of bupropion within
previous 12m, use of NRT within past 3m
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Interventions 1. varenicline tartrate 0.3 mg x 1/day for 6wks, + 1 wk placebo
2. varenicline tartrate 1.0 mg x 1/day for 6 wks, + 1 wk placebo
3. varenicline tartrate 1.0 mg x 2/day for 6 wks, + 1 wk placebo
4. bupropion 150 mg x 2/day (titrated in wk 1) for 7 wks
5. placebo tablets x 2/day for 7 wks
All groups received self-help booklet Clearing the Air at baseline, + brief (≤ 10 mins)
counselling at weekly clinic visits throughout treatment phase. At each visit smoking
status reported and verified; lab samples taken at screening, baseline and wks 1, 2, 4, 6
and 7
Follow-up phase (optional): Clinic visits at wks 12, 24, 52 for brief counselling, smoking
status and vital signs. Phone calls every 4 wks from wk 16
Outcomes Primary outcome: Continuous verified 4-wk abstinence for any part of treatment period
Secondary outcomes: CQR wks 4 - 7; CQR from wk 4 to wks 12, 24, and 52
Other outcomes: Weight change; reduction of craving and withdrawal using MNWS,
QSU-brief and mCEQ; adverse events
Validation was by expired CO ≤ 10 ppm
Trial report ITT analysis based on numbers treated (N = 626); for consistency our MA
used numbers randomised (N = 638). Attrition was 30% during treatment period, 25%
of follow-up consenters lost during follow-up phase
Treatment type Medication: VARENICLINE / BUPROPION
Notes Previous users of bupropion > 12m before were not excluded, unlike Gonzalez and
Jorenby trials; prior use ranged from 13% to 20.6% across groups
Denominator in trial report is all treated; we have used all randomised in our MA
The trial was funded by Pfizer Inc
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “computer-generated using a method of
randomly permuted blocks and a pseudo-
random number generator”
Allocation concealment (selection bias) Low risk “assigned ... medication to subjects in nu-
merical order of acceptance into the study”
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk “double-blind”, “to preserve treatment
blinding”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No information
Selective reporting (reporting bias) Low risk All expected and predicted outcomes cov-
ered
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Other bias Unclear risk None noted
Oncken 2006
Methods Country: USA
Setting: 10 research centres
Aim: To evaluate efficacy and safety of 4 varenicline dose regimens
Dates conducted: Not stated
Study Design: Phase 2 double-blind placebo-controlled RCT
Analysis: Power calculation (90%, 2-tailed, alpha = 0.05); Logistic regression with treat-
ment and centre as independent variables. Likelihood ratio Chi² statistic
Participants 647 healthy volunteer smokers, aged 18 - 65, smoking at least 10 CPD. 49.5% men,
80% white, av CPD 21, mean FTND 5.5. Allocated to group 1 (129), group 2 (130),
group 3 (129), group 4 (130) or placebo (129)
Exclusion criteria: Standard pharmacotherapy trial criteria, + use of NRT or bupropion
within last 3m; use of marijuana or tobacco other than cigarettes with last month
Interventions 1. 0.5 mg nontitrated (2/day for 12 wks)
2. 0.5 mg titrated (wk1 1/day, wks 2 - 12 2/day)
3. 1.0 mg nontitrated (2/day for 12 wks)
4. 1.0 mg titrated (0.5 mg 1/day for 3 days, 0.5 mg 2/day for 4 days, 1.0 mg 2/day wks
2 - 12)
5. placebo tablets 2/d 12 wks
All groups received self-help booklet at baseline, + brief (≤ 10mins) counselling at weekly
clinic visits throughout treatment phase, and phone call 3 days post-TQD. At each visit
smoking status reported and CO verified; vital signs, weight and adverse events. Urine,
blood tests and ECGs at screening, baseline, wks 1, 2, 4, 7 and 12.
Follow-up phase: smoking status + CO measured at wks 13, 24, 52; self-reported status
by phone at wks 16, 20, 28, 32, 36, 40, 44
Outcomes Primary outcome: Continuous verified 4-wk abstinence at wks 4 - 7 and 9 - 12
Secondary outcomes: Continuous verified abstinence at wks 2 - 12 and 9 - 52; 7-day
PPA throughout treatment phase and at wks 12, 24 and 52
Other outcomes: weight change; craving and withdrawal changes using MNWS and
mCEQ; adverse events
Validation was by expired CO ≤ 10 ppm
Cessation analyses were ITT (all participants randomised), while tolerability and safety
analyses were based only on those known to have used the intervention drug (N = 627)
. Attrition was 27% during treatment phase, and 22% of follow-up consenters lost in
follow-up phase
Treatment type Medication: VARENICLINE
Notes For cessation analyses, titrated and nontitrated results were reported separately and
pooled. 24-wk continuous cessation data supplied by authors
The trial was funded by Pfizer Inc
87Nicotine receptor partial agonists for smoking cessation (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Oncken 2006 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Unclear risk “Eligible subjects were randomly assigned
to 1 of 5 groups”
Blinding (performance bias and detection
bias)
All outcomes
Low risk “Subjects and investigators were blinded to
the study drug treatment [, and] were not
encouraged to guess their treatment assign-
ment”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing COs or visits OK if confirmed ab-
stinent before and after missed measure
Selective reporting (reporting bias) Low risk All expected and predicted outcomes cov-
ered
Other bias Unclear risk None noted
Rennard 2012
Methods Countries: Argentina, Brazil, Canada, China, Czech Republic, France, Germany, Hun-
gary, Italy, Korea, Mexico, Taiwan, UK, USA
Setting: 33 research centres
Aim: To evaluate efficacy and safety of varenicline allowing a self-selected quit date
Dates conducted: September 2008 - December 2009
Study Design: Double-blind placebo-controlled RCT
Analysis: Power calculation (90%, alpha = 0.05) assuming a true abstinence rate at 9 -
12 wks of 0.24 (placebo) and 0.46 (varenicline); Logistic regression with treatment and
centre as independent variables
Participants 659 healthy volunteer smokers, aged 18 - 75, motivated to quit, smoking at least 10
CPD. 60% men, mean age 43, 68% white, mean CPD 21, mean FTND 5.5, 66% had
tried to quit at least once before. Allocated to varenicline (493) or placebo (166)
Exclusion criteria: Standard pharmacotherapy trial criteria, + use of NRT, bupropion,
clonidine or nortriptyline within last 3m, ever use of varenicline; use of marijuana or
tobacco other than cigarettes with last month
Interventions 1. Varenicline 1 mg x 2/day, titrated in 1st wk
2. Placebo inactive tablets, same regimen
Participants could choose their own quit date between days 8 and 35
Treatment period was 12 wks. All participants received Clearing the Air: Quit smoking
today booklet at baseline, + brief counselling (≤ 10 mins) at each clinic visit. Weekly
visits throughout treatment phase, and in follow-up phase clinic visits at wks 13, 16, 20
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and 24. Phone calls at wks 14, 18 and 22
Outcomes Primary outcome: CO-validated CAR at 9 - 12 wks
Secondary outcomes: CO-validated CAR at 9 - 24 wks; 7-day PPA at wks 12 and 24
Other outcomes: Adverse events, SAEs; timing and number of quit attempts
Validation was by expired CO ≤ 10 ppm
Dropouts and losses to follow-up were included in the analyses as continuing smokers
(ITT analysis) Attrition to end of study (24 wks) was 12.4% from varenicline, 20.5%
from placebo
Treatment type Medication: VARENICLINE
Notes New for 2012 update. Additional information supplied by the authors
The study was funded and managed by Pfizer Inc
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “a predefined, central, computer-generated
randomization sequence...assigned sub-
jects in a 3:1 ratio”. Block size: 4, stratified
by centre
Allocation concealment (selection bias) Low risk See above
Blinding (performance bias and detection
bias)
All outcomes
Low risk Triple-blind (participant, care-giver, inves-
tigator)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Dropouts and attrition rates fully reported
Selective reporting (reporting bias) Low risk All predicted and expected outcomes re-
ported
Other bias Unclear risk None noted
Rigotti 2010
Methods Country: 15 countries in Europe, Asia, Americas
Setting: 39 research centres
Aim: To evaluate efficacy and safety of varenicline in patients with stable CVD
Dates conducted: February 2006 - August 2008
Study Design: Phase 3 double-blind placebo-controlled RCT
Analysis: Logistic regressionwith treatment group and study site as independent variables
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Rigotti 2010 (Continued)
Participants 714 adult smokers, aged 35 - 75, smoking at least 10 CPD, with stable CVD and
motivated to quit. 79% men, 80% white, mean CPD 22, mean FTND 5.6. Allocated
to varenicline (355) or placebo (359), stratified by site
Exclusion criteria: Standard pharmacotherapy trial criteria, + use of NRT or bupropion
within previous month. All had been diagnosed for at least 2m with CVD, but not
hypertension alone
Interventions 1. Varenicline 1.0 mg 2/day for 12 wks, including wk 1 at titrated dose
2. Placebo tablets as above
Both groups received brief (≤ 10mins) counselling at weekly clinic visits throughout
treatment phase, and phone call 3 days post-TQD. At each visit smoking status reported
and CO verified; vital signs, weight and adverse events. Urine, blood tests and ECGs at
screening, baseline, wks 12 and 52
Follow-up phase: smoking status + CO measured at wks 13, 16, 24, 32, 40 and 52;
counselling and self-reported status by phone at wks 14, 20, 28, 36 and 44
Outcomes Primary outcome: CO-validated CAR at wks 9 - 12
Secondary outcomes: CO-validated CAR at wks 9 - 52 and 9 - 24; 7-day PPA at wks
12, 24 and 52
Other outcomes: Adverse events; serious adverse events; cardiovascular events; changes
in blood pressure and heart rate
Validation was by expired CO ≤ 10 ppm
Cessation analyses were ITT (all participants randomised minus deaths), while tolera-
bility and safety analyses were based only on those known to have used the intervention
drug (N = 703). Attrition was 17.5% from the varenicline group and 20.3% from the
placebo group during treatment phase, and 14.9% varenicline and 19.5% placebo who
did not complete the study. This includes 2 deaths in the varenicline group and 5 in the
placebo group by 52-wk follow-up
Treatment type Medication: VARENICLINE
Notes The study was funded by Pfizer Inc
New for 2010 update
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “The study sponsor conducted the ran-
domization centrally using a computer-
generated list that prespecified the order of
treatment allocation”
Allocation concealment (selection bias) Low risk See above
Blinding (performance bias and detection
bias)
All outcomes
Low risk Described as “double-blind” (participants
and study implementation). Cardiovascu-
lar outcomes “were reviewed separately and
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Rigotti 2010 (Continued)
adjudicated under blinded conditions by
an independent event committee made up
of 3 board-certified cardiologists”
Incomplete outcome data (attrition bias)
All outcomes
Low risk ITT analyses conducted; participants who
missed a visit but had validated abstinence
at next visit were considered continuously
abstinent. But 52-wk status had to be at-
tended and confirmed
Selective reporting (reporting bias) Low risk All expected and predicted outcomes cov-
ered
Other bias Unclear risk None noted
Rose 2013
Methods Country: USA
Setting: Duke University Medical Center, Durham, NC
Aim: “Given the safety and tolerability profile of nicotine replacement therapy, our
rationale in this study was to use nicotine replacement therapy as an initial line of
treatment, and then identify early on which smokers are unlikely to benefit from nicotine
alone”
StudyDesign: Randomised double-blindparallel-arm adaptive treatment trial in 2 phases
Dates conducted: Not stated
Analysis: Logistic regression
Participants 606 adult smokers, motivated to quit, aged 18 - 65, mean CPD 10+ for 3 yrs, expired
CO level 10+ ppm. 46% women, 63% white, mean CPD 21.7, mean FTND 5.8.
Participants could receive up to USD 320 for study participation
Interventions Two phase study:
All participants seen weekly for 2 wks before TQD, and attended 4 - 6 sessions after
the TQD. At each session, participant received brief (< 15 mins) support, + clinical trial
materials. Smoking diaries, expired CO, withdrawal symptoms and reports of adverse
events were collected each time. Participants were recontacted at 6m, and those reporting
abstinence were invited to return to give a CO sample
All participants were given open-label active NRT patch, either 42 mg/day (baseline CO
> 30 ppm) or 21 mg/day (baseline CO < 30 ppm) for 2 wks; dose reductions allowed if
side effects dictated. At 1 wk, participants were classified as ’responders’ (reduced ad lib
smoking by > 50%, CO-verified) or ’non-responders’ (< 50%)
Phase 1 (12 weeks):
Non-responders only (N = 371 - 36 who withdrew, = 335) allocated to:
1. Double-blind varenicline, stopping NRT (N = 112)
2. Double-blind augmentation of NRT with bupropion (N = 109)
3. Continuation on open-label NRT alone (N = 114)
All participants received dummy (placebo) versions of the other 2 treatments as well as
their own active treatment
Phase 2:
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235 responders after wk 1 assessed at 1st wk after TQD (wk 3). Lapsers (N = 105) were
assigned a 2nd TQD1 wk later, and were allocated to the same 3 double-blind treatment
conditions as Phase 1 non-responders
1. Double-blind varenicline, stopping NRT (N = 36)
2. Double-blind augmentation of NRT with bupropion (N = 34)
3. Continuation on open-label NRT alone (N = 35)
Non-lapsers (N = 130) remained on open-label NRT throughout study duration
All participants received dummy (placebo) versions of the other 2 treatments as well as
their own active treatment
47 participants were excluded from the analysis (27 Phase 1, 20 Phase 2) because of
using contra-indicated medications during the study or failing to meet other entry re-
quirements. 1 individual died before end of treatment, and 1 was excluded for extreme
CO change from the mean sample range
Outcomes Primary: CAR at wks 8 - 11
Secondary: CA from TQD for 11 wks (EoT); 7-day PPA at 6m: CA from TQD to 6m
Validation: CO ≤ 10 ppm
AEs and SAEs (reported, but not by treatment group)
Treatment type Medication: VARENICLINE, BUPROPION, NRT
Notes Funding by a grant from Philip Morris USA, with NRT supplied free by GSK
Phase 1 and Phase 2 groups combined for varenicline vs NRT analysis
New for 2016 update
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “randomly assigned”
Allocation concealment (selection bias) Unclear risk No information
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk No information
Incomplete outcome data (attrition bias)
All outcomes
Low risk Losses fully reported; exclusions for
protocol violations or contra-indicated
medicines. 1 death and 1 ’rogue’ CO read-
ing excluded
Selective reporting (reporting bias) Low risk None noted
Other bias Unclear risk Unexplained disparity between CON-
SORT (N = 103) and Results table (N =
108) denominators for rescue varenicline
group
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Stein 2013
Methods Country: USA
Setting: 9 methadone-maintained treatment centres in New England
Aim: “[to] test varenicline versus placebo, and include a comparison condition of com-
bination nicotine replacement therapy”
Study Design: Randomised 3-armed double-blind controlled trial
Dates conducted: December 2008 - January 2012
Analysis: Sample sizes of 132 (varenicline) and 44 (placebo) estimated to give 80% power
to detect quit rates of 20% and 2.5% respectively; the study was not powered to detect
differences between varenicline and combination NRT
Participants 315 adult methadone-maintained smokers, smoking 10+ CPD, willing to set a quit date
within the 1st wk Allocated 3:1:3 to varenicline (137): placebo (45): combination NRT
(133). Mean age 39.9, 47.6% women, 78.5% white, mean CPD 20, mean FTND 5.7
Interventions All participants received a standardised 15-min session of advice to quit (5As model),
and were asked to set a TQD for 8 days time. All made monthly visits for support and
top-up medication
1. Varenicline: 24-wk course of varenicline tablets, 1st wk titrated
2. Placebo: 24-wk course of identical tablets and regimen
3. Combination NRT: 24-wk course of NRT patch (42 mg for > 30 CPD, 21 mg if <
30 CPD), + ad lib nicotine gum (4 mg) as needed
Participants were paid USD 30 for the baseline assessment and USD 40 for the 6m
assessment
Outcomes Primary: 7-day PPA at 6m
Secondary: CA from wk 2 to 6m; for non-quitters: CPD reduction in the 28 days prior
to 6m assessment
Validation: CO < 8 ppm; urinary cotinine in varenicline and placebo participants claim-
ing abstinence
Treatment type Medication: VARENICLINE / NRT
Notes Funding: NCI grant RO1 CA129226; MDS supported by a NIDA mid-career investi-
gator award K24 DA000512
New for 2016 update
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Participants were randomized to treat-
ment after completing the baseline assess-
ment”. No further information
Allocation concealment (selection bias) Unclear risk No information
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Blinding (performance bias and detection
bias)
All outcomes
Low risk “double-blind”; research assistants were
“blind to participant group assignment”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Losses to treatment and follow-up re-
ported; ITT analyses conducted
Selective reporting (reporting bias) Low risk None noted
Other bias Low risk None noted
Steinberg 2011
Methods Country: New Jersey, USA
Setting: Robert Wood Johnson Hospital (584-bed University-based)
Aim: To evaluate efficacy and safety of varenicline in hospital inpatients
Dates conducted: August 2007 - March 2009
Study Design: Phase III triple-blind pilot RCT
Participants 79 adult smokers, aged 18+, smoking 10+ CPD; randomised to varenicline (40) or
placebo (39)
59% men, mean age: 51, 72% white, 57% > 20 cpd, 40% FTND > 6
Admission diagnoses 57% CVD, 14% orthopaedic, 13% pulmonary, 16% other
Exclusion criteria: Standard pharmacotherapy criteria, + current use of any SC medica-
tions
Interventions 1. Varenicline 1.0 mg x 2/day for 12 wks, including wk 1 at titrated dose
2. Placebo tablets as above
Initial visit by Clinic Co-ordinator of local Tobacco Dependence Program for 5 - 10 min
counselling Subsequent sessions of 15 mins post-discharge
After discharge, data collection sessions at 4, 12 and 26 wks, + 1 phone call at 2 wks
with research nurse USD 25 gift card for attendance at each follow-up visit
Outcomes Primary outcome: 7-day PPA at 26 wks
Secondary outcomes: 7-day PPA at 4, 12 wks. Repeated PPA at 4, 12 and 24 wks. AEs
and SAEs; withdrawal and craving on MNWS; motivation; CPD; utilisation of OP
services; composite medical outcome
Validation: CO validation ≤ 8 ppm. Self report accepted if unable to attend
Treatment type Medication: VARENICLINE
Notes Study was funded and support by Robert Wood Johnson Foundation and Pfizer
Repeated PPA at 4, 12 and 24 wks used as strictest definition of abstinence and included
in main MA
New for 2012 update
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “randomized in a 1:1 ratio through central-
ized telephone randomization process by
the study statistician and hospital research
pharmacist”
Allocation concealment (selection bias) Low risk see above
Blinding (performance bias and detection
bias)
All outcomes
Low risk “The subject, research nurse, and treatment
staff were blinded to treatment assignment”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk ITT analysis conducted;
unvalidated smoking status included where
ascertained for non-attenders, but % of un-
validated status not reported
Selective reporting (reporting bias) Low risk All expected and predicted outcomes cov-
ered, except for detailed identification of
SAEs
Other bias Unclear risk None noted
Tashkin 2011
Methods Country: USA (17 centres), Spain (3 centres), France (4 centres), Italy (3 centres)
Setting: 27 research centres.
Aim: To test efficacy and safety of varenicline in smokers with COPD
Dates conducted: May 2006 - April 2009
Study Design: Double-blind placebo-controlled RCT
Analysis: Power calculation (81% to detect a diff in CAR 9 - 52 wks based on an OR of
2.21 and a placebo rate of 9%); ITT denominators. Logistic regression with treatment
group and study site as independent variables
Participants 504 adult smokers with mild-to-moderate COPD, aged 35+, smoking 10+ CPD, moti-
vated to quit; allocated to varenicline (250), or placebo (254). 62% men, mean age 57,
CPD 24 - 25, FTND score 5.9 - 6.2 Treatment groups were comparable at baseline
Exclusion criteria: Standard pharmacotherapy trial criteria, + treatment with systemic
corticosteroids or hospitalised for COPD in previous 4 wks
Interventions 1. Varenicline 1.0 mg x 2/day for 12 wks, preceded by 1 wk titrated dose
2. Placebo tablets as above
Both groups received SC educational booklet, + brief (≤ 10mins) counselling at weekly
clinic visits throughout treatment phase, and phone call 3 days post-TQD. At each visit
smoking status reported and CO verified; throughout treatment and at wk 52 lung
function, respiratory symptoms, weight, BP, pulse, temperature, ECGs, haematology
and serum chemistry assessed, + adverse events
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Follow-up phase: smoking status + CO measured at wks 13, 16, 24, 32, 40, 48 and 52;
counselling and self-reported status by phone at wks 14, 20, 28, 36 and 44
Outcomes Primary outcome: CO-validated CAR at wks 9 - 12
Secondary outcomes: CO-validated CAR at wks 9 - 52 and 9 - 24; 7-day PPA at wks
12, 24 and 52
Other outcomes: Adverse events; serious adverse events; weight change
Validation was by expired CO ≤ 10 ppm
Cessation analyses were ITT (all participants randomised), while tolerability and safety
analyses were based only on those known to have used the intervention drug (N = 499)
. Attrition was 17% in the varenicline group and 24% in the placebo group during
treatment phase, and 29% varenicline and 38% placebo who did not complete the study.
This includes 2 deaths in the varenicline group and 1 in the placebo group
Treatment type Medication: VARENICLINE
Notes The study was funded by Pfizer Inc
New for 2010 update
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “participants were randomized”
Allocation concealment (selection bias) Unclear risk Not stated
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk “double blind” but details not stated
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not stated
Selective reporting (reporting bias) Unclear risk All expected and predicted outcomes cov-
ered
Other bias Unclear risk None noted
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Tønnesen 2013
Methods Country: Denmark
Setting: 1 hospital-based smoking cessation specialist clinic
Aim: “to evaluate whether varenicline used for 12 weeks would be more effective than
placebo to get long-term NRT users to stop using NRT”
Study Design: Randomised placebo-controlled quadruple-blind trial
Dates conducted: Not given
Analysis: Sample sizes of 66 in each group, estimated to give 80% power to detect quit
rates of 50% and 25% respectively at 12 weeks in active and placebo groups
Participants 139 adult ex-smokers, aged 18+, reporting long-term (> 11m) abstinence, using flexible-
dose NRT (i.e. > 4 pieces of nicotine gum/sublingual tablets or lozenges per day, or > 3
inhaler cartridges per day, or > 10 puffs of nasal spray per day), wishing and willing to
try to stop using NRT; allocated to varenicline (70) or placebo (69)
Participants used gums (2 mg 68.3%; 4 mg 11.5%), inhalers (5.8%), sublingual tablets
(7.2%), lozenge (9.4%); mean daily NRT unit intake was 16 (SD 8.1), and mean NRT
usage had lasted 6 years. Mean age 54.6, 54% women, mean CPD when smoking 23.5,
mean FTND (recalled) 6.5
Interventions All participants attended clinic visits at wks 0, 2, 4, 6, 9, 12, 52, + 2 phone calls at wks
26 and 38. Each visit included assessments, < 5 mins counselling from SC nurses. All
participants advised to gradually reduce NRT and to stop completely by TQD at 1 - 2
wks
1. Varenicline: standard 12-wk regimen, titrated 1st wk
2. Placebo: identical tablets, same regimen
Outcomes 7-day PPA at 12 weeks, not smoking or on NRT; also no NRT (7-day PPA) + abstinence
at 52 wks. CAR from wk 2 to wk 52, proven abstinent at all clinic visits
Validation: expired CO < 7 ppm and plasma cotinine < 15 ng/ml
Treatment type Medication: VARENICLINE
Notes Not included in the main analysis, as smoking cessation was not the aim
Funding was from an Independent Investigator Grant from Pfizer A/S, Denmark and
Pfizer, Europe
New for 2016 update
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Subjects were randomized to active or
placebo using a computer-generated list
with random numbers”
Allocation concealment (selection bias) Unclear risk Not stated
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Described as a “double-blind” trial. No ad-
ditional information
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Incomplete outcome data (attrition bias)
All outcomes
Low risk By 52wks, 9 had dropped out of the vareni-
cline group and 15 out of the placebo group
(PRISMA flow diagram says 15, text says
14). ITT analyses conducted
Selective reporting (reporting bias) Low risk None noted
Other bias Low risk None noted
Tonstad 2006
Methods Country:USA (6 centres) and ’international’ (18 centres, acrossCanada,CzechRepublic,
Denmark, Norway, Sweden, UK*)
Setting: 24 research centres
Aim: To test the efficacy and safety of extended varenicline treatment for preventing
relapse in adults who have quit smoking on open-label varenicline
Dates conducted: April 2003 - February 2004 (initial recruitment phase)
Study Design: Double-blind placebo-controlled RCT.
Analysis: Power calculation (80%, alpha = 0.05); ITT denominators and logistic regres-
sion analysis for binary data, and Kaplan-Meier curve for time to first lapse
Participants 1210 successful quitters (62.8% of initial cohort) following a 12-wk open-label course
of varenicline for smoking cessation, randomised to varenicline (603) or placebo (607)
for a further 12 wks. 49% men, 97% white, mean age 45, BMI < 15 or > 38 or weight
< 45.5 kg, mean CPD 21, mean FTND score 5.4
Exclusion criteria: Standard pharmacotherapy trial criteria, + use of marijuana or tobacco
products other than cigarettes within last month; use of NRT, bupropion, clonidine,
nortriptyline within last month
Interventions 1. Varenicline 1 mg x 2/day for 11 wks after 1 wk titrated dosage
2. Placebo tablets, same regimen
All participants also received brief counselling (≤ 10 mins) at each clinic visit throughout
treatment phase (wks 13 - 24). Treatment phase clinic visits were at wks 13, 14, 16, 20
and 24
Follow-up phase: 5 visits and 4 phone calls from wks 25 - 52
Outcomes Primary outcome: Relapse prevention: maintenance of CO-validated CAR at 24 wks
Secondary outcome: CO-validated CAR at wk 52; 7-day PPA at wks 24 and 52. 2 deaths
removed from varenicline denominator at 52 wks
Other outcomes: weight change, withdrawal symptoms (using MNWS), time to first
lapse, adverse events
Validation was by expired CO ≤ 10 ppm
Dropouts and losses to follow-up were included in the analyses as continuing smokers
(ITT analysis) Attrition was 12% during treatment phase, and 10% of treatment com-
pleters lost during follow-up phase
Treatment type Medication: VARENICLINE
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Tonstad 2006 (Continued)
Notes * additional information supplied by author
The trial was funded by Pfizer Inc
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “computer-generated randomization se-
quence (stratified by center with a block
size of 4)”
Allocation concealment (selection bias) Low risk “a single, centralised [system]”
Blinding (performance bias and detection
bias)
All outcomes
Low risk “double-blind treatment phase”; “partici-
pant blinding was maintained during this
[non-treatment follow-up] phase”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing COs were considered abstinent if
other criteria OK; at wk 52 all criteria had
to be met
Selective reporting (reporting bias) Low risk All expected and predicted outcomes cov-
ered
Other bias Unclear risk None noted
Tsai 2007
Methods Country: Taiwan and Korea
Setting: 5 sites in each country
Aim: To test the efficacy and safety of varenicline for smoking cessation in Taiwanese
and Korean smokers
Dates conducted: February 2005 - March 2006
Study Design: Double-blind placebo-controlled RCT
Analysis: Power calculation (I am happy to talk to the CEU team and Jo while you’re
away, to keep things moving forward. (≥ 90%, alpha = 0.05); ITT denominators and
logistic regression model including treatment and centre
Participants 250 healthy adult volunteers, motivated to quit, aged 18 - 75; allocated to varenicline
(126), or placebo (124). 89% men, mean age 40.3, BMI < 15 or > 38 or weight < 45.
5 kg, mean CPD 24, mean FTND score 5.1. Treatment groups were comparable at
baseline
Exclusion criteria: Standard pharmacotherapy trial criteria
Interventions 1. Varenicline 1.0 mg x 2/day
2. Placebo tablet x 2/day
Treatment period 12 wks, 1st wk titrated dosage. All participants received a smoking
cessation booklet Clearing the Air at baseline, + brief counselling (≤ 10 mins) at each
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clinic visit. Clinic visits at baseline and at wks 1, 2, 3, 4, 6, 8, 10, 12, plus a 5-min phone
call at +3 days post-TQD, and at wks 5, 7, 9, 11
In follow-up phase, clinic visits at wks 13, 16, 20, 24 plus brief phone calls at wks 14,
18, 22
Outcomes Primary outcome: CO-validated CAR at 9 - 12 wks
Secondary outcomes: CO-validated CAR at 9 - 24 wks; 7-day PPA at wks 12 and 24
Validation was by expired CO ≤ 10 ppm
Other outcomes: Withdrawal symptoms (using MNWS, QSU-brief and mCEQ), ad-
verse events
Dropouts and losses to follow-up were included in the analyses as continuing smokers
(ITT analysis)
Attrition in treatment phase was 2.8%, losses to follow-up 2.5% of treatment completers
Treatment type Medication: VARENICLINE
Notes Trial was funded by Pfizer Inc
New for 2008 update.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “randomly permuted blocks” (block size=
4)
Allocation concealment (selection bias) Low risk web- and telephone-based assignment
Blinding (performance bias and detection
bias)
All outcomes
Low risk Subjects, investigators, study staff and
sponsor personnel
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No information, but very high compliance
rates
Selective reporting (reporting bias) Unclear risk All expected and predicted outcomes cov-
ered
Other bias Unclear risk None noted
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Tsukahara 2010
Methods Country: Japan
Setting: Cessation clinic in Fukuoka University Hospital
Aim: To test the efficacy and safety of varenicline for smoking cessation in Japanese
smokers
Dates conducted: Aug 2008 - November 2009
Study Design: Randomised controlled open-label trial
Study name: The VN-SEESAW Study
Participants 32 adult smokers, motivated to quit, allocated to varenicline (16) or nicotine patch (16).
75%men, mean age 46, mean CPD 28 (varenicline), 25 (patch), mean TDS (addiction)
score 7.6, mean Brinkman index score (CPD x yrs smoking) 702. 71% had tried to quit
previously, and 7% had used nicotine patches before
Standard pharmacotherapy trial exclusion criteria, plus attendance at any smoking ces-
sation clinic during previous 12m
Interventions 1. Open-label varenicline 1.0 mg x 2/day for 12 wks, following 1 wk titration
2. Open-label nicotine patch for 8 wks (52.5 mg/day for 4 wks, 35 mg/day for 2 wks,
17.5 mg/day for 2 wks)
No non-treatment or placebo control group
Varenicline group received 8 clinic visits and nicotine group 5 visits over 12 wks, with 5
brief counselling sessions (≤ 10 mins)
Outcomes CO-confirmed CAR at 9 - 12 wks, and self-reported at 9 - 24 wks by phone interview
Validation by expired CO < 8 ppm at 12 wks, but not at 24 wks
Other outcomes: Safety and tolerability by wk 12, using MNWS at wks 2, 4, 8 and 12.
Also used Stress Check List and Strait-trait Anxiety Inventory
Dropouts and losses to follow-up were included in the analyses as continuing smokers
(ITT analysis)
Attrition in treatment phase was 12.5% from each group
Treatment type Medication: VARENICLINE / NRT OPEN-LABEL
Notes The study was supported by the Japanese Ministry of Education, Science and Culture,
Fukuoka University and FU-Global program
Not included in main MA, as no placebo group
New for 2010 update
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “by computer” allocating men: women 3:1
to reflect Japanese smoking prevalence (M:
40%, F: 12%)
Allocation concealment (selection bias) Unclear risk Not stated
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Blinding (performance bias and detection
bias)
All outcomes
High risk Participants and personnel were not
blinded to treatment
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not stated
Selective reporting (reporting bias) Low risk All expected and predicted outcomes cov-
ered
Other bias Unclear risk None noted
Wang 2009
Methods Country: China (10 sites), Singapore (3 sites), Thailand (2 sites)
Aim: To test the efficacy and safety of varenicline for smoking cessation in Chinese,
Singaporean and Thai smokers
Dates conducted: Not stated
Study Design: Double-blind placebo-controlled RCT.
Analysis: Power calculation (≥ 90%, alpha = 0.05); ITT denominators and logistic
regression model including treatment with site, country, FTND score, CPD and time
to first cigarette. No interactions found
Participants 333 healthy adult volunteers, aged 18 - 75; allocated to varenicline (165), or placebo
(168). 97% men, mean age 39, BMI > 15 and < 38 or weight > 45.5 kg, mean CPD 20,
mean FTND score 5.4. Treatment groups were comparable at baseline. 58% had never
tried to quit before
Exclusion criteria: Standard pharmacotherapy trial criteria, plus any use of NRT or
bupropion in previous 6m
Interventions 1. Varenicline 1.0 mg x 2/day
2. Placebo tablet x 2/day
Treatment period 12 wks, 1st wk titrated dosage. All participants received a smoking
cessation booklet at baseline, + brief counselling (≤ 10 mins) at each clinic visit, except
for wks 5 and 7, when counselling was conducted by phone
In follow-up phase, clinic visits at wks 13, 16, 20, 24 plus brief phone calls at wks 14,
18, 22. Dosing and CO checked at each visit, and lab samples taken at wks 12 and 24
Outcomes Primary outcome: CO-confirmed CAR for wks 9 - 12
Secondary outcomes: CO-confirmed CAR for wks 9 - 24; 7-day PPA at 24 wks
Validation by expired CO < 10 ppm
Other outcomes: adverse events; long-term quit rates
Dropouts and losses to follow-up were included in the analyses as continuing smokers
(ITT analysis)
Attrition in treatment phase was 3.0% in varenicline group, and 3.6% in placebo group.
By wk 24, 4.2% of had dropped out of each group
Treatment type Medication: VARENICLINE
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Wang 2009 (Continued)
Notes The trial was funded by Pfizer Inc
New for 2010 update
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “eligible subjects were randomized in a 1:1
ratio”
Allocation concealment (selection bias) Unclear risk See above
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk “double-blind”, but no further information
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No information, but very high compliance
rates
Selective reporting (reporting bias) Low risk All expected and predicted outcomes cov-
ered
Other bias Unclear risk None noted
Westergaard 2015
Methods Country: Denmark
Aim: To evaluate the effect of varenicline on tobacco cessation in young smokers suffering
from asthma
Dates conducted: Not stated
Study Design: Double-blind placebo-controlled RCT
Participants 52 young (aged 19 - 40) smokers with asthma, randomised to varenicline (26) or placebo
(26). CPD ≥ 10; FTND 5.6
Interventions 1. Varenicline: presumed standard regimen: Varenicline 1.0 mg x 2/day
2. Placebo tablet x 2/day
No further details
Outcomes Primary: presumed PPA at 12 wks
Secondary: presumed PPA at 0, 6, 24 wks
Validation by expired CO < 10 ppm
Also assessed asthma symptom score, general health quality score (15D) and metha-
choline challenge
Treatment type Medication: VARENICLINE
Notes Author supplied further details
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated. “”randomized, placebo-con-
trolled, double-blinded trial“
Allocation concealment (selection bias) Unclear risk Not stated
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Not stated. ”double-blinded
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not stated; ITT analysis conducted
Selective reporting (reporting bias) Unclear risk Not stated
Other bias Unclear risk Not stated
Williams 2007
Methods Country: USA and Australia
Setting: 9 research centres (8 USA, 1 Aus)
Aim: To test the safety of long-term (12m) use of varenicline in smokers trying to quit
Study Design: Double-blind placebo-controlled RCT
Dates conducted: October 2003 - March 2005
Participants 377 adult smokers, aged 18 - 75, smoking at least 10 CPD. 49.9% men, 88.6% white,
av CPD at baseline 23, mean FTND 5.5 in treatment group, 6.05 in control group.
Allocated to varenicline (251) or placebo (126)
Exclusion criteria: Standard pharmacotherapy trial criteria, + no use of NRT, antidepres-
sants, antipsychotics, naltrexone during study period
Interventions 1. Varenicline 1mg x 2/day, titrated for first wk
2. Placebo inactive tablets, same regimen
All participants received S-H booklet Clearing the Air. Brief counselling (≤ 10 mins) at
each visit
TQD was 1st day of wk 1 visit (7 - 10 days post-randomisation)
Treatment period was 52 wks. Weekly visits throughout wks 1 - 8, then every 4 wks to
wk 52, + wk 53 assessment
Blood and urine samples taken at screening, baseline, wks 2, 12, 24, 36, 52 (or early
termination) Complete physical exam at baseline, wks 24 and 52; BP, pulse and weight
measured at all visits, ECG at screening, baseline, wks 2, 24 and 52 (or early termination)
Outcomes Primary outcome: Safety of smokers treated continuously with varenicline over 52 wks,
measured at wk 53 by level and tolerability of adverse events and incidence of SAEs
Secondary outcome: 7-day CO-verified PPA at all clinic visits (expired CO ≤ 10 ppm)
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Williams 2007 (Continued)
Other outcomes: Weight change; changes in vital signs
Attrition was 46.2% in varenicline group, 53.2% in control group by end of study
Treatment type Medication: VARENICLINE
Notes This was a safety study, with cessation rates collected as a secondary outcome
The trial was funded and conducted by Pfizer Inc
In the first version of this review, this trial appeared as Reeves 2006 (unpublished data)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomisation 2:1 varenicline to placebo.
No detailed information reported
Allocation concealment (selection bias) Unclear risk No information reported
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk No information reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing CO and/or visit taken as smokers
Selective reporting (reporting bias) Low risk Primary outcome was safety, so minimal
cessation data
Other bias Unclear risk None noted
Williams 2012
Methods Countries: Canada, USA
Setting: 12 sites
Aim: To evaluate primarily safety, but also efficacy of varenicline in smokers with
schizophrenia or schizoaffective disorders
Dates conducted: May 2008 - April 2010
Study Design: Double-blind placebo-controlled RCT. Sample size [120] was considered
sufficient to detect a between-group difference in 7-day PPA “for a medium effect size”
Participants 128 adults, diagnosed with stable schizophrenia or schizoaffective disorders, smoking at
least 15 CPD and motivated to quit. Randomised to varenicline (85) or placebo (43).
77% men aged 18 - 75
Interventions 1. Varenicline 1.0 mg x 2/d for 12 wks, including wk 1 at titrated dose
2. Placebo tablets as above.
Weekly clinic visits, for safety and efficacy,≤ 30-min counselling sessions; after treatment
phase, clinic visits at wks 13, 16, 20, 24, with brief phone calls at wks 14, 18 and 22.
105Nicotine receptor partial agonists for smoking cessation (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Williams 2012 (Continued)
Follow-up sessions included brief (≤ 10 mins) counselling. AEs collected to 30 days after
treatment, and neuropsychiatric AEs to wk 24
Outcomes Primary outcome:N of participants with adverse and serious adverse events frombaseline
to 30 days after end of treatment (12 wks). N of participants with psychiatric adverse
events, including suicidal ideation or behaviour
Secondary outcomes: CO-confirmed PPA at wks 12 and 24; 50%+ reduction in CPD;
change in CPD from baseline. Assessments on mood and psychiatric scales
Validation was by exhaled CO ≤ 10 ppm
Dropouts in treatment phase: 14 (varenicline), 3 (placebo); follow-up phase: 10 (vareni-
cline), 3 (placebo) 1 varenicline participant died during follow-up phase
Treatment type Medication: VARENICLINE
Notes The study was funded by Pfizer
New for 2012 update
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Subjects were randomized (2:1) to vareni-
cline or placebo ... and were stratified ac-
cording to antipsychotic medication type
(typical vs atypical).”
Allocation concealment (selection bias) Unclear risk Not stated
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not yet reported
Wong 2012
Methods Country: Canada
Setting: 2 Toronto hospitals
Aim: “to determine the effectiveness and safety of a perioperative smoking cessation
intervention including varenicline and counseling versus placebo and counseling to in-
crease short- and long-term abstinence in surgical patients”
Study Design: Randomised placebo-controlled double-blind trial
Dates conducted: June 2008 - November 2010
Analysis: Sample sizes of 145 in each group, estimated to give 80% power to detect a
risk difference of 15% at 12 months between active and placebo groups
Participants 286 non-cardiac elective surgery patients, smoking 10+ CPD, no abstinence > 3m in
last year, scheduled for surgery in the next 8 - 30 days. Allocated to varenicline (151) or
placebo (135). Mean age 52.6, 47% women, mean CPD 17.4, mean FTND 4.8
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Wong 2012 (Continued)
Interventions All participants received 2 standardised 15-min counselling sessions by researchers, 1
in pre-op clinic and 1 24 hours after surgery, supplemented by written materials. All
participants retained the same counsellor throughout the process
Weekly counselling phone calls for 4 weeks, and at the end of 8 weeks. From 3 - 12
months, phone calls every 4 weeks for smoking status, nicotine dependence, stage of
change, CPD, brief (< 5 mins) counselling. TQD was set for 24 hours before surgery,
and medication begun 7 days before TQD
1. Varenicline: 12 wks standard regimen, 1st wk titrated
2. Placebo: Identical-looking tablets and regimen
Participants were invited to visit the hospital at 3, 6, and 12m, for assessment and testing.
Participants unable to visit the hospital were sent a self-test urinary kit
Outcomes 7-day PPA at 12m; abstinence on TQD; 7-day PPA at 3m and 6m. Self-reported changes
in CPD and stage of change at 3, 6 and 12m
Validation: Expired CO and urinary cotinine (cut-offs not given)
Treatment type Medication: VARENICLINE
Notes Supported by Canadian academic institutes and Pfizer Canada
New for 2016 update
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Smokers were randomly assigned to re-
ceive varenicline (Pfizer Inc., Kirkland,
Quebec, Canada) or matching placebo us-
ing a computer-generated randomization
list at each center. A stratified random-
ization with blocks of 40, based on the
smoker’s stage of change, was employed be-
cause the stage of change may predict suc-
cessful abstinence from smoking.”
Allocation concealment (selection bias) Low risk “The patient assignments were placed into
sequentially numbered, opaque sealed en-
velopes, and were kept by an independent
research pharmacist at each center who was
not involved with patient care or outcome
assessments. For each patient, the research
pharmacist opened the envelope and pro-
vided the research coordinator with the
medication or placebo (lactose, identical in
appearance) according to the randomiza-
tion schedule.”
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Wong 2012 (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Low risk “The patients, healthcare personnel, and
research staff were blinded to the random-
ization throughout the study period.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Losses fully reported:Varenicline: 6 discon-
tinued treatment, 11 discontinued follow-
up. Placebo: 6 discontinued treatment, 10
discontinued follow-up. ITT analyses con-
ducted
Selective reporting (reporting bias) Low risk None noted
Other bias Low risk None noted
Brandon 2011*
Methods
Participants
Interventions
Outcomes
Treatment type
Notes Treated as an included study in order to contribute to adverse event meta-analyses; Excluded for efficacy: Short-
term (15 days) RCT, to test craving and psychological reward; cessation was not an outcome
Ebbert 2011*
Methods
Participants
Interventions
Outcomes
Treatment type
Notes Treated as an included study in order to contribute to adverse event meta-analyses; Excluded for efficacy: Pilot
study of varenicline for smokeless tobacco users. 12-wk outcome (EoT) reported, not long-term post-treatment
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Faessel 2009*
Methods
Participants
Interventions
Outcomes
Treatment type
Notes Treated as an included study in order to contribute to adverse event meta-analyses; Excluded for efficacy: Outcomes
were safety, tolerability and pharmacokinetics, not smoking cessation
Fagerström 2010*
Methods
Participants
Interventions
Outcomes
Treatment type
Notes Treated as an included study in order to contribute to adverse event meta-analyses; Excluded for efficacy: 431
smokeless tobacco users in Norway and Sweden, randomised to varenicline or placebo; CAR assessed at 12 and 26
weeks
Garza 2011*
Methods
Participants
Interventions
Outcomes
Treatment type
Notes Treated as an included study in order to contribute to adverse event meta-analyses; Excluded for efficacy: 110
abstinent smokers treatedwith varenicline or placebo, to assess incidence and severity of neuropsychiatric symptoms;
not a cessation trial
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Hughes 2011*
Methods
Participants
Interventions
Outcomes
Treatment type
Notes Treated as an included study in order to contribute to adverse event meta-analyses; Excluded for efficacy: 218
smokers not ready to quit assigned to varenicline or placebo for 2 - 8 weeks for cigarette reduction; abstinence was
not the outcome of interest, although measured in those who made a quit attempt. Primary outcome was incidence
of quit attempts over 6m
McClure 2013* NCT00944554
Methods
Participants
Interventions
Outcomes
Treatment type
Notes Treated as an included study in order to contribute to adverse event meta-analyses; Excluded for efficacy: New for
2016 update. Laboratory study following an RCT of varenicline in a programmed lapse; abstinence only to 4 weeks
Meszaros 2013*
Methods
Participants
Interventions
Outcomes
Treatment type
Notes Treated as an included study in order to contribute to adverse event meta-analyses; Excluded for efficacy: New for
2016 update. Pilot study (10 participants, only 4 completers), only followed to 3m; objective was reduction, not
cessation
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Mitchell 2012*
Methods
Participants
Interventions
Outcomes
Treatment type
Notes Treated as an included study in order to contribute to adverse event meta-analyses; Excluded for efficacy: New for
2016 update. Varenicline was for drinking reduction, not smoking cessation; only followed for 12 weeks
BMI: Body Mass Index (kg/m2)
CAR: Continuous Abstinence Rate
CO: carbon monoxide
COPD: chronic obstructive pulmonary disease
CPD: cigarettes per day
CQR: continuous quit rate
CVD: cardiovascular disease
EoT: end of treatment
FTND: Fagerström Test for Nicotine Dependence
ITT: intention-to-treat
LOCF: last observation carried forward
MA: meta-analysis
MDD: major depressive disorder
MI: motivational interviewing
mCEQ: Modified Cigarette Evaluation Questionnaire
MNWS: Minnesota Nicotine Withdrawal Scale
PA prolonged abstinence
PPA: point-prevalence abstinence
QoL: quality of life
QSU-brief: Brief Questionnaire of Smoking Urges
RCT: randomised controlled trial
SAE: serious adverse event
SC: smoking cessation
TQD: target quit date
Characteristics of excluded studies [ordered by study ID]
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Study Reason for exclusion
Burstein 2006 RCT of tolerability and safety of varenicline in 24 elderly (≥ 65) smokers for 1 week. Not a cessation
trial
Chantix 2006 39 smokers randomised to NRT alone (17) or varenicline + NRT (22) for 12 days to test safety and
side effects of co-administration. 36% of combined group discontinued, compared with 6% of NRT
alone group
Cui 2012 Open-label non-randomised pre/post study of 36 HIV+ participants; all got varenicline, assessed at
wks 12 and 24
Dezee 2013 New for 2016 update. RCT in which all participants were given varenicline; intervention tested was
in-person vs internet counselling
Dutra 2012 53 participants with schizophrenia given varenicline + CBT. Abstinence assessed at 12 weeks (end of
treatment)
Ebbert 2009a Open-label, single-arm Phase II study, for safety and efficacy of varenicline plus bupropion
Ebbert 2009b Cohort analysis of 104 participants on varenicline +NRT and 135 participants treated prior to release
of varenicline (93% used NRT)
Ebbert 2014 New for 2016 update. RCT in which all participants were given varenicline; the intervention being
tested was bupropion vs placebo. See also Hong 2011 NCT00492349
Falk 2014 Varenicline was used for alcohol reduction, not for smoking
Fatemi 2013 NCT01111149 New for 2016 update. 3-arm RCT of varenicline, bupropion and placebo; only assessed to end of
treatment (12 weeks)
Ferketich 2012 New for 2016 update. Pilot study of varenicline vs NRT; participants could choose their treatment;
intervention being tested was the addition of a lung cancer screening programme
Ferketich 2013 New for 2016 update. Safety of varenicline among smokers enrolled in the Lung HIV study. Partic-
ipants could choose varenicline or NRT, and were only followed for 3 months
Frye 2013 New for 2016 update. Small (9 participants) feasibility study in bipolar participants, open-label,
followed only until end of treatment (12 weeks)
Fucito 2011 RCT of 30 heavy-drinking smokers, assigned to pre-treatment varenicline or placebo, prior to 4 wks
varenicline; primary outcome was effects on drinking behaviour, but smoking status at end of study
(8 wks) was also measured
Granatowicz 1976 Polish uncontrolled study of 1968 smokers, 71% taking cytisine, followed for 6m
Gray 2012 New for 2016 update. Pilot study of varenicline vs bupropion in older adolescents; outcome was
reduction rather than cessation, and participants were only followed for 3 months
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(Continued)
Hajek 2011 101 smokers randomised to preloaded varenicline or placebo; abstinence not measured beyond 12
weeks
Hajek 2013 New for 2016 update. All were given varenicline, with the intervention tested being the addition of
a NRT patch. Only followed to 3 months
Hartwell 2014 Varenicline for drinking and smoking; smoking topography and pharmacogenetics rather than smok-
ing cessation
Hawk 2012 NCT00835900 New for 2016 update. RCT of extended pre-TQD varenicline vs standard regimen; all participants
got varenicline, and were followed only until end of treatment (12 weeks)
Hong 2011 NCT00492349 New for 2016 update. Secondary analysis to Ebbert 2014, looking at depression in recipients of
varenicline + bupropion vs varenicline alone
Hoogsteder 2014 New for 2016 update. All participants were given open-label varenicline; the intervention being tested
was the addition of NicVAX
Hsueh 2014 New for 2016 update. Open-label cohort study of smokers taking varenicline or NRT
Jain 2014 New for 2016 update. RCT of smokeless tobacco users in India (to be covered in our review of
interventions for smokeless tobacco)
Jennings 2014 New for 2016 update. The EUROACTION PLUS study; a complex nurse-led intervention for
smokers at high risk of CVD. Varenicline was a treatment option. Only followed to 16 weeks
Jiménez-Ruiz 2013 New for 2016 update. Cohort study of smokers not responding to standard varenicline dosage by 8
weeks treated with varenicline 3 mg/day in 2 Spanish smoking cessation clinics
Kempe 1967 Bulgarian 1965 observational uncontrolled study of 30 male smokers given cytisine (Tabex) for 25
days and followed up for 6m
Koegelenberg 2014 New for 2016 update. All participants took varenicline; the intervention being tested was the addition
of NRT
Maliszewski 1972 Polish uncontrolled study of 14 smokers on a 25-day course of cytisine (Tabex); followed up for 2
wks
Marakulin 1984 Russian trial of 620 smokers; no placebo, but autogenic training for control group. Follow-up 6 wks
McColl 2008 RCT of varenicline’s potential as an abuse drug in smokers and non-smokers; not a smoking cessation
trial
McNaughton 2013 New for 2016 update. All participants received varenicline; the intervention being tested, as a relapse
prevention aid, was interactive voice response phone calls
Metelitsa 1987 Russian uncontrolled study of 281 smokers, comparing anabasine hydrochloride, cytisine or a com-
bination of both drugs, taken as biosoluble film on a paper or fabric patches. Followed for 6 - 14m
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(Continued)
Mocking 2013 New for 2016 update. 7-day administration of varenicline for emotional and cognitive processing in
non-smokers
Mocking 2014 New for 2016 update. 7-day administration of varenicline for cortisol levels, not for smoking cessation
Monova 2004 BulgarianRCTof 150moderate+ smokers; investigators did not instruct participants to stop smoking,
but monitored their smoking behaviour during and after a 25-day course of cytisine (Tabex). Follow-
up was 60 days
NCT00502216 New for 2016 update. Study of varenicline and naltrexone for tolerability and weight gain in smokers,
not cessation
NCT01308736 Outcome was 50% reduction in smoking, not abstinence (none succeeded in quitting completely)
NCT01806779 All participants got varenicline; the addition of bupropion was the intervention being tested
Nollen 2011 RCT of 72 black smokers; all received varenicline, but half got extended counselling and half a single
session. Cessation only measured to 3m endpoint
Ostrovskaia 1994 Russian uncontrolled study of 74 smokers, comparing anabasin, cytisine or combination therapy, in
film patches. (Relates to Metelitsa 4-stage study). Followed for 6 - 14m
Park 2011 RCT of 49 smokers with lung cancer randomised to varenicline or placebo; Follow-up only for 12
weeks to end of treatment
Patterson 2010 New for 2016 update. Short-term (3-week) study of propensity to relapse with working memory
deficits after 10 days of varenicline
Paun 1968 Bulgarian controlled trial of cytisine (Tabex) (366 smokers) vs placebo (239 smokers) but followed
only for 8 wks. Observational study of 230 cytisine-users followed for 26 wks, but no comparator
group
Pfizer 2006 Phase II flexible-dosing trial of varenicline in 312 participants. Treatment lasted 12 weeks, and
cessation outcomes reported for continuous abstinence through weeks 9 - 12
Poling 2010 RCT of varenicline in 31 methadone-maintained smokers; trial lasted 3m, and reduction was an
outcome of interest (though 3m abstinence was reported)
Ramon 2014 New for 2016 update. RCT in which all participants received varenicline; intervention being tested
was the addition of NRT
Rose 2014 New for 2016 update. RCT of varenicline versus varenicline + bupropion, in smokers who had failed
to quit on NRT. All got varenicline
Schlienz 2014 New for 2016 update. 4 weeks treatment with varenicline; outcome was impact on behavioural
economic indices, not smoking cessation
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(Continued)
Schmidt 1974 Non-randomised trial of 16 smoking cessation preparations, including cytisine (Tabex) (200 smokers)
; participants allocated to treatment ’by chance’, and followed up over 3m. Placebo group not directly
matched to cytisine (Tabex) group
Schnoll 2011 New for 2016 update. RCT of open-label varenicline + counselling; intervention being tested was
recruitment strategies, not smoking cessation
Shim 2011 60 smokers with schizophrenia randomised to varenicline or placebo for 8 weeks; assessment at end
of treatment, reduction but not abstinence rates reported
Sicras-Mainar 2010 Multicentre observational non-randomised non-controlled study
Stapleton 2008 Non-randomised trial of 412 attenders at a London smoking cessation clinic, choosing either NRT
(single product or combination) or varenicline. NRT arm were historical controls. Effectiveness and
safety were assessed separately in a subset of 111 participants receiving treatment for mental illness
Stoyanov 1972 87 smokers (17 of them psychiatric patients); observational study with no comparator group and
short but unstated length of follow-up
Swan 2010 All participants were given varenicline (treated as an included study for 2012 update)
Weiner 2011 9 smokers with schizophrenia randomised to varenicline or placebo; final assessment was at 12 weeks
(end of treatment)
Zatonski 2006 Polish uncontrolled observational study of 342 smokers; at 12 months 13.8% abstinent
Characteristics of studies awaiting assessment [ordered by study ID]
Wiratmoko 2013
Methods
Participants
Interventions
Outcomes
Notes Abstract only; further details awaited
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Yujie 2014
Methods
Participants
Interventions
Outcomes
Notes Abstract only; further details awaited
Zincir 2013
Methods
Participants
Interventions
Outcomes
Notes Not in English; may be too short-term to include
Characteristics of ongoing studies [ordered by study ID]
ACTRN12613000854730
Trial name or title TALANOA Samoa: A randomised controlled trial to evaluate the efficacy of a cessation support programme
for smokers delivered by radio
Methods Open-label parallel-group efficacy RCT
Participants Up to 130 adults (16+), tobacco smoker, speaking Samoan, resident in Auckland NZ
Interventions 10 weekly ½-hour radio programmes of behavioural advice
Outcomes Prevalence of quitting at 3m, CO-verified (< 10 ppm). N of quit attempts, successful or not
Starting date September 2013
Contact information PI: v.nosa@auckland.ac.nz; Scientific enquiries: d.gentles@auckland.ac.nz
Notes
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ACTRN12614000329662
Trial name or title Examination of mechanism of action of pre-quit use of nicotine patch and varenicline for smoking cessation
[PQT]
Methods Open-label parallel-group efficacy RCT
Participants Up to 216 adults (18+), smoking 15+ CPD, highmotivation to quit, willing and able to take eithermedication
Interventions (i) Varenicline, 2 wks before TQD and 4 wks after; or (ii) NRT 21 mg patch, starting 2 wks before TQD
Outcomes Primary:
1. CPD reduction in 1st 2 wks
2. Measures of craving
3. Smoking satisfaction
Secondary:
1. CO-validated abstinence at 28 days post-TQD
Starting date March 2014
Contact information PI and enquiries: stuart.ferguson@utas.edu.au
Notes
ACTRN12614000876695
Trial name or title Improving radiotherapy outcomes with smoking cessation: feasibility trial in head and neck cancer patients
[Health Steps]
Methods Parallel blinded safety/efficacy RCT
Participants Up to 40 head-and-neck cancer patients, smoking at least 5 CPD, scheduled for radiotherapy
Interventions 3m varenicline + 10 sessions manual-based MI; control get TAU, no varenicline
Outcomes Feasibility and acceptability, i.e. compliance, tolerability
Continuous abstinence up to 6m post-radiotherapy, CO-validated
Starting date August 2014
Contact information PI and enquiries: ben.britton@hnehealth.nsw.gov.au
Notes
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Ameridian 2007
Trial name or title Efficacy and safety of dianicline treatment as an aid to smoking cessation in cigarette smokers (AMERIDIAN)
Methods Double-blind placebo-controlled RCT; companion study to EURODIAN trial (see Tonstad 2011).
Participants 600 adult smokers in USA, Canada
Interventions Dianicline 40 mg bid for 7 wks, vs placebo (same regimen)
Outcomes CAR at wks 4 - 7. Craving and withdrawal symptoms
Starting date September 2006
Contact information Sanofi-Aventis
Notes Information taken from ClinicalTrials.gov; results not yet reported.
EUCTR2009-017599-26-IT
Trial name or title Efficacy and safety of smoking cessation with varenicline tartrate in diabetic smokers: a double-blind, placebo-
controlled randomised trial
Methods RCT
Participants Elderly adults, aged 75+, with type 2 diabetes
Interventions 1 mg x 2/day
Outcomes CQR at wk 24
Starting date 22nd January 2010
Contact information
Notes
ISRCTN25441641
Trial name or title Evaluation of the impact of systematic delivery of cessation interventions on delivery of smoking cessation in
secondary care [Exploring ways to help hospital patients stop smoking]
Methods RCT
Participants Adult smokers
Interventions NRT + counselling, with varenicline or bupropion offered to those who do not wish to take NRT
Outcomes 1m abstinence after discharge from hospital
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ISRCTN25441641 (Continued)
Starting date October 2010
Contact information Kapka Nilan, University of Nottingham, UK
Notes
Nahvi 2014b
Trial name or title Varenicline smoking cessation treatment for methadone maintenance patients
Methods Open-label parallel-group efficacy RCT
Participants 100 adult methadone-maintained smokers, at least 5 CPD, interested in quitting
Interventions Directly-observed varenicline treatment versus TAU (self-administered varenicline)
Outcomes CO-verified abstinence at 12 wks
Varenicline adherence; tobacco use measures; reduction in CPD
Starting date July 2011
Contact information Shadi Nahvi
Notes
NCT00554840
Trial name or title Comparison of varenicline and placebo for smoking cessation in schizophrenia
Methods Randomised double-blind placebo-controlled trial
Participants 44 smokers with schizophrenia
Interventions 12 weeks varenicline 1.0 mg x 2/day vs placebo
Outcomes PPA at 12 weeks, neuropsychiatric symptoms
Starting date November 2007
Contact information E Weiner
Notes
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NCT00580853
Trial name or title The effect of varenicline (Chantix) and bupropion (Zyban) on smoking lapse behavior
Methods Randomised triple-blind factorial trial
Participants 60 adult smokers
Interventions 8-day course of varenicline, bupropion or placebo
Outcomes Latency to initiate ad-lib smoking
Starting date April 2007
Contact information SA McKee
Notes
NCT00683280
Trial name or title Contingency management and pharmacotherapy for smoking cessation (Donaghue)
Methods Open-label parallel-group efficacy RCT
Participants 59 adults, smoking 10+ CPD, motivated to quit (intended to recruit 70)
Interventions All on 12 wks varenicline + brief counselling; tested intervention is the addition of contingent prizes for
quitting
Outcomes CO- and cotinine-verified abstinence at wks 5, 12 and 24
Starting date May 2008
Contact information Sheila M Alessi
Notes
NCT00786149
Trial name or title Improving varenicline adherence and outcomes in homeless smokers
Methods Open-label parallel-group efficacy RCT
Participants 428 adult homeless smokers, at least 5 CPD
Interventions Varenicline + MI sessions vs varenicline + brief advice (testing MI)
Outcomes 7-day PPA at 6m
Adherence at 12 wks and 6m; moderating effects of psychiatric comorbidities
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NCT00786149 (Continued)
Starting date September 2007
Contact information Kolawole S Okuyemi
Notes
NCT00879177
Trial name or title Smoking study with behavioural therapy for hypertensive patients (VANQUISH)
Methods Open-label parallel-group efficacy RCT
Participants 260 hypertensive adult smokers
Interventions Varenicline alone vs varenicline + behavioural therapy
Outcomes Abstinence at 5, 6, 8, 12, 24, 36, 52 wks
Starting date April 2009
Contact information William B White
Notes
NCT00906386
Trial name or title Methadone maintenance treatment and smoking cessation (MMTASC)
Methods Randomised double-blind placebo-controlled trial
Participants 112 smokers on methadone maintenance for opioid dependence
Interventions Varenicline 1.0 mg x 2/day vs placebo for 12 wks
Outcomes 7-day PPA at 26 weeks
Starting date May 2009
Contact information Milan Khara
Notes
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NCT00918307
Trial name or title Comparison of the efficacy and safety of varenicline versus placebo for smoking cessation amongHIV-infected
patients (Inter-ACTIV)
Methods Randomised quadruple-blind placebo-controlled trial
Participants 254 smokers diagnosed with HIV infection
Interventions Varenicline 1.0 mg x 2/day vs placebo for 12 weeks
Outcomes CAR for wks 9 - 48
Starting date October 2009
Contact information Patrick Mercie
Notes
NCT00921388
Trial name or title Exercise or relaxation for smoking cessation
Methods Open-label parallel-group efficacy RCT
Participants 364 postmenopausal (aged 45+) women smokers, 10+ CPD, motivated to quit and to exercise
Interventions Varenicline + counselling + exercise programme vs varenicline + counselling + relaxation programme
Outcomes Abstinence at wks 12 and 64
Starting date March 2009
Contact information Cheryl Oncken
Notes
NCT00931021
Trial name or title Smoking cessation treatment for head and neck cancer patients
Methods Randomised open-label trial
Participants 30 smokers diagnosed with head and neck cancer
Interventions Varenicline 1.0 mg x 2/day vs 21 mg nicotine patch for 8 weeks
Outcomes CAR at wks 5 - 8
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NCT00931021 (Continued)
Starting date July 2009
Contact information Benjamin Toll
Notes
NCT00937235
Trial name or title Treatment of smoking among individuals with PTSD
Methods Single-blind parallel-group RCT
Participants 166 treatment-seeking smokers, aged 18 - 75, ≥ 10 CPD, diagnosed with chronic PTSD
Interventions Varenicline + SC counselling + CBT vs varenicline + SC counselling
Outcomes 7-day PPA at end of treatment and at 6m
Starting date January 2009
Contact information Edna B Foa
Notes
NCT00943618
Trial name or title Effectiveness of varenicline vs. varenicline plus bupropion or placebo for smoking cessation
Methods Randomised triple-blind placebo-controlled trial
Participants 350 adult smokers
Interventions (Varenicline + bupropion) vs (varenicline + placebo) vs double placebo, for 12 weeks
Outcomes Quit rate at 12 weeks
Starting date May 2010
Contact information Paul Cinciripini
Notes
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NCT01067612
Trial name or title Extended treatment for smoking cessation
Methods Randomised open-label trial
Participants 400 adult smokers
Interventions 10-wk open-label phase of CBT + bupropion and NRT; those still smoking at 10 wks will be switched to 16
wks of varenicline. All will get CBT to 26 wks
Outcomes Smoking abstinence at 52 and 104 wks
Starting date March 2010
Contact information Joel D Killen
Notes
NCT01093937
Trial name or title Varenicline for smoking cessation/reduction in patients with bipolar disorder
Methods Randomised placebo-controlled quadruple-blind trial
Participants 30 adult smokers with bipolar disorder
Interventions Varenicline flexible dosing (0.5 to 2.0 mg/day) vs placebo for 10 weeks. All get group CBT
Outcomes Smoking cessation and safety at 10 weeks
Starting date November 2009
Contact information Tony George
Notes
NCT01162239
Trial name or title Maintaining nonsmoking
Methods Open-label 4-arm randomised trial
Participants 271 adult smokers (5+ CPD), who have all completed 12-wk course of varenicline + counselling
Interventions After treatment, participants are randomised to:
1. Extended brief contact, or
2. Extended health education, or
3. Extended relapse prevention + varenicline, or
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NCT01162239 (Continued)
4. Extended relapse prevention
Outcomes Smoking status at 12, 24, 52, 64 and 104 wks
Starting date May 2010
Contact information Not named (U of California, San Francisco)
Notes
NCT01170338
Trial name or title Safety and efficacy of varenicline in patients with acute coronary syndrome
Methods Randomised placebo-controlled double-blind trial
Participants 100 adult smokers with acute coronary syndrome
Interventions Varenicline 100 [sic] mg bid
Outcomes Nicotine levels at 1 month; recurrent myocardial ischaemia
Starting date January 2008
Contact information Marc Cohen
Notes
NCT01243203
Trial name or title Smoking cessation program in the preadmission clinic: the use of a teachable moment
Methods Double-blind parallel-group RCT
Participants 300 smokers scheduled for elective surgery, aged 18+, smoking 10+ CPD
Interventions Varenicline vs placebo
Outcomes Abstinence at 24 and 52 wks
Starting date November 2007
Contact information Francis Chung
Notes
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NCT01286584
Trial name or title Varenicline in residential treatment (ViRT)
Methods Phase IV randomised triple-blind controlled trial
Participants 50 smokers undergoing inpatient treatment for alcohol dependence
Interventions Varenicline 1 mg x 2/day for 12 weeks vs placebo
Outcomes Abstinence at end of treatment and 30-day CAR at 6m
Starting date June 2011
Contact information Laurie Zawertailo
Notes
NCT01312909
Trial name or title Smoking cessation study in healthy adolescent smokers
Methods Phase IV randomised triple-blind placebo-controlled trial
Participants 300 healthy adolescents (12 - 19 yrs) smoking at least 5 CPD, with at least 1 failed quit attempt
Interventions Varenicline 1 mg x 2/day vs varenicline 0.5 mg x 2/day vs placebo
Outcomes CAR at weeks 9 - 12, 9 - 24, 9 - 52; 7-day PPA at wks 12, 24, 52; CPD reduction
Starting date April 2011
Contact information Pfizer Inc
Notes
NCT01314001
Trial name or title Pharmacogenetics of nicotine addiction treatment
Methods Phase III randomised triple-blind placebo-controlled trial
Participants 1350 adult smokers, stratified by nicotine metabolite ratio (NMR)
Interventions Varenicline 1 mg x 2/day + placebo patch vs NRT patch + placebo pills vs placebo pills + placebo patch
Outcomes 7-day PPA at 11 weeks, CAR at 11 weeks, cost effectiveness, time to relapse
Starting date January 2011
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NCT01314001 (Continued)
Contact information Caryn Lerman
Notes
NCT01320462
Trial name or title Smoking cessation program in the preadmission clinic: the combination of counseling, pharmacotherapy and
quit line
Methods Randomised open-label controlled trial
Participants 296 adult smokers scheduled for elective surgery
Interventions Counselling + 12 weeks varenicline + proactive telephone support, vs standard care (brief information +
smokers help line)
Outcomes 4-wk CAR at 4, 12, 24 and 52 weeks; 24 hr PPA
Starting date December 2010
Contact information Francis Chung
Notes
NCT01387425
Trial name or title Efficacy and safety of smoking cessation with varenicline tartrate in diabetic smokers (DIASMOKE)
Methods Randomised double-blind placebo-controlled trial
Participants 300 adult smokers with type 2 diabetes
Interventions Varenicline 1 mg x 2/day for 12 weeks vs placebo
Outcomes CAR at week 24; safety; CAR at week 52; adverse events
Starting date June 2011
Contact information Riccardo Polosa
Notes
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NCT01413516
Trial name or title Varenicline inpatient study [VIP]
Methods Double-blind parallel-group RCT
Participants 80 (40m, 40f ) smokers hospitalised, 10+ CPD, with admission of at least 3 days
Interventions Varenicline + counselling vs placebo + counselling
Outcomes 7-day PPA after 4 wks of treatment
Starting date August 2011
Contact information Judith J Prochaska
Notes
NCT01509547
Trial name or title Varenicline for adolescent smoking cessation
Methods Double-blind parallel-group RCT
Participants 166 adolescents aged 14 - 21, daily smoker for 6+ months, motivated to quit and failed at least 1 quit attempt
Interventions Varenicline vs placebo for 12 wks
Outcomes Self-reported CPD; CO-validated smoking status at 26 wks; adverse events
Starting date August 2012
Contact information Kevin M Gray
Notes
NCT01531049
Trial name or title Smoking habits and smoking cessation in young adults
Methods Single-blind 4-arm parallel-group RCT
Participants 300 young adults (18 - 26), smoking at least 1 CPD
Interventions Varenicline, 10 mg nicotine patch, 15 mg nicotine patch, placebo
Outcomes CAR at 12m
Starting date May 2012
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NCT01531049 (Continued)
Contact information Tuula Toljamo
Notes
NCT01532232
Trial name or title Tobacco dependence in beast cancer patients trial of varenicline (Chantix)
Methods Double-blind parallel-group RCT
Participants 30 women smokers diagnosed with breast cancer, scheduled for mastectomy and breast reconstruction
Interventions Varenicline + counselling vs placebo + counselling
Outcomes PPA and CA at 2 yrs
Starting date February 2012
Contact information Jamie Ostroff
Notes
NCT01538394
Trial name or title Clinical trial to evaluate the efficacy of smoking cessation (COMBIVAR)
Methods Double-blind parallel-group RCT
Participants Adult smokers (18 - 65), smoking 20+ CPD
Interventions Varenicline + nicotine patches versus varenicline + placebo patches
Outcomes CAR at wk 12, 24, 36. 52; safety
Starting date February 2012
Contact information Josep Maria Ramon Torrell
Notes Will be excluded, as intervention being tested is nicotine patches
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NCT01553136
Trial name or title Varenicline treatment of alcohol dependence in smokers
Methods Double-blind parallel-group RCT
Participants Smokers seeking treatment for alcohol dependence
Interventions Varenicline versus placebo, 16 weeks
Outcomes Primarily N of drinking days, but also self-reported abstinence in the last month of treatment
Starting date February 2012
Contact information SS O’Malley
Notes May be excluded, as primarily about alcohol abuse
NCT01574703
Trial name or title Study to evaluate cardiac assessments following different treatments of smoking cessation medications in
subjects with and without psychiatric disorders [CATS]
Methods Double-blind 4-arm parallel-group RCT
Participants 6800 adult smokers, 10+ CPD, motivated to quit; Neuropsychiatric subgroup must have ’proper diagnosis
as outlined in protocol’
Interventions Placebo, varenicline, NRT patch, bupropion
Outcomes 1. Time to major adverse cardiac event (MACE) up to 52 wks
2. Abstinence at wk 12, 24
Starting date May 2012
Contact information Pfizer,GSK
Notes
NCT01592695
Trial name or title Tailored tobacco quitline for rural veterans
Methods Double-blind parallel-group RCT
Participants 50 adult smokers, rural-dwelling veterans
Interventions Tailored behavioural and pharmacotherapy group vs Enhanced standard of care + pharmacotherapy group
130Nicotine receptor partial agonists for smoking cessation (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
NCT01592695 (Continued)
Outcomes Treatment satisfaction; 7-day PPA and PA at 6m
Starting date June 2012
Contact information Mark VanderWeg
Notes
NCT01623505
Trial name or title Reducing cardiovascular disease by combining smoking cessation pharmacotherapy and behavioural coun-
seling (RW)
Methods Open-label parallel-assignment RCT
Participants Adult smokers, 10+ CPD
Interventions Nicotine patch versus nicotine patch + gum or inhaler versus varenicline
Outcomes CO-confirmed CAR at 10, 22 and 52 weeks
Starting date July 2011
Contact information Heather Tulloch
Notes May be related to Tulloch 2014
NCT01639560
Trial name or title Varenicline for light smokers (ChanLight)
Methods Double-blind parallel-group RCT
Participants Adult smokers, smoking 5 - 10 CPD for last 6m
Interventions Varenicline versus placebo
Outcomes Abstinence at 12 weeks (end of treatment)
Starting date July 2012
Contact information Jon Ebbert
Notes
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NCT01694732
Trial name or title Efficacy of varenicline on smoking cessation at the acute phase of an exacerbation of chronic obstructive
pulmonary disease (SAVE)
Methods Double-blind parallel-group RCT
Participants 276 adult patients hospitalised with acute COPD, smoking 10+ CPD, motivated to quit
Interventions Varenicline + counselling vs placebo + counselling
Outcomes Abstinence at 1 yr; side effects and tolerance at 3m
Starting date August 2012
Contact information Francis Couturaud
Notes
NCT01710137
Trial name or title Varenicline for nicotine dependence among those with HIV/AIDS
Methods Double-blind parallel-group RCT
Participants 350 adult smokers diagnosed with HIV, 5+ CPD
Interventions Varenicline + counselling vs placebo + counselling
Outcomes 7-day PPA and CA cotinine-confirmed at 24 wks
Starting date October 2012
Contact information Robert A Schnoll
Notes
NCT01756885
Trial name or title Extended varenicline treatment for smoking among cancer patients
Methods Double-blind parallel-group RCT
Participants 400 adult smokers with a current or last 5 years cancer diagnosis, 5+ CPD
Interventions 24 wks varenicline + counselling vs 12 wks varenicline + 12 wks placebo + counselling
Outcomes 7-day PPA, CA, PA CO-verified at wk 24, wk 52
132Nicotine receptor partial agonists for smoking cessation (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
NCT01756885 (Continued)
Starting date January 2013
Contact information
Notes
NCT01771627
Trial name or title Varenicline or nicotine patch in promoting smoking cessation among current smokers
Methods Open-lable parallel-group RCT
Participants 300 adult smokers calling quitline
Interventions Varenicline + counselling vs nicotine patch + counselling
Outcomes 4m quit rate
Starting date October 2012
Contact information Martin Mahoney
Notes
NCT01772641
Trial name or title A smoking intervention study using scheduled gradual reduction with varenicline to help with cessation
Methods Double-blind factorial RCT
Participants 192 adult smokers, 10+ CPD
Interventions 4-wk scheduled gradual reduction programme + varenicline vs 4-wk scheduled gradual reduction programme
+ placebo
Outcomes PA at 4, 12 wks
Starting date December 2012
Contact information Joel Erblich
Notes
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NCT01800019
Trial name or title The Canadian HIV Quit Smoking Trial: tackling the co-morbidities of depression and cardiovascular disease
in HIV+ smokers (CANQUIT)
Methods Open-label 4-arm factorial RCT
Participants 256 adults HIV+ smokers, 5+ CPD, willing to set a quit date
Interventions NRT, NRT + HIV-tailored quit smoking counselling, varenicline, varenicline + HIV-tailored quit smoking
counselling
Outcomes 7-day PPA and 4-wk CA at wk 48, CO-verified
Starting date January 2014
Contact information
Notes
NCT01850953
Trial name or title Varenicline lapse study
Methods Double-blind cross-over RCT
Participants 50 adult smokers, 10+ CPD, not trying to quit, with schizophrenia or schizoaffective disorder; controls not
on psychotropic meds or diagnosed with any Axis 1 disorder
Interventions Varenicline vs placebo
Outcomes Time to lapse
Starting date June 2013
Contact information Tony George
Notes
NCT01892813
Trial name or title Dissemination of a tailored tobacco quitline for rural veteran smokers
Methods Double-blind parallel-group RCT
Participants 500 adult veteran daily smokers, willing to try to quit
Interventions Tailored intervention (behavioural and meds) vs Enhanced standard of care
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NCT01892813 (Continued)
Outcomes 7-day and 30-day PPA at 6m
Starting date July 2013
Contact information Mark W Vander Weg
Notes
NCT01898195
Trial name or title Improving adherence to smoking cessation medication among PLWHA (HIV)
Methods Open-label RCT
Participants 220 adult HIV+ smokers, 5+ CPD, willing to quit
Interventions Varenicline (standard care), vs varenicline: text messages + adherence behavioural therapy
Outcomes Adherence to treatment; abstinence at wks 1, 4, 8, EoT, 3m
Starting date March 2013
Contact information Donna Shelley
Notes
NCT02048917
Trial name or title Smoking cessation strategies in community cancer programs for lung and head and neck cancer patients
Methods Open-label 12-arm RCT
Participants 180 adult smoking patients with current lung, head and neck cancer diagnosis, smoked at least 1 cigarette
within 4 wks of enrolment
Interventions High vs low intensity counselling, long-acting vs PRN NRT, bupropion, varenicline in various combinations
Outcomes 7-day CO-confirmed PPA at 8 wks
Starting date July 2014
Contact information Joseph Valentino
Notes May be too short
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NCT02106637
Trial name or title Early in-hospital initiation of pharmacotherapy for smoking cessation, Patients after ACS
Methods Double-blind parallel-group RCT
Participants 300 adult smokers with ACS
Interventions Varenicline vs placebo
Outcomes CAR at 1m, 6m, 1 yr after hospitalisation; SAE rate
Starting date June 2014
Contact information Haim Lotan
Notes
NCT02136498
Trial name or title Internet-based medication adherence program for nicotine dependence treatment
Methods Double-blind parallel-group RCT
Participants 70 adult members of Group Health insurance, smoking 10+ CPD, motivated to quit, smart phone access
Interventions Online self help + varenicline vs augmented online self help + varenicline
Outcomes 7-day PPA at 5m
Starting date October 2014
Contact information Sherryl Catz, Larry An
Notes
NCT02146911
Trial name or title The MATCH (medication aids for tobacco cessation) Study
Methods Open-label RCT
Participants 1500 adult smokers, 10+ CPD, motivated to quit
Interventions Bupropion + weekly motivational emails vs varenicline + weekly motivational emails
Outcomes CA at 12, 26, 52 wks
Starting date May 2014
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NCT02146911 (Continued)
Contact information Laurie Zawertailo
Notes
NCT02147132
Trial name or title Pilot study of nicotine nasal spray and varenicline on smoking in methadone-maintained patients
Methods Double-blind 4-arm cross-over RCT
Participants 20 adult smokers on methadone maintenance, 10+ CPD
Interventions Nasal spray (active and placebo), varenicline (active and placebo), taken in different orders
Outcomes Proportion of CPD taken within 4 hours of receiving methadone dose; abstinence, CO-verified
Starting date December 2014
Contact information Theresa Winhusen
Notes
NCT02162849
Trial name or title Reward sensitivity and pharmacotherapy for smoking cessation
Methods Double-blind parallel-group RCT
Participants 90 adults smokers, 5+ CPD,
Interventions Varenicline + placebo patch vs nicotine patch + placebo tablet; all get behavioural counselling
Outcomes CAR at EoT, 3m, 6m
Starting date April 2015
Contact information Paul Cinciripini
Notes
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NCT02271919
Trial name or title Varenicline and combined nicotine replacement therapy (NRT) for smoking cessation
Methods Double-blind 5-arm cross-over RCT
Participants 310 adult smokers, 5+ CPD
Interventions Varenicline vs nicotine patch + lozenge vs extra tablets or patches vs switch to different therapy vs extra tablet
or patch
Outcomes 7-day PPA at 12 wks
Starting date May 2015
Contact information Paul Cinciripini
Notes
NCT02328794
Trial name or title Randomised clinical trial to reduce harm from tobacco
Methods Single-blind parallel-group RCT
Participants 6000 adult smokers, Vitality beneficiaries
Interventions Standardised Vitality program vs Vitality + choice of e-cigarette/varenicline/bupropion/NRT vs Vitality +
choice of meds + deposit-refund programme
Outcomes CO-verified abstinence at 6m, 12m
Starting date January 2015
Contact information Scott Halpern
Notes
NCT02351167
Trial name or title Genetically informed smoking cessation trial
Methods Double-blind 3-arm parallel-group RCT
Participants 720 adults, 5+ CPD, motivated to quit smoking
Interventions NRT + counselling vs varenicline + counselling vs combination NRT + counselling
Outcomes 7-day PPA at wk 12, wk 24
138Nicotine receptor partial agonists for smoking cessation (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
NCT02351167 (Continued)
Starting date May 2015
Contact information Li-Shiun Chen
Notes
NCT02360631
Trial name or title Advancing tobacco use treatment for African-American smokers (KIS-IV)
Methods Double-blind parallel-group RCT
Participants 500 adult A-A smokers, 5+ CPD, motivated to quit
Interventions Varenicline vs placebo
Outcomes 7-day PPA at 6m
Starting date April 2015
Contact information Lisa Sanderson Cox
Notes
NCT02367391
Trial name or title Penn State TXT2Quit study
Methods Single-blind parallel-group RCT
Participants 150 adult smokers, 4+ CPD, motivated to quit
Interventions Varenicline + motivation text messages vs varenicline alone
Outcomes 7-day PPA CO-verified at wk 12
Starting date January 2015
Contact information Jonathan Foulds
Notes
139Nicotine receptor partial agonists for smoking cessation (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Reid 2010
Trial name or title Varenicline versus transdermal nicotine patch for smoking cessation in patients with coronary heart disease
Methods Randomised open-label trial
Participants 60 adult smokers
Interventions Varenicline or NRT patch for 12 weeks
Outcomes CO-confirmed CAR for wks 12 - 26
Starting date April 2009
Contact information Robert Reid
Notes
Rohsenow 2015
Trial name or title Varenicline helps smokers with SUD stop smoking without harming recovery
Methods Randomised quadruple-blind placebo-controlled trial
Participants 274 adult smokers with substance use disorders
Interventions Varenicline vs NRT patches for 12 weeks, plus motivational advice
Outcomes 7-day PPA at 3, 6 and 12m
Starting date
Contact information Damaris Rohsenow@brown.edu
Notes New for 2016 update; extraction based on Powerpoint slides in 137 participants
Smith 2013b
Trial name or title Varenicline for cognitive deficits and cigarette smoking in schizophrenia
Methods Randomised double-blind placebo-controlled trial
Participants 60 adult smokers with schizophrenia
Interventions Varenicline 1 - 2 mg/day vs placebo
Outcomes Cotinine-verified cessation, + Measurement and Treatment Research to Improve Cognition in Schizophrenia
(MATRICS), Positive and Negative Syndrome Scale (PANNS), Hamilton Depression Scale
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Smith 2013b (Continued)
Starting date September 2008
Contact information RC Smith
Notes
Tulloch 2014
Trial name or title Flexible and extended dosing of nicotine replacement therapy or varenicline in comparison to fixed dose
nicotine replacement therapy for smoking cessation: the FLEX trial
Methods Randomised controlled trial
Participants 737 adult smokers
Interventions NRT vs combination NRT vs varenicline
Outcomes CAR wks 5 - 52, + neuropsychiatric and withdrawal symptoms
Starting date
Contact information hetulloch@ottawaheart.ca
Notes New for 2016 update
Van Rossem 2015
Trial name or title Helping more smokers to quit by combining varenicline with counselling for smoking cessation. The COV-
ACO randomized controlled trial
Methods Open-label RCT
Participants 295 primary-care smoking patients, no minimum CPD
Interventions Varenicline + brief GP advice vs varenicline + PN or GP extended counselling
Outcomes PA at wk 52
Starting date
Contact information C van Rossem
Notes
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This list does not include all registered studies of varenicline, dianicline and cytisine. It covers only those studies expected to be eventual
candidates for inclusion within future updates of this review, i.e. RCTs of smoking cessation interventions with a minimum follow-
up of six months, or for shorter duration if safety issues are the main outcome.
ACS: acute coronary syndrome
CAR: continuous abstinence rate
COPD: chronic obstructive pulmonary disease
CPD: cigarettes per day
CQR: continuous quit rate
MI: motivational interviewing
PLWHA: people living with HIV/AIDS
PN: psychiatric nurse
PPA: point prevalence abstinence
PTSD: post-traumatic stress disorder
TAU: treatment as usual
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D A T A A N D A N A L Y S E S
Comparison 1. Cytisine vs placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 CAR at longest follow-up 2 937 Risk Ratio (M-H, Fixed, 95% CI) 3.98 [2.01, 7.87]
2 Point prevalence abstinence at 2
years
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
Comparison 2. Cytisine vs NRT
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Continuous abstinence at 6m 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
Comparison 3. Dianicline vs placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 CAR at weeks 4 - 26 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
Comparison 4. Varenicline (1.0 mg 2/d) vs placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Continuous or sustained
abstinence at longest follow-up
(24+ weeks)
27 12625 Risk Ratio (M-H, Fixed, 95% CI) 2.24 [2.06, 2.43]
2 Abstinence at six months 25 12304 Risk Ratio (M-H, Fixed, 95% CI) 2.25 [2.08, 2.44]
3 Abstinence for long-term use (up
to 52 weeks) of varenicline
4 2170 Risk Ratio (M-H, Fixed, 95% CI) 3.64 [2.81, 4.72]
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Comparison 5. Varenicline vs bupropion
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Varenicline vs bupropion at 6m 5 5877 Risk Ratio (M-H, Fixed, 95% CI) 1.39 [1.25, 1.54]
2 Continuous abstinence at 52
weeks
3 1618 Risk Ratio (M-H, Fixed, 95% CI) 1.52 [1.22, 1.88]
3 Varenicline vs bupropion at 3m 5 5877 Risk Ratio (M-H, Fixed, 95% CI) 1.46 [1.35, 1.58]
Comparison 6. Varenicline vs NRT
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Point prevalence abstinence at
24 weeks
8 6264 Risk Ratio (M-H, Fixed, 95% CI) 1.25 [1.14, 1.37]
Comparison 7. Variations in usage
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Flexible quit date 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
2 Non-standard dose varenicline
versus placebo at 52 weeks
9 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 Low-dose varenicline vs
placebo at 52 weeks
4 1266 Risk Ratio (M-H, Fixed, 95% CI) 2.08 [1.56, 2.78]
2.2 Variable dosage at
participant’s or physician’s
discretion
6 1789 Risk Ratio (M-H, Fixed, 95% CI) 2.29 [1.81, 2.89]
3 Standard dose varenicline versus
low dose at 52 weeks
3 1079 Risk Ratio (M-H, Fixed, 95% CI) 1.25 [1.00, 1.55]
4 Standard dose varenicline versus
high dose at 12 weeks
1 200 Risk Ratio (M-H, Fixed, 95% CI) 0.88 [0.54, 1.44]
5 Reducing to quit 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
6 Varenicline as maintenance
therapy (relapse prevention) to
sustain quitting
2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
6.1 Abstinence at 52 weeks 2 1295 Risk Ratio (M-H, Fixed, 95% CI) 1.24 [1.08, 1.42]
6.2 Abstinence at 24 weeks 1 1210 Risk Ratio (M-H, Fixed, 95% CI) 1.42 [1.29, 1.56]
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Comparison 8. Varenicline in specific patient groups
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Cardiovascular disease 2 1006 Risk Ratio (M-H, Fixed, 95% CI) 1.88 [1.44, 2.47]
2 COPD 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
3 Asthma 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
4 Schizophrenia/bipolar/
psychiatric disorder
4 2332 Risk Ratio (M-H, Fixed, 95% CI) 2.28 [1.82, 2.87]
5 Depression 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
6 Substance use disorder/
methadone-maintained at 24
weeks
2 294 Risk Ratio (M-H, Fixed, 95% CI) 3.72 [0.50, 27.59]
7 Alcohol-dependent smokers 1 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
8 Long-term use of NRT 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
Comparison 9. Varenicline in different settings/subgroups
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Hospital inpatients/perioperative
patients
3 744 Risk Ratio (M-H, Fixed, 95% CI) 1.39 [1.09, 1.77]
2 Smokers who have failed on
other cessation therapies
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
3 Light or heavy smokers 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
Comparison 10. Adverse event meta-analyses
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Nausea 32 14963 Risk Ratio (M-H, Fixed, 95% CI) 3.27 [3.00, 3.55]
2 Insomnia 29 14447 Risk Ratio (M-H, Fixed, 95% CI) 1.49 [1.35, 1.65]
3 Abnormal dreams 26 13682 Risk Ratio (M-H, Fixed, 95% CI) 2.12 [1.88, 2.38]
4 Headache 25 13835 Risk Ratio (M-H, Fixed, 95% CI) 1.17 [1.07, 1.29]
5 Depression 36 16189 Risk Ratio (M-H, Fixed, 95% CI) 0.94 [0.77, 1.14]
6 Suicidal ideation 24 11193 Risk Ratio (M-H, Fixed, 95% CI) 0.68 [0.43, 1.07]
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Comparison 11. Serious adverse events
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 SAEs in the varenicline trials 29 15370 Risk Ratio (M-H, Fixed, 95% CI) 1.25 [1.04, 1.49]
2 SAEs in the varenicline trials, exc
post-treat events
26 15000 Risk Ratio (M-H, Fixed, 95% CI) 1.25 [1.02, 1.52]
3 Neuropsychiatric SAEs (not
deaths)
23 8955 Risk Ratio (M-H, Fixed, 95% CI) 0.82 [0.57, 1.19]
4 Cardiac SAEs, including deaths 21 8587 Risk Ratio (M-H, Fixed, 95% CI) 1.36 [0.91, 2.04]
Comparison 12. Losses to follow-up
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Participants remaining at end of
varenicline trials
Other data No numeric data
Comparison 13. Sensitivity analysis
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 ITT treatment vs per protocol
control
28 12422 Risk Ratio (M-H, Fixed, 95% CI) 1.79 [1.65, 1.94]
2 Continuous abstinence at 9 - 12
weeks
24 12339 Risk Ratio (M-H, Fixed, 95% CI) 2.49 [2.33, 2.65]
3 Continuous abstinence at 24
weeks
26 14016 Risk Ratio (M-H, Fixed, 95% CI) 2.44 [2.26, 2.63]
146Nicotine receptor partial agonists for smoking cessation (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.1. Comparison 1 Cytisine vs placebo, Outcome 1 CAR at longest follow-up.
Review: Nicotine receptor partial agonists for smoking cessation
Comparison: 1 Cytisine vs placebo
Outcome: 1 CAR at longest follow-up
Study or subgroup Cytisine Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Vinnikov 2008 9/100 1/97 10.1 % 8.73 [ 1.13, 67.61 ]
West 2011 31/370 9/370 89.9 % 3.44 [ 1.66, 7.13 ]
Total (95% CI) 470 467 100.0 % 3.98 [ 2.01, 7.87 ]
Total events: 40 (Cytisine), 10 (Placebo)
Heterogeneity: Chi2 = 0.72, df = 1 (P = 0.40); I2 =0.0%
Test for overall effect: Z = 3.97 (P = 0.000072)
Test for subgroup differences: Not applicable
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Favours placebo Favours cytisine
Analysis 1.2. Comparison 1 Cytisine vs placebo, Outcome 2 Point prevalence abstinence at 2 years.
Review: Nicotine receptor partial agonists for smoking cessation
Comparison: 1 Cytisine vs placebo
Outcome: 2 Point prevalence abstinence at 2 years
Study or subgroup Cytisine Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Scharfenberg 1971 127/607 79/607 1.61 [ 1.24, 2.08 ]
0.5 0.7 1 1.5 2
Favours control Favours cytisine
147Nicotine receptor partial agonists for smoking cessation (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.1. Comparison 2 Cytisine vs NRT, Outcome 1 Continuous abstinence at 6m.
Review: Nicotine receptor partial agonists for smoking cessation
Comparison: 2 Cytisine vs NRT
Outcome: 1 Continuous abstinence at 6m
Study or subgroup Cytisine NRT Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Walker 2014 143/655 100/655 1.43 [ 1.13, 1.80 ]
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours NRT Favours cytisine
Analysis 3.1. Comparison 3 Dianicline vs placebo, Outcome 1 CAR at weeks 4 - 26.
Review: Nicotine receptor partial agonists for smoking cessation
Comparison: 3 Dianicline vs placebo
Outcome: 1 CAR at weeks 4 - 26
Study or subgroup Dianicline Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Tonstad 2011 50/300 42/302 1.20 [ 0.82, 1.75 ]
0.01 0.1 1 10 100
Favours placebo Favours dianicline
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Analysis 4.1. Comparison 4 Varenicline (1.0 mg 2/d) vs placebo, Outcome 1 Continuous or sustained
abstinence at longest follow-up (24+ weeks).
Review: Nicotine receptor partial agonists for smoking cessation
Comparison: 4 Varenicline (1.0 mg 2/d) vs placebo
Outcome: 1 Continuous or sustained abstinence at longest follow-up (24+ weeks)
Study or subgroup Varenicline Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
De Dios 2012 (1) 3/10 0/11 0.1 % 7.64 [ 0.44, 131.75 ]
Nahvi 2014a (2) 3/57 0/55 0.1 % 6.76 [ 0.36, 127.89 ]
Chengappa 2014 6/31 2/29 0.3 % 2.81 [ 0.61, 12.81 ]
Westergaard 2015 (3) 5/26 4/25 0.6 % 1.20 [ 0.36, 3.97 ]
Evins 2014 12/40 5/47 0.7 % 2.82 [ 1.09, 7.32 ]
Heydari 2012 (4) 29/89 6/91 0.9 % 4.94 [ 2.16, 11.32 ]
Nides 2006 18/125 6/123 0.9 % 2.95 [ 1.21, 7.19 ]
Oncken 2006 58/259 5/129 1.0 % 5.78 [ 2.38, 14.05 ]
Gonzales 2014 50/249 8/245 1.2 % 6.15 [ 2.98, 12.70 ]
NCT00828113 10/50 11/51 1.6 % 0.93 [ 0.43, 1.99 ]
Steinberg 2011 (5) 8/40 11/39 1.6 % 0.71 [ 0.32, 1.57 ]
Niaura 2008 35/160 12/160 1.7 % 2.92 [ 1.57, 5.41 ]
Cinciripini 2013 24/86 15/106 2.0 % 1.97 [ 1.11, 3.52 ]
Tashkin 2011 46/248 14/253 2.0 % 3.35 [ 1.89, 5.94 ]
Rigotti 2010 68/353 26/354 3.8 % 2.62 [ 1.71, 4.02 ]
Anthenelli 2013 52/254 28/269 3.9 % 1.97 [ 1.28, 3.01 ]
Tsai 2007 59/126 27/124 3.9 % 2.15 [ 1.47, 3.15 ]
Gonzales 2006 77/352 29/344 4.3 % 2.59 [ 1.74, 3.87 ]
Rennard 2012 171/493 21/166 4.6 % 2.74 [ 1.81, 4.16 ]
Bolliger 2011 155/394 26/199 5.0 % 3.01 [ 2.06, 4.40 ]
Nakamura 2007 56/155 35/154 5.1 % 1.59 [ 1.11, 2.28 ]
Jorenby 2006 79/344 35/341 5.1 % 2.24 [ 1.55, 3.24 ]
Wong 2012 (6) 55/151 34/135 5.2 % 1.45 [ 1.01, 2.07 ]
Carson 2014 (7) 56/190 36/189 5.2 % 1.55 [ 1.07, 2.23 ]
Eisenberg 2016 53/148 39/151 5.6 % 1.39 [ 0.98, 1.96 ]
0.005 0.1 1 10 200
Favours placebo Favours varenicline
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(. . . Continued)
Study or subgroup Varenicline Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Wang 2009 63/165 42/168 6.0 % 1.53 [ 1.10, 2.12 ]
EAGLES 2016 (8) 444/2037 191/2035 27.7 % 2.32 [ 1.98, 2.72 ]
Total (95% CI) 6632 5993 100.0 % 2.24 [ 2.06, 2.43 ]
Total events: 1695 (Varenicline), 668 (Control)
Heterogeneity: Chi2 = 64.85, df = 26 (P = 0.00004); I2 =60%
Test for overall effect: Z = 19.01 (P < 0.00001)
Test for subgroup differences: Not applicable
0.005 0.1 1 10 200
Favours placebo Favours varenicline
(1) 7-day PPA at 6m
(2) 7-day PPA at 24 wks
(3) PPA at 24 wks
(4) PPA at 12m
(5) 7-day PPA at 24 weeks
(6) 7-day PPA at 12m
(7) 24-month follow-up
(8) Extrapolated from % reported quit
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Analysis 4.2. Comparison 4 Varenicline (1.0 mg 2/d) vs placebo, Outcome 2 Abstinence at six months.
Review: Nicotine receptor partial agonists for smoking cessation
Comparison: 4 Varenicline (1.0 mg 2/d) vs placebo
Outcome: 2 Abstinence at six months
Study or subgroup Varenicline Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Anthenelli 2013 64/256 33/269 4.3 % 2.04 [ 1.39, 2.99 ]
Bolliger 2011 155/394 26/199 4.6 % 3.01 [ 2.06, 4.40 ]
Carson 2014 78/191 54/194 7.2 % 1.47 [ 1.10, 1.95 ]
Chengappa 2014 6/31 2/29 0.3 % 2.81 [ 0.61, 12.81 ]
Cinciripini 2013 24/86 15/106 1.8 % 1.97 [ 1.11, 3.52 ]
De Dios 2012 (1) 3/10 0/11 0.1 % 7.64 [ 0.44, 131.75 ]
EAGLES 2016 (2) 444/2037 191/2035 25.5 % 2.32 [ 1.98, 2.72 ]
Eisenberg 2016 53/148 39/151 5.2 % 1.39 [ 0.98, 1.96 ]
Gonzales 2006 104/352 36/344 4.9 % 2.82 [ 1.99, 4.00 ]
Gonzales 2014 72/249 19/245 2.6 % 3.73 [ 2.32, 5.99 ]
Jorenby 2006 102/344 45/341 6.0 % 2.25 [ 1.64, 3.09 ]
Nahvi 2014a (3) 3/57 0/55 0.1 % 6.76 [ 0.36, 127.89 ]
Nakamura 2007 63/155 44/154 5.9 % 1.42 [ 1.04, 1.95 ]
NCT01347112 4/16 0/17 0.1 % 9.53 [ 0.55, 164.01 ]
Niaura 2008 44/160 14/160 1.9 % 3.14 [ 1.80, 5.50 ]
Nides 2006 26/125 9/123 1.2 % 2.84 [ 1.39, 5.82 ]
Oncken 2006 75/259 7/129 1.2 % 5.34 [ 2.53, 11.24 ]
Rennard 2012 171/493 21/166 4.2 % 2.74 [ 1.81, 4.16 ]
Rigotti 2010 100/353 34/359 4.5 % 2.99 [ 2.09, 4.29 ]
Steinberg 2011 (4) 8/40 11/39 1.5 % 0.71 [ 0.32, 1.57 ]
Tashkin 2011 64/248 18/254 2.4 % 3.64 [ 2.22, 5.96 ]
Tsai 2007 (5) 59/126 27/124 3.6 % 2.15 [ 1.47, 3.15 ]
Wang 2009 63/165 42/168 5.6 % 1.53 [ 1.10, 2.12 ]
Westergaard 2015 (6) 5/26 4/25 0.5 % 1.20 [ 0.36, 3.97 ]
Wong 2012 (7) 54/151 35/135 4.9 % 1.38 [ 0.97, 1.97 ]
Total (95% CI) 6472 5832 100.0 % 2.25 [ 2.08, 2.44 ]
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Favours placebo Favours varenicline
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(. . . Continued)
Study or subgroup Varenicline Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Total events: 1844 (Varenicline), 726 (Control)
Heterogeneity: Chi2 = 71.43, df = 24 (P<0.00001); I2 =66%
Test for overall effect: Z = 20.20 (P < 0.00001)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours placebo Favours varenicline
(1) 7-day PPA
(2) Extrapolated from % reported quit
(3) 7-day PPA
(4) 7-day PPA
(5) Extrapolated from graphical data
(6) 7-day PPA
(7) 7-day PPA
Analysis 4.3. Comparison 4 Varenicline (1.0 mg 2/d) vs placebo, Outcome 3 Abstinence for long-term use
(up to 52 weeks) of varenicline.
Review: Nicotine receptor partial agonists for smoking cessation
Comparison: 4 Varenicline (1.0 mg 2/d) vs placebo
Outcome: 3 Abstinence for long-term use (up to 52 weeks) of varenicline
Study or subgroup varenicline placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ebbert 2015 (1) 182/760 45/750 65.7 % 3.99 [ 2.93, 5.44 ]
NCT00828113 (2) 10/50 11/51 15.8 % 0.93 [ 0.43, 1.99 ]
Stein 2013 (3) 2/137 0/45 1.1 % 1.67 [ 0.08, 34.08 ]
Williams 2007 (4) 88/251 9/126 17.4 % 4.91 [ 2.56, 9.42 ]
Total (95% CI) 1198 972 100.0 % 3.64 [ 2.81, 4.72 ]
Total events: 282 (varenicline), 65 (placebo)
Heterogeneity: Chi2 = 13.77, df = 3 (P = 0.003); I2 =78%
Test for overall effect: Z = 9.78 (P < 0.00001)
Test for subgroup differences: Not applicable
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(1) 24 wks of treatment; PPA
(2) PPA at 52 wks (52 wks treatment)
(3) 24 wks of treatment
(4) 52 wks of treatment
Analysis 5.1. Comparison 5 Varenicline vs bupropion, Outcome 1 Varenicline vs bupropion at 6m.
Review: Nicotine receptor partial agonists for smoking cessation
Comparison: 5 Varenicline vs bupropion
Outcome: 1 Varenicline vs bupropion at 6m
Study or subgroup Varenicline Bupropion Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Cinciripini 2013 24/86 23/102 4.2 % 1.24 [ 0.75, 2.03 ]
EAGLES 2016 (1) 444/2037 330/2034 65.6 % 1.34 [ 1.18, 1.53 ]
Gonzales 2006 104/352 68/329 14.0 % 1.43 [ 1.10, 1.87 ]
Jorenby 2006 102/344 69/342 13.7 % 1.47 [ 1.13, 1.92 ]
Nides 2006 26/125 13/126 2.6 % 2.02 [ 1.09, 3.74 ]
Total (95% CI) 2944 2933 100.0 % 1.39 [ 1.25, 1.54 ]
Total events: 700 (Varenicline), 503 (Bupropion)
Heterogeneity: Chi2 = 2.08, df = 4 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 6.25 (P < 0.00001)
Test for subgroup differences: Not applicable
0.2 0.5 1 2 5
Favours bupropion Favours varenicline
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Analysis 5.2. Comparison 5 Varenicline vs bupropion, Outcome 2 Continuous abstinence at 52 weeks.
Review: Nicotine receptor partial agonists for smoking cessation
Comparison: 5 Varenicline vs bupropion
Outcome: 2 Continuous abstinence at 52 weeks
Study or subgroup Varenicline Bupropion Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Gonzales 2006 77/352 53/329 48.5 % 1.36 [ 0.99, 1.86 ]
Jorenby 2006 79/344 50/342 44.4 % 1.57 [ 1.14, 2.17 ]
Nides 2006 18/125 8/126 7.1 % 2.27 [ 1.02, 5.02 ]
Total (95% CI) 821 797 100.0 % 1.52 [ 1.22, 1.88 ]
Total events: 174 (Varenicline), 111 (Bupropion)
Heterogeneity: Chi2 = 1.50, df = 2 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 3.77 (P = 0.00016)
Test for subgroup differences: Not applicable
0.2 0.5 1 2 5
Favours bupropion Favours varenicline
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Analysis 5.3. Comparison 5 Varenicline vs bupropion, Outcome 3 Varenicline vs bupropion at 3m.
Review: Nicotine receptor partial agonists for smoking cessation
Comparison: 5 Varenicline vs bupropion
Outcome: 3 Varenicline vs bupropion at 3m
Study or subgroup Varenicline Bupropion Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Cinciripini 2013 34/86 36/102 4.6 % 1.12 [ 0.77, 1.62 ]
EAGLES 2016 (1) 682/2037 460/2034 63.9 % 1.48 [ 1.34, 1.64 ]
Gonzales 2006 155/352 97/329 13.9 % 1.49 [ 1.22, 1.83 ]
Jorenby 2006 151/344 102/342 14.2 % 1.47 [ 1.20, 1.80 ]
Nides 2006 36/125 25/126 3.5 % 1.45 [ 0.93, 2.27 ]
Total (95% CI) 2944 2933 100.0 % 1.46 [ 1.35, 1.58 ]
Total events: 1058 (Varenicline), 720 (Bupropion)
Heterogeneity: Chi2 = 2.09, df = 4 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 9.39 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 6.1. Comparison 6 Varenicline vs NRT, Outcome 1 Point prevalence abstinence at 24 weeks.
Review: Nicotine receptor partial agonists for smoking cessation
Comparison: 6 Varenicline vs NRT
Outcome: 1 Point prevalence abstinence at 24 weeks
Study or subgroup Varenicline NRT Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Aubin 2008 (1) 145/376 126/370 21.5 % 1.13 [ 0.94, 1.37 ]
Baker 2016 100/424 55/241 11.9 % 1.03 [ 0.77, 1.38 ]
De Dios 2012 3/10 0/11 0.1 % 7.64 [ 0.44, 131.75 ]
EAGLES 2016 (2) 444/2037 320/2038 54.1 % 1.39 [ 1.22, 1.58 ]
Heydari 2012 (3) 52/89 47/92 7.8 % 1.14 [ 0.88, 1.49 ]
Rose 2013 (4) 11/138 9/136 1.5 % 1.20 [ 0.52, 2.81 ]
Stein 2013 5/137 11/133 1.9 % 0.44 [ 0.16, 1.24 ]
Tsukahara 2010 (5) 7/16 7/16 1.2 % 1.00 [ 0.46, 2.19 ]
Total (95% CI) 3227 3037 100.0 % 1.25 [ 1.14, 1.37 ]
Total events: 767 (Varenicline), 575 (NRT)
Heterogeneity: Chi2 = 11.44, df = 7 (P = 0.12); I2 =39%
Test for overall effect: Z = 4.70 (P < 0.00001)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours NRT Favours varenicline
(1) Open-label, unblinded
(2) CAR at 24 weeks; extrapolated from % reported quit
(3) Open-label, unblinded
(4) Rescue treatments for non-responders or relapsers, Phases 1 and 2 combined
(5) Open-label, unblinded
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Analysis 7.1. Comparison 7 Variations in usage, Outcome 1 Flexible quit date.
Review: Nicotine receptor partial agonists for smoking cessation
Comparison: 7 Variations in usage
Outcome: 1 Flexible quit date
Study or subgroup Varenicline Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Rennard 2012 171/493 21/166 2.74 [ 1.81, 4.16 ]
0.01 0.1 1 10 100
Favours placebo Favours varenicline
Analysis 7.2. Comparison 7 Variations in usage, Outcome 2 Non-standard dose varenicline versus placebo
at 52 weeks.
Review: Nicotine receptor partial agonists for smoking cessation
Comparison: 7 Variations in usage
Outcome: 2 Non-standard dose varenicline versus placebo at 52 weeks
Study or subgroup Varenicline Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Low-dose varenicline vs placebo at 52 weeks
Nakamura 2007 (1) 51/155 35/154 58.7 % 1.45 [ 1.00, 2.09 ]
Niaura 2008 (2) 35/160 12/160 20.0 % 2.92 [ 1.57, 5.41 ]
Nides 2006 (3) 7/126 6/123 10.1 % 1.14 [ 0.39, 3.29 ]
Oncken 2006 (4) 48/259 5/129 11.2 % 4.78 [ 1.95, 11.72 ]
Subtotal (95% CI) 700 566 100.0 % 2.08 [ 1.56, 2.78 ]
Total events: 141 (Varenicline), 58 (Control)
Heterogeneity: Chi2 = 9.44, df = 3 (P = 0.02); I2 =68%
Test for overall effect: Z = 4.99 (P < 0.00001)
2 Variable dosage at participant’s or physician’s discretion
Anthenelli 2013 52/254 28/269 31.7 % 1.97 [ 1.28, 3.01 ]
Chengappa 2014 6/31 2/29 2.4 % 2.81 [ 0.61, 12.81 ]
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(. . . Continued)
Study or subgroup Varenicline Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Cinciripini 2013 24/86 15/106 15.7 % 1.97 [ 1.11, 3.52 ]
Gonzales 2014 50/249 8/245 9.4 % 6.15 [ 2.98, 12.70 ]
Hajek 2015 (5) 26/100 23/100 26.8 % 1.13 [ 0.69, 1.84 ]
Niaura 2008 35/160 12/160 14.0 % 2.92 [ 1.57, 5.41 ]
Subtotal (95% CI) 880 909 100.0 % 2.29 [ 1.81, 2.89 ]
Total events: 193 (Varenicline), 88 (Control)
Heterogeneity: Chi2 = 16.58, df = 5 (P = 0.01); I2 =70%
Test for overall effect: Z = 6.93 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.25, df = 1 (P = 0.62), I2 =0.0%
0.05 0.2 1 5 20
Favours placebo Favours varenicline
(1) 0.5 mg twice a day
(2) ad lib, between 0.5 and 2.0 mg daily
(3) 1 mg once a day
(4) 0.5 mg twice a day (titrated and non-titrated combined)
(5) 12 weeks
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Analysis 7.3. Comparison 7 Variations in usage, Outcome 3 Standard dose varenicline versus low dose at 52
weeks.
Review: Nicotine receptor partial agonists for smoking cessation
Comparison: 7 Variations in usage
Outcome: 3 Standard dose varenicline versus low dose at 52 weeks
Study or subgroup Standard dose low dose Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Nakamura 2007 (1) 56/155 51/155 48.1 % 1.10 [ 0.81, 1.49 ]
Nides 2006 (2) 18/125 7/126 6.6 % 2.59 [ 1.12, 5.99 ]
Oncken 2006 (3) 58/259 48/259 45.3 % 1.21 [ 0.86, 1.70 ]
Total (95% CI) 539 540 100.0 % 1.25 [ 1.00, 1.55 ]
Total events: 132 (Standard dose), 106 (low dose)
Heterogeneity: Chi2 = 3.62, df = 2 (P = 0.16); I2 =45%
Test for overall effect: Z = 1.95 (P = 0.051)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
Favours low dose Favours standard dose
(1) 1 mg twice a day vs 0.5 mg twice a day
(2) 1 mg twice a day vs 1 mg once a day
(3) 1 mg twice a day vs 0.5 mg twice a day (titrated and non-titrated combined)
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Analysis 7.4. Comparison 7 Variations in usage, Outcome 4 Standard dose varenicline versus high dose at
12 weeks.
Review: Nicotine receptor partial agonists for smoking cessation
Comparison: 7 Variations in usage
Outcome: 4 Standard dose varenicline versus high dose at 12 weeks
Study or subgroup Standard dose High dose Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Hajek 2015 (1) 23/100 26/100 100.0 % 0.88 [ 0.54, 1.44 ]
Total (95% CI) 100 100 100.0 % 0.88 [ 0.54, 1.44 ]
Total events: 23 (Standard dose), 26 (High dose)
Heterogeneity: not applicable
Test for overall effect: Z = 0.49 (P = 0.62)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
Favours high dose Favours standard dose
(1) 12 weeks sustained abstinence
Analysis 7.5. Comparison 7 Variations in usage, Outcome 5 Reducing to quit.
Review: Nicotine receptor partial agonists for smoking cessation
Comparison: 7 Variations in usage
Outcome: 5 Reducing to quit
Study or subgroup Varenicline Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ebbert 2015 182/760 45/750 3.99 [ 2.93, 5.44 ]
0.01 0.1 1 10 100
Favours placebo Favours varenicline
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Analysis 7.6. Comparison 7 Variations in usage, Outcome 6 Varenicline as maintenance therapy (relapse
prevention) to sustain quitting.
Review: Nicotine receptor partial agonists for smoking cessation
Comparison: 7 Variations in usage
Outcome: 6 Varenicline as maintenance therapy (relapse prevention) to sustain quitting
Study or subgroup Varenicline Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Abstinence at 52 weeks
Evins 2014 18/40 7/47 2.8 % 3.02 [ 1.41, 6.49 ]
Tonstad 2006 263/601 224/607 97.2 % 1.19 [ 1.03, 1.36 ]
Subtotal (95% CI) 641 654 100.0 % 1.24 [ 1.08, 1.42 ]
Total events: 281 (Varenicline), 231 (Control)
Heterogeneity: Chi2 = 5.60, df = 1 (P = 0.02); I2 =82%
Test for overall effect: Z = 3.08 (P = 0.0021)
2 Abstinence at 24 weeks
Tonstad 2006 425/603 301/607 100.0 % 1.42 [ 1.29, 1.56 ]
Subtotal (95% CI) 603 607 100.0 % 1.42 [ 1.29, 1.56 ]
Total events: 425 (Varenicline), 301 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 7.22 (P < 0.00001)
Test for subgroup differences: Chi2 = 2.69, df = 1 (P = 0.10), I2 =63%
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Analysis 8.1. Comparison 8 Varenicline in specific patient groups, Outcome 1 Cardiovascular disease.
Review: Nicotine receptor partial agonists for smoking cessation
Comparison: 8 Varenicline in specific patient groups
Outcome: 1 Cardiovascular disease
Study or subgroup Varenicline Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Eisenberg 2016 (1) 53/148 39/151 59.8 % 1.39 [ 0.98, 1.96 ]
Rigotti 2010 (2) 68/353 26/354 40.2 % 2.62 [ 1.71, 4.02 ]
Total (95% CI) 501 505 100.0 % 1.88 [ 1.44, 2.47 ]
Total events: 121 (Varenicline), 65 (Placebo)
Heterogeneity: Chi2 = 5.32, df = 1 (P = 0.02); I2 =81%
Test for overall effect: Z = 4.61 (P < 0.00001)
Test for subgroup differences: Not applicable
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Favours placebo Favours varenicline
(1) 24 wk follow-up
(2) 52 wk follow-up
Analysis 8.2. Comparison 8 Varenicline in specific patient groups, Outcome 2 COPD.
Review: Nicotine receptor partial agonists for smoking cessation
Comparison: 8 Varenicline in specific patient groups
Outcome: 2 COPD
Study or subgroup Varenicline Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Tashkin 2011 46/248 14/253 3.35 [ 1.89, 5.94 ]
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Analysis 8.3. Comparison 8 Varenicline in specific patient groups, Outcome 3 Asthma.
Review: Nicotine receptor partial agonists for smoking cessation
Comparison: 8 Varenicline in specific patient groups
Outcome: 3 Asthma
Study or subgroup Varenicline Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Westergaard 2015 5/26 4/26 1.25 [ 0.38, 4.14 ]
0.01 0.1 1 10 100
Favours placebo Favours varenicline
Analysis 8.4. Comparison 8 Varenicline in specific patient groups, Outcome 4
Schizophrenia/bipolar/psychiatric disorder.
Review: Nicotine receptor partial agonists for smoking cessation
Comparison: 8 Varenicline in specific patient groups
Outcome: 4 Schizophrenia/bipolar/psychiatric disorder
Study or subgroup Varenicline Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Chengappa 2014 6/31 2/29 2.2 % 2.81 [ 0.61, 12.81 ]
EAGLES 2016 (1) 188/1032 85/1026 91.4 % 2.20 [ 1.73, 2.80 ]
Evins 2014 12/40 5/47 4.9 % 2.82 [ 1.09, 7.32 ]
Williams 2012 (2) 10/84 1/43 1.4 % 5.12 [ 0.68, 38.69 ]
Total (95% CI) 1187 1145 100.0 % 2.28 [ 1.82, 2.87 ]
Total events: 216 (Varenicline), 93 (Placebo)
Heterogeneity: Chi2 = 0.97, df = 3 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 7.05 (P < 0.00001)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours placebo Favours varenicline
(1) Extrapolated from % reported quit
(2) 7-day PPA at 24 weeks
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Analysis 8.5. Comparison 8 Varenicline in specific patient groups, Outcome 5 Depression.
Review: Nicotine receptor partial agonists for smoking cessation
Comparison: 8 Varenicline in specific patient groups
Outcome: 5 Depression
Study or subgroup Varenicline Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Anthenelli 2013 52/254 28/269 1.97 [ 1.28, 3.01 ]
0.01 0.1 1 10 100
Favours placebo Favours varenicline
Analysis 8.6. Comparison 8 Varenicline in specific patient groups, Outcome 6 Substance use
disorder/methadone-maintained at 24 weeks.
Review: Nicotine receptor partial agonists for smoking cessation
Comparison: 8 Varenicline in specific patient groups
Outcome: 6 Substance use disorder/methadone-maintained at 24 weeks
Study or subgroup Varenicline Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Nahvi 2014a 3/57 0/55 40.4 % 6.76 [ 0.36, 127.89 ]
Stein 2013 2/137 0/45 59.6 % 1.67 [ 0.08, 34.08 ]
Total (95% CI) 194 100 100.0 % 3.72 [ 0.50, 27.59 ]
Total events: 5 (Varenicline), 0 (Placebo)
Heterogeneity: Chi2 = 0.43, df = 1 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 1.29 (P = 0.20)
Test for subgroup differences: Not applicable
0.005 0.1 1 10 200
Favours placebo Favours varenicline
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Analysis 8.7. Comparison 8 Varenicline in specific patient groups, Outcome 7 Alcohol-dependent smokers.
Review: Nicotine receptor partial agonists for smoking cessation
Comparison: 8 Varenicline in specific patient groups
Outcome: 7 Alcohol-dependent smokers
Study or subgroup Varenicline Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
NCT01347112 4/16 0/17 12.60 [ 0.62, 255.76 ]
Test for subgroup differences: Not applicable
0.005 0.1 1 10 200
Favours placebo Favours varenicline
Analysis 8.8. Comparison 8 Varenicline in specific patient groups, Outcome 8 Long-term use of NRT.
Review: Nicotine receptor partial agonists for smoking cessation
Comparison: 8 Varenicline in specific patient groups
Outcome: 8 Long-term use of NRT
Study or subgroup Varenicline Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
T nnesen 2013 28/70 21/69 1.31 [ 0.83, 2.08 ]
0.01 0.1 1 10 100
Favours placebo Favours varenicline
165Nicotine receptor partial agonists for smoking cessation (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 9.1. Comparison 9 Varenicline in different settings/subgroups, Outcome 1 Hospital
inpatients/perioperative patients.
Review: Nicotine receptor partial agonists for smoking cessation
Comparison: 9 Varenicline in different settings/subgroups
Outcome: 1 Hospital inpatients/perioperative patients
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Carson 2014 56/190 36/189 43.4 % 1.55 [ 1.07, 2.23 ]
Steinberg 2011 (1) 8/40 11/39 13.4 % 0.71 [ 0.32, 1.57 ]
Wong 2012 (2) 55/151 34/135 43.2 % 1.45 [ 1.01, 2.07 ]
Total (95% CI) 381 363 100.0 % 1.39 [ 1.09, 1.77 ]
Total events: 119 (Experimental), 81 (Control)
Heterogeneity: Chi2 = 3.12, df = 2 (P = 0.21); I2 =36%
Test for overall effect: Z = 2.66 (P = 0.0077)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours placebo Favours varenicline
(1) 7-day PPA at 24 weeks
(2) 7-day PPA at 12m
Analysis 9.2. Comparison 9 Varenicline in different settings/subgroups, Outcome 2 Smokers who have failed
on other cessation therapies.
Review: Nicotine receptor partial agonists for smoking cessation
Comparison: 9 Varenicline in different settings/subgroups
Outcome: 2 Smokers who have failed on other cessation therapies
Study or subgroup Experimental Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Gonzales 2014 50/249 8/245 6.15 [ 2.98, 12.70 ]
0.01 0.1 1 10 100
Favours placebo Favours varenicline
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Analysis 9.3. Comparison 9 Varenicline in different settings/subgroups, Outcome 3 Light or heavy smokers.
Review: Nicotine receptor partial agonists for smoking cessation
Comparison: 9 Varenicline in different settings/subgroups
Outcome: 3 Light or heavy smokers
Study or subgroup Experimental Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
De Dios 2012 (1) 3/10 0/11 7.64 [ 0.44, 131.75 ]
0.002 0.1 1 10 500
Favours placebo Favours varenicline
(1) 7-day PPA at 6m
Analysis 10.1. Comparison 10 Adverse event meta-analyses, Outcome 1 Nausea.
Review: Nicotine receptor partial agonists for smoking cessation
Comparison: 10 Adverse event meta-analyses
Outcome: 1 Nausea
Study or subgroup Varenicline Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Anthenelli 2013 69/256 28/269 4.4 % 2.59 [ 1.73, 3.88 ]
Bolliger 2011 103/390 16/198 3.4 % 3.27 [ 1.99, 5.38 ]
Carson 2014 32/196 3/196 0.5 % 10.67 [ 3.32, 34.26 ]
Chengappa 2014 13/31 9/29 1.5 % 1.35 [ 0.68, 2.67 ]
Cinciripini 2013 23/86 8/106 1.2 % 3.54 [ 1.67, 7.52 ]
EAGLES 2016 511/2016 137/2014 22.1 % 3.73 [ 3.12, 4.45 ]
Ebbert 2015 209/751 67/742 10.8 % 3.08 [ 2.39, 3.98 ]
Eisenberg 2016 21/151 13/151 2.1 % 1.62 [ 0.84, 3.11 ]
Evins 2014 (1) 15/40 10/47 1.5 % 1.76 [ 0.89, 3.48 ]
Gonzales 2006 98/349 29/344 4.7 % 3.33 [ 2.26, 4.90 ]
Gonzales 2014 66/249 22/245 3.6 % 2.95 [ 1.88, 4.63 ]
0.005 0.1 1 10 200
Worse on placebo Worse on varenicline
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Study or subgroup Varenicline Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Hajek 2015 80/100 18/100 2.9 % 4.44 [ 2.89, 6.83 ]
Heydari 2012 8/89 0/91 0.1 % 17.38 [ 1.02, 296.64 ]
Jorenby 2006 101/343 33/340 5.3 % 3.03 [ 2.11, 4.36 ]
Nahvi 2014a 29/57 14/55 2.3 % 2.00 [ 1.19, 3.36 ]
Nakamura 2007 38/156 12/154 1.9 % 3.13 [ 1.70, 5.75 ]
NCT00828113 2/33 0/34 0.1 % 5.15 [ 0.26, 103.33 ]
NCT01347112 4/16 0/17 0.1 % 9.53 [ 0.55, 164.01 ]
Niaura 2008 21/157 8/155 1.3 % 2.59 [ 1.18, 5.67 ]
Nides 2006 65/125 23/123 3.7 % 2.78 [ 1.85, 4.17 ]
Oncken 2006 97/253 18/121 3.9 % 2.58 [ 1.64, 4.06 ]
Rennard 2012 142/486 15/165 3.6 % 3.21 [ 1.95, 5.31 ]
Rigotti 2010 104/353 30/350 4.8 % 3.44 [ 2.35, 5.02 ]
Stein 2013 7/111 2/33 0.5 % 1.04 [ 0.23, 4.77 ]
Steinberg 2011 11/40 2/39 0.3 % 5.36 [ 1.27, 22.65 ]
Tashkin 2011 67/248 20/251 3.2 % 3.39 [ 2.12, 5.41 ]
Tsai 2007 55/126 14/124 2.3 % 3.87 [ 2.27, 6.58 ]
T nnesen 2013 40/70 8/69 1.3 % 4.93 [ 2.49, 9.75 ]
Wang 2009 48/165 20/168 3.2 % 2.44 [ 1.52, 3.93 ]
Williams 2007 101/251 10/126 2.1 % 5.07 [ 2.75, 9.36 ]
Williams 2012 7/84 2/43 0.4 % 1.79 [ 0.39, 8.26 ]
Wong 2012 20/151 5/135 0.8 % 3.58 [ 1.38, 9.27 ]
Total (95% CI) 7929 7034 100.0 % 3.27 [ 3.00, 3.55 ]
Total events: 2207 (Varenicline), 596 (Placebo)
Heterogeneity: Chi2 = 39.89, df = 31 (P = 0.13); I2 =22%
Test for overall effect: Z = 27.50 (P < 0.00001)
Test for subgroup differences: Not applicable
0.005 0.1 1 10 200
Worse on placebo Worse on varenicline
(1) maintenance phase (12 - 40 wks post-quit)
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Analysis 10.2. Comparison 10 Adverse event meta-analyses, Outcome 2 Insomnia.
Review: Nicotine receptor partial agonists for smoking cessation
Comparison: 10 Adverse event meta-analyses
Outcome: 2 Insomnia
Study or subgroup Varenicline Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Anthenelli 2013 28/256 13/269 2.2 % 2.26 [ 1.20, 4.27 ]
Bolliger 2011 50/390 13/198 2.9 % 1.95 [ 1.09, 3.51 ]
Carson 2014 10/196 4/196 0.7 % 2.50 [ 0.80, 7.84 ]
Chengappa 2014 14/31 8/29 1.4 % 1.64 [ 0.81, 3.32 ]
Cinciripini 2013 20/86 21/106 3.2 % 1.17 [ 0.68, 2.02 ]
EAGLES 2016 189/2016 139/2014 23.8 % 1.36 [ 1.10, 1.68 ]
Ebbert 2015 80/751 51/742 8.8 % 1.55 [ 1.11, 2.17 ]
Eisenberg 2016 27/151 19/151 3.2 % 1.42 [ 0.83, 2.44 ]
Evins 2014 (1) 11/40 11/47 1.7 % 1.18 [ 0.57, 2.42 ]
Gonzales 2006 49/349 44/344 7.6 % 1.10 [ 0.75, 1.60 ]
Gonzales 2014 17/249 10/245 1.7 % 1.67 [ 0.78, 3.58 ]
Hajek 2015 21/100 20/100 3.4 % 1.05 [ 0.61, 1.81 ]
Heydari 2012 (2) 3/89 0/91 0.1 % 7.16 [ 0.37, 136.56 ]
Jorenby 2006 49/343 42/340 7.2 % 1.16 [ 0.79, 1.70 ]
Nahvi 2014a 15/57 13/55 2.3 % 1.11 [ 0.58, 2.12 ]
NCT01347112 2/16 0/17 0.1 % 5.29 [ 0.27, 102.49 ]
Niaura 2008 34/157 17/155 2.9 % 1.97 [ 1.15, 3.38 ]
Nides 2006 44/125 27/123 4.7 % 1.60 [ 1.06, 2.41 ]
Oncken 2006 75/253 14/121 3.2 % 2.56 [ 1.51, 4.34 ]
Rennard 2012 43/486 6/165 1.5 % 2.43 [ 1.05, 5.61 ]
Rigotti 2010 42/353 23/350 3.9 % 1.81 [ 1.11, 2.94 ]
Stein 2013 39/111 12/33 3.2 % 0.97 [ 0.58, 1.62 ]
Steinberg 2011 3/40 3/39 0.5 % 0.98 [ 0.21, 4.54 ]
Tashkin 2011 24/248 15/251 2.5 % 1.62 [ 0.87, 3.01 ]
Tsai 2007 19/126 17/124 2.9 % 1.10 [ 0.60, 2.02 ]
Wang 2009 10/165 5/168 0.8 % 2.04 [ 0.71, 5.83 ]
0.005 0.1 1 10 200
Worse on placebo Worse on varenicline
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Study or subgroup Varenicline Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Williams 2007 48/251 12/126 2.7 % 2.01 [ 1.11, 3.64 ]
Williams 2012 8/84 2/43 0.5 % 2.05 [ 0.45, 9.23 ]
Wong 2012 2/151 1/135 0.2 % 1.79 [ 0.16, 19.50 ]
Total (95% CI) 7670 6777 100.0 % 1.49 [ 1.35, 1.65 ]
Total events: 976 (Varenicline), 562 (Placebo)
Heterogeneity: Chi2 = 26.48, df = 28 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 7.98 (P < 0.00001)
Test for subgroup differences: Not applicable
0.005 0.1 1 10 200
Worse on placebo Worse on varenicline
(1) maintenance phase (12 - 40 wks post-quit)
(2) described as ”abnormal sleep and bad dreams”
Analysis 10.3. Comparison 10 Adverse event meta-analyses, Outcome 3 Abnormal dreams.
Review: Nicotine receptor partial agonists for smoking cessation
Comparison: 10 Adverse event meta-analyses
Outcome: 3 Abnormal dreams
Study or subgroup Varenicline Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Anthenelli 2013 29/256 22/269 5.6 % 1.39 [ 0.82, 2.35 ]
Bolliger 2011 66/390 15/198 5.2 % 2.23 [ 1.31, 3.81 ]
Carson 2014 12/196 2/196 0.5 % 6.00 [ 1.36, 26.46 ]
Chengappa 2014 18/31 9/29 2.4 % 1.87 [ 1.01, 3.48 ]
Cinciripini 2013 13/86 11/106 2.6 % 1.46 [ 0.69, 3.09 ]
EAGLES 2016 201/2016 92/2014 24.0 % 2.18 [ 1.72, 2.77 ]
Ebbert 2015 86/751 43/742 11.3 % 1.98 [ 1.39, 2.81 ]
Eisenberg 2016 23/151 7/151 1.8 % 3.29 [ 1.45, 7.43 ]
0.05 0.2 1 5 20
Worse on placebo Worse on varenicline
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Study or subgroup Varenicline Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Evins 2014 (1) 1/40 2/47 0.5 % 0.59 [ 0.06, 6.24 ]
Gonzales 2006 (2) 36/349 19/344 5.0 % 1.87 [ 1.09, 3.19 ]
Gonzales 2014 36/249 8/245 2.1 % 4.43 [ 2.10, 9.33 ]
Hajek 2015 15/100 18/100 4.7 % 0.83 [ 0.45, 1.56 ]
Jorenby 2006 45/343 12/340 3.1 % 3.72 [ 2.00, 6.90 ]
Nahvi 2014a 18/57 22/55 5.8 % 0.79 [ 0.48, 1.30 ]
NCT01347112 1/16 1/17 0.3 % 1.06 [ 0.07, 15.60 ]
Nides 2006 19/125 10/123 2.6 % 1.87 [ 0.91, 3.86 ]
Oncken 2006 46/253 6/121 2.1 % 3.67 [ 1.61, 8.35 ]
Rennard 2012 61/486 5/165 1.9 % 4.14 [ 1.69, 10.13 ]
Rigotti 2010 28/353 6/350 1.6 % 4.63 [ 1.94, 11.04 ]
Stein 2013 23/111 8/33 3.2 % 0.85 [ 0.42, 1.73 ]
Tashkin 2011 27/248 7/251 1.8 % 3.90 [ 1.73, 8.80 ]
Tsai 2007 7/126 1/124 0.3 % 6.89 [ 0.86, 55.17 ]
T nnesen 2013 35/70 26/69 6.8 % 1.33 [ 0.90, 1.95 ]
Williams 2007 57/251 9/126 3.1 % 3.18 [ 1.63, 6.21 ]
Williams 2012 6/84 4/43 1.4 % 0.77 [ 0.23, 2.58 ]
Wong 2012 3/151 0/135 0.1 % 6.26 [ 0.33, 120.16 ]
Total (95% CI) 7289 6393 100.0 % 2.12 [ 1.88, 2.38 ]
Total events: 912 (Varenicline), 365 (Placebo)
Heterogeneity: Chi2 = 65.97, df = 25 (P = 0.00002); I2 =62%
Test for overall effect: Z = 12.61 (P < 0.00001)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
Worse on placebo Worse on varenicline
(1) maintenance phase (12 - 40 wks post-quit)
(2) Bolliger 2011 groups all sleep disorders together
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Analysis 10.4. Comparison 10 Adverse event meta-analyses, Outcome 4 Headache.
Review: Nicotine receptor partial agonists for smoking cessation
Comparison: 10 Adverse event meta-analyses
Outcome: 4 Headache
Study or subgroup Varenicline Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Anthenelli 2013 43/256 30/269 4.2 % 1.51 [ 0.98, 2.32 ]
Bolliger 2011 64/390 24/198 4.6 % 1.35 [ 0.87, 2.10 ]
Carson 2014 12/196 3/196 0.4 % 4.00 [ 1.15, 13.96 ]
Chengappa 2014 11/31 12/29 1.8 % 0.86 [ 0.45, 1.63 ]
Cinciripini 2013 10/86 12/106 1.5 % 1.03 [ 0.47, 2.26 ]
EAGLES 2016 245/2016 199/2014 28.5 % 1.23 [ 1.03, 1.47 ]
Ebbert 2015 62/751 54/742 7.8 % 1.13 [ 0.80, 1.61 ]
Eisenberg 2016 8/151 12/151 1.7 % 0.67 [ 0.28, 1.58 ]
Evins 2014 (1) 17/40 11/44 1.5 % 1.70 [ 0.91, 3.18 ]
Gonzales 2006 54/349 42/344 6.1 % 1.27 [ 0.87, 1.84 ]
Gonzales 2014 26/249 24/245 3.5 % 1.07 [ 0.63, 1.80 ]
Hajek 2015 7/100 6/100 0.9 % 1.17 [ 0.41, 3.35 ]
Jorenby 2006 44/343 43/340 6.2 % 1.01 [ 0.68, 1.50 ]
Nahvi 2014a 11/57 18/55 2.6 % 0.59 [ 0.31, 1.13 ]
Nakamura 2007 16/156 4/154 0.6 % 3.95 [ 1.35, 11.54 ]
Niaura 2008 25/157 20/155 2.9 % 1.23 [ 0.72, 2.13 ]
Nides 2006 30/125 33/123 4.8 % 0.89 [ 0.58, 1.37 ]
Oncken 2006 59/253 21/121 4.1 % 1.34 [ 0.86, 2.10 ]
Rennard 2012 55/486 20/165 4.3 % 0.93 [ 0.58, 1.51 ]
Rigotti 2010 45/353 39/350 5.6 % 1.14 [ 0.76, 1.71 ]
Stein 2013 7/111 6/33 1.3 % 0.35 [ 0.13, 0.96 ]
Tashkin 2011 20/248 20/251 2.8 % 1.01 [ 0.56, 1.83 ]
Wang 2009 9/165 7/168 1.0 % 1.31 [ 0.50, 3.43 ]
Williams 2012 9/84 8/43 1.5 % 0.58 [ 0.24, 1.39 ]
Wong 2012 5/151 0/135 0.1 % 9.84 [ 0.55, 176.35 ]
Total (95% CI) 7304 6531 100.0 % 1.17 [ 1.07, 1.29 ]
0.05 0.2 1 5 20
Worse on placebo Worse on varenicline
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Study or subgroup Varenicline Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Total events: 894 (Varenicline), 668 (Placebo)
Heterogeneity: Chi2 = 32.90, df = 24 (P = 0.11); I2 =27%
Test for overall effect: Z = 3.30 (P = 0.00097)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
Worse on placebo Worse on varenicline
(1) maintenance phase (12 - 40 wks post-quit)
Analysis 10.5. Comparison 10 Adverse event meta-analyses, Outcome 5 Depression.
Review: Nicotine receptor partial agonists for smoking cessation
Comparison: 10 Adverse event meta-analyses
Outcome: 5 Depression
Study or subgroup Varenicline Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Anthenelli 2013 17/256 13/269 6.5 % 1.37 [ 0.68, 2.77 ]
Bolliger 2011 8/390 4/198 2.7 % 1.02 [ 0.31, 3.33 ]
Brandon 2011* (1) 0/46 0/54 Not estimable
Carson 2014 4/196 2/196 1.0 % 2.00 [ 0.37, 10.79 ]
Chengappa 2014 8/31 2/29 1.1 % 3.74 [ 0.87, 16.18 ]
Cinciripini 2013 6/86 14/106 6.4 % 0.53 [ 0.21, 1.32 ]
EAGLES 2016 7/2016 6/2014 3.1 % 1.17 [ 0.39, 3.46 ]
Ebbert 2011* 0/38 1/38 0.8 % 0.33 [ 0.01, 7.93 ]
Ebbert 2015 25/751 35/742 18.1 % 0.71 [ 0.43, 1.17 ]
Eisenberg 2016 1/151 0/151 0.3 % 3.00 [ 0.12, 73.06 ]
Evins 2014 1/40 1/47 0.5 % 1.18 [ 0.08, 18.19 ]
Faessel 2009* 0/14 0/7 Not estimable
Fagerstro¨m 2010* 2/213 5/218 2.5 % 0.41 [ 0.08, 2.09 ]
0.02 0.1 1 10 50
Worse on placebo Worse on varenicline
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Study or subgroup Varenicline Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Garza 2011* 1/55 1/55 0.5 % 1.00 [ 0.06, 15.59 ]
Gonzales 2006 4/349 7/344 3.6 % 0.56 [ 0.17, 1.91 ]
Gonzales 2014 5/249 2/245 1.0 % 2.46 [ 0.48, 12.56 ]
Hajek 2015 7/100 8/100 4.1 % 0.88 [ 0.33, 2.32 ]
Hughes 2011* 1/107 2/111 1.0 % 0.52 [ 0.05, 5.64 ]
Jorenby 2006 6/343 1/340 0.5 % 5.95 [ 0.72, 49.14 ]
McClure 2013* NCT00944554 17/41 20/42 10.1 % 0.87 [ 0.54, 1.41 ]
Meszaros 2013* 1/5 1/5 0.5 % 1.00 [ 0.08, 11.93 ]
Nahvi 2014a 2/57 1/55 0.5 % 1.93 [ 0.18, 20.68 ]
NCT01347112 0/16 1/17 0.7 % 0.35 [ 0.02, 8.08 ]
Niaura 2008 3/157 2/155 1.0 % 1.48 [ 0.25, 8.74 ]
Nides 2006 2/125 1/123 0.5 % 1.97 [ 0.18, 21.42 ]
Oncken 2006 6/253 4/121 2.8 % 0.72 [ 0.21, 2.50 ]
Rennard 2012 4/486 5/165 3.8 % 0.27 [ 0.07, 1.00 ]
Rigotti 2010 5/353 3/350 1.5 % 1.65 [ 0.40, 6.86 ]
Stein 2013 17/111 7/33 5.5 % 0.72 [ 0.33, 1.59 ]
Steinberg 2011 2/40 2/39 1.0 % 0.98 [ 0.14, 6.58 ]
Tashkin 2011 6/248 5/251 2.5 % 1.21 [ 0.38, 3.93 ]
Tonstad 2006 15/602 17/604 8.7 % 0.89 [ 0.45, 1.76 ]
Tsai 2007 1/126 2/124 1.0 % 0.49 [ 0.05, 5.36 ]
Williams 2007 12/251 4/126 2.7 % 1.51 [ 0.50, 4.58 ]
Williams 2012 4/84 3/43 2.0 % 0.68 [ 0.16, 2.91 ]
Wong 2012 2/151 2/135 1.1 % 0.89 [ 0.13, 6.26 ]
Total (95% CI) 8537 7652 100.0 % 0.94 [ 0.77, 1.14 ]
Total events: 202 (Varenicline), 184 (Placebo)
Heterogeneity: Chi2 = 22.93, df = 33 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 0.65 (P = 0.52)
Test for subgroup differences: Not applicable
0.02 0.1 1 10 50
Worse on placebo Worse on varenicline
(1) Studies marked with an asterisk (*) contribute data to the neuropsychiatric adverse events analyses, but not to efficacy results
174Nicotine receptor partial agonists for smoking cessation (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 10.6. Comparison 10 Adverse event meta-analyses, Outcome 6 Suicidal ideation.
Review: Nicotine receptor partial agonists for smoking cessation
Comparison: 10 Adverse event meta-analyses
Outcome: 6 Suicidal ideation
Study or subgroup Varenicline Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Anthenelli 2013 0/256 3/269 7.9 % 0.15 [ 0.01, 2.89 ]
Bolliger 2011 2/390 0/198 1.5 % 2.54 [ 0.12, 52.75 ]
Brandon 2011* (1) 0/46 0/54 Not estimable
Carson 2014 0/196 0/196 Not estimable
Chengappa 2014 2/31 1/29 2.4 % 1.87 [ 0.18, 19.55 ]
Cinciripini 2013 0/86 1/106 3.1 % 0.41 [ 0.02, 9.94 ]
EAGLES 2016 (2) 5/2016 5/2014 11.6 % 1.00 [ 0.29, 3.45 ]
Ebbert 2011* 0/38 0/38 Not estimable
Ebbert 2015 6/751 10/742 23.3 % 0.59 [ 0.22, 1.62 ]
Evins 2014 2/40 2/47 4.3 % 1.18 [ 0.17, 7.97 ]
Gonzales 2014 0/249 0/245 Not estimable
Hajek 2015 0/100 0/100 Not estimable
Hughes 2011* 0/107 1/111 3.4 % 0.35 [ 0.01, 8.39 ]
Jorenby 2006 0/343 1/340 3.5 % 0.33 [ 0.01, 8.08 ]
McClure 2013* NCT00944554 0/41 0/42 Not estimable
Meszaros 2013* 2/5 2/5 4.6 % 1.00 [ 0.22, 4.56 ]
Mitchell 2012* 0/33 1/31 3.6 % 0.31 [ 0.01, 7.42 ]
Nahvi 2014a 3/57 4/55 9.4 % 0.72 [ 0.17, 3.09 ]
Rennard 2012 1/486 2/165 6.9 % 0.17 [ 0.02, 1.86 ]
Stein 2013 1/111 0/33 1.8 % 0.91 [ 0.04, 21.85 ]
Steinberg 2011 0/40 0/39 Not estimable
Tashkin 2011 0/248 1/251 3.5 % 0.34 [ 0.01, 8.24 ]
Williams 2012 5/84 3/43 9.2 % 0.85 [ 0.21, 3.40 ]
Wong 2012 0/151 0/135 Not estimable
Total (95% CI) 5905 5288 100.0 % 0.68 [ 0.43, 1.07 ]
Total events: 29 (Varenicline), 37 (Placebo)
Heterogeneity: Chi2 = 5.76, df = 15 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 1.66 (P = 0.096)
Test for subgroup differences: Not applicable
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(1) Studies marked with an asterisk (*) contribute data to the neuropsychiatric adverse events analyses, but not to efficacy results
(2) All 5 events occurred in the psychiatric cohort
Analysis 11.1. Comparison 11 Serious adverse events, Outcome 1 SAEs in the varenicline trials.
Review: Nicotine receptor partial agonists for smoking cessation
Comparison: 11 Serious adverse events
Outcome: 1 SAEs in the varenicline trials
Study or subgroup Varenicline Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Anthenelli 2013 8/256 8/269 3.9 % 1.05 [ 0.40, 2.76 ]
Bolliger 2011 11/394 2/199 1.3 % 2.78 [ 0.62, 12.41 ]
Carson 2014 10/119 8/117 4.0 % 1.23 [ 0.50, 3.00 ]
Chengappa 2014 6/31 4/29 2.0 % 1.40 [ 0.44, 4.47 ]
Cinciripini 2013 2/86 2/106 0.9 % 1.23 [ 0.18, 8.57 ]
EAGLES 2016 39/2016 41/2014 20.3 % 0.95 [ 0.62, 1.47 ]
Ebbert 2015 28/751 16/742 8.0 % 1.73 [ 0.94, 3.17 ]
Eisenberg 2016 18/151 17/151 8.4 % 1.06 [ 0.57, 1.97 ]
Evins 2014 4/40 7/47 3.2 % 0.67 [ 0.21, 2.13 ]
Gonzales 2006 6/352 9/344 4.5 % 0.65 [ 0.23, 1.81 ]
Gonzales 2014 7/249 4/245 2.0 % 1.72 [ 0.51, 5.81 ]
Jorenby 2006 8/344 6/341 3.0 % 1.32 [ 0.46, 3.77 ]
Nahvi 2014a 5/57 3/55 1.5 % 1.61 [ 0.40, 6.41 ]
Nakamura 2007 10/155 3/154 1.5 % 3.31 [ 0.93, 11.80 ]
NCT00828113 1/33 1/34 0.5 % 1.03 [ 0.07, 15.80 ]
Niaura 2008 3/160 0/160 0.2 % 7.00 [ 0.36, 134.43 ]
Nides 2006 2/127 0/127 0.2 % 5.00 [ 0.24, 103.12 ]
Oncken 2006 11/259 2/129 1.3 % 2.74 [ 0.62, 12.18 ]
Rennard 2012 6/493 1/166 0.7 % 2.02 [ 0.25, 16.66 ]
Rigotti 2010 23/353 21/354 10.4 % 1.10 [ 0.62, 1.95 ]
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(. . . Continued)
Study or subgroup Varenicline Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Stein 2013 4/111 0/33 0.4 % 2.73 [ 0.15, 49.48 ]
Steinberg 2011 6/40 5/39 2.5 % 1.17 [ 0.39, 3.52 ]
Tashkin 2011 12/248 15/253 7.4 % 0.82 [ 0.39, 1.71 ]
Tonstad 2006 10/603 5/607 2.5 % 2.01 [ 0.69, 5.86 ]
Tsai 2007 3/126 3/124 1.5 % 0.98 [ 0.20, 4.78 ]
T nnesen 2013 5/70 4/69 2.0 % 1.23 [ 0.35, 4.40 ]
Wang 2009 0/165 2/168 1.2 % 0.20 [ 0.01, 4.21 ]
Williams 2007 15/251 3/126 2.0 % 2.51 [ 0.74, 8.51 ]
Williams 2012 6/85 4/43 2.6 % 0.76 [ 0.23, 2.55 ]
Total (95% CI) 8125 7245 100.0 % 1.25 [ 1.04, 1.49 ]
Total events: 269 (Varenicline), 196 (Placebo)
Heterogeneity: Chi2 = 18.78, df = 28 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 2.36 (P = 0.018)
Test for subgroup differences: Not applicable
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Analysis 11.2. Comparison 11 Serious adverse events, Outcome 2 SAEs in the varenicline trials, exc post-
treat events.
Review: Nicotine receptor partial agonists for smoking cessation
Comparison: 11 Serious adverse events
Outcome: 2 SAEs in the varenicline trials, exc post-treat events
Study or subgroup Varenicline Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Anthenelli 2013 7/256 7/269 4.0 % 1.05 [ 0.37, 2.95 ]
Bolliger 2011 11/394 2/199 1.6 % 2.78 [ 0.62, 12.41 ]
Carson 2014 5/119 3/117 1.8 % 1.64 [ 0.40, 6.70 ]
Chengappa 2014 5/31 3/29 1.8 % 1.56 [ 0.41, 5.95 ]
Cinciripini 2013 2/86 2/106 1.1 % 1.23 [ 0.18, 8.57 ]
EAGLES 2016 39/2016 41/2014 24.3 % 0.95 [ 0.62, 1.47 ]
Ebbert 2015 18/751 10/742 6.0 % 1.78 [ 0.83, 3.83 ]
Eisenberg 2016 18/151 17/151 10.1 % 1.06 [ 0.57, 1.97 ]
Gonzales 2006 4/352 7/344 4.2 % 0.56 [ 0.16, 1.89 ]
Gonzales 2014 7/249 4/245 2.4 % 1.72 [ 0.51, 5.81 ]
Jorenby 2006 6/344 5/341 3.0 % 1.19 [ 0.37, 3.86 ]
Nahvi 2014a 3/57 2/55 1.2 % 1.45 [ 0.25, 8.33 ]
Nakamura 2007 10/155 3/154 1.8 % 3.31 [ 0.93, 11.80 ]
NCT00828113 0/33 1/34 0.9 % 0.34 [ 0.01, 8.13 ]
Niaura 2008 3/160 0/160 0.3 % 7.00 [ 0.36, 134.43 ]
Nides 2006 2/127 0/127 0.3 % 5.00 [ 0.24, 103.12 ]
Oncken 2006 9/259 1/129 0.8 % 4.48 [ 0.57, 35.00 ]
Rennard 2012 6/493 1/166 0.9 % 2.02 [ 0.25, 16.66 ]
Rigotti 2010 23/353 21/354 12.4 % 1.10 [ 0.62, 1.95 ]
Steinberg 2011 6/40 5/39 3.0 % 1.17 [ 0.39, 3.52 ]
Tashkin 2011 7/248 11/253 6.5 % 0.65 [ 0.26, 1.65 ]
Tonstad 2006 10/603 5/607 3.0 % 2.01 [ 0.69, 5.86 ]
Tsai 2007 3/126 3/124 1.8 % 0.98 [ 0.20, 4.78 ]
Wang 2009 0/165 2/168 1.5 % 0.20 [ 0.01, 4.21 ]
Williams 2007 15/251 3/126 2.4 % 2.51 [ 0.74, 8.51 ]
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Study or subgroup Varenicline Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Williams 2012 6/85 4/43 3.1 % 0.76 [ 0.23, 2.55 ]
Total (95% CI) 7904 7096 100.0 % 1.25 [ 1.02, 1.52 ]
Total events: 225 (Varenicline), 163 (Placebo)
Heterogeneity: Chi2 = 18.97, df = 25 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 2.16 (P = 0.030)
Test for subgroup differences: Not applicable
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Analysis 11.3. Comparison 11 Serious adverse events, Outcome 3 Neuropsychiatric SAEs (not deaths).
Review: Nicotine receptor partial agonists for smoking cessation
Comparison: 11 Serious adverse events
Outcome: 3 Neuropsychiatric SAEs (not deaths)
Study or subgroup Varenicline Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Anthenelli 2013 2/256 4/269 7.8 % 0.53 [ 0.10, 2.84 ]
Bolliger 2011 4/394 0/199 1.3 % 4.56 [ 0.25, 84.22 ]
Carson 2014 5/119 3/117 6.1 % 1.64 [ 0.40, 6.70 ]
Chengappa 2014 2/31 0/29 1.0 % 4.69 [ 0.23, 93.70 ]
Eisenberg 2016 1/151 0/151 1.0 % 3.00 [ 0.12, 73.06 ]
Evins 2014 (1) 2/40 5/47 9.2 % 0.47 [ 0.10, 2.29 ]
Gonzales 2006 0/352 1/344 3.0 % 0.33 [ 0.01, 7.97 ]
Jorenby 2006 2/344 0/341 1.0 % 4.96 [ 0.24, 102.86 ]
Nahvi 2014a (2) 18/57 25/55 51.1 % 0.69 [ 0.43, 1.12 ]
Nakamura 2007 0/155 0/154 Not estimable
Niaura 2008 0/160 0/160 Not estimable
Nides 2006 0/127 0/127 Not estimable
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Study or subgroup Varenicline Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Oncken 2006 0/259 1/129 4.0 % 0.17 [ 0.01, 4.06 ]
Rennard 2012 0/493 1/166 4.5 % 0.11 [ 0.00, 2.75 ]
Rigotti 2010 0/353 0/354 Not estimable
Stein 2013 2/111 0/33 1.5 % 1.52 [ 0.07, 30.86 ]
Steinberg 2011 0/40 0/39 Not estimable
Tashkin 2011 0/248 1/253 3.0 % 0.34 [ 0.01, 8.31 ]
Tonstad 2011 0/603 0/607 Not estimable
Tsai 2007 0/126 0/124 Not estimable
Wang 2009 0/165 0/168 Not estimable
Williams 2007 0/251 0/126 Not estimable
Williams 2012 3/85 2/43 5.3 % 0.76 [ 0.13, 4.37 ]
Total (95% CI) 4920 4035 100.0 % 0.82 [ 0.57, 1.19 ]
Total events: 41 (Varenicline), 43 (Placebo)
Heterogeneity: Chi2 = 9.98, df = 13 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 1.02 (P = 0.31)
Test for subgroup differences: Not applicable
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(1) maintenance phase (12 - 40 wks post-quit) in pts with schizophrenia, schizoaffective or bipolar disorder
(2) in methadone-maintained patients
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Analysis 11.4. Comparison 11 Serious adverse events, Outcome 4 Cardiac SAEs, including deaths.
Review: Nicotine receptor partial agonists for smoking cessation
Comparison: 11 Serious adverse events
Outcome: 4 Cardiac SAEs, including deaths
Study or subgroup Varenicline Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bolliger 2011 1/394 0/199 1.6 % 1.52 [ 0.06, 37.12 ]
Carson 2014 5/119 5/117 12.2 % 0.98 [ 0.29, 3.31 ]
Chengappa 2014 0/31 1/29 3.7 % 0.31 [ 0.01, 7.38 ]
Cinciripini 2013 1/86 1/106 2.2 % 1.23 [ 0.08, 19.42 ]
Eisenberg 2016 8/151 10/151 24.1 % 0.80 [ 0.32, 1.97 ]
Evins 2014 (1) 0/40 1/47 3.3 % 0.39 [ 0.02, 9.32 ]
Gonzales 2006 2/352 4/344 9.8 % 0.49 [ 0.09, 2.65 ]
Gonzales 2014 1/249 1/245 2.4 % 0.98 [ 0.06, 15.64 ]
Jorenby 2006 3/344 1/341 2.4 % 2.97 [ 0.31, 28.45 ]
Nakamura 2007 1/155 1/154 2.4 % 0.99 [ 0.06, 15.74 ]
Niaura 2008 2/160 0/160 1.2 % 5.00 [ 0.24, 103.33 ]
Nides 2006 1/127 0/127 1.2 % 3.00 [ 0.12, 72.95 ]
Oncken 2006 2/259 0/129 1.6 % 2.50 [ 0.12, 51.69 ]
Rennard 2012 2/493 0/166 1.8 % 1.69 [ 0.08, 35.03 ]
Rigotti 2010 3/353 4/354 9.6 % 0.75 [ 0.17, 3.34 ]
Tashkin 2011 7/248 5/253 11.9 % 1.43 [ 0.46, 4.44 ]
Tonstad 2011 4/603 0/607 1.2 % 9.06 [ 0.49, 167.90 ]
Tsai 2007 1/126 0/124 1.2 % 2.95 [ 0.12, 71.79 ]
T nnesen 2013 3/70 0/69 1.2 % 6.90 [ 0.36, 131.17 ]
Williams 2007 9/251 1/126 3.2 % 4.52 [ 0.58, 35.27 ]
Williams 2012 1/85 0/43 1.6 % 1.53 [ 0.06, 36.91 ]
Total (95% CI) 4696 3891 100.0 % 1.36 [ 0.91, 2.04 ]
Total events: 57 (Varenicline), 35 (Placebo)
Heterogeneity: Chi2 = 11.09, df = 20 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 1.52 (P = 0.13)
Test for subgroup differences: Not applicable
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Analysis 12.1. Comparison 12 Losses to follow-up, Outcome 1 Participants remaining at end of varenicline
trials.
Participants remaining at end of varenicline trials
Study Placebo [%] Varenicline [%] Bupropion [%] NRT [%] Chi² and P value
Anthenelli 2013 179/269 (66.5%) 175/256 (68.4) 0.20, P = 0.66
Aubin 2008 247/378 (65.3) 230/379 (60.7) 1.76, P = 0.18
Baker 2016 389/424 (91.7) Patch: 226/241 (93.
8)
C-NRT: 408/421
(96.9)
10.42, P = 0.005**
Bolliger 2011 156/199 (78.4) 336/394 (85.3) 4.44, P = 0.04*
Carson 2014 160/196 (81.6) 165/196 (84.2) 0.45, P = 0.50
Chengappa 2014 20/29 (69.0) 24/31 (77.4) 0.55, P = 0.46
Cinciripini 2013 76/106 (71.7) 65/86 (75.6) 73/102 (71.6) 0.37, P = 0.54
De Dios 2012 7/11 (63.6) 7/10 (70.0) 9/11 (81.8) 0.10, P = 0.76
EAGLES 2016 1552/2035 (76.3) 1598/2037 (78.4) 1586/2034 (80.0) 1557/2038 (76.4) 4.24, P = 0.24
Ebbert 2015 516/750 (68.8) 559/760 (73.6) 4.16, P = 0.04*
Eisenberg 2016 112/151 (74.2) 118/151 (78.1) 0.66, P = 0.42
Evins 2014 33/40 (82.5) 26/47 (55.3) 7.31, P = 0.007**
Gonzales 2006 187/344 (54.4) 213/352 (60.5) 184/329 (55.9) 2.90, P = 0.23
Gonzales 2014 144/247 (58.8) 169/251 (67.9) 4.35, P = 0.04
Hajek 2015 60/100 (60.0) 66/100 (66.0) 0.77, P = 0.38
Heydari 2012 91/91 (100.0) 89/89 (100.0) 92/92 (100.0) 0, P = 1
Jorenby 2006 204/341 (59.8) 240/344 (69.8) 221/342 (64.6) 7.42, P = 0.02*
Nahvi 2014a 43/55 (78.2) 49/57 (86.0) 1.16, P = 0.28
Nakamura 2007 132/154 (85.7) 124/155 (79.5) 1.78, P = 0.18
NCT00828113 20/51 (39.2) 20/50 (40.0) 0.01, P = 0.94
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Participants remaining at end of varenicline trials (Continued)
NCT01347112 12/16 (75.0) 5/17 (29.4) 10.24, P = 0.001**
Niaura 2008 89/160 (55.6) 100/160 (62.5) 1.56, P = 0.21
Nides 2006 68/127 (53.5) 77/127 (60.6) 68/128 (53.1) 1.83, P = 0.40
Oncken 2006 40/129 (31.0) 146/253 (57.7) 24.38, P < 0.001**
Rennard 2012 132/166 (79.5) 432/493 (87.6) 6.62, P = 0.01*
Rigotti 2010 289/359 (80.5) 302/355 (85.1) 2.61, P = 0.11
Stein 2013 35/45 (77.8) 115/137 (83.9) 107/133 (80.5) 1.05, P = 0.59
Steinberg 2011 21/39 (53.8) 22/40 (55.0) 0.01, P = 0.92
Tashkin 2011 157/254 (61.8) 176/250 (70.4) 4.14, P = 0.04*
Tonstad 2006 463/607 (76.3) 494/603 (81.9) 5.83, P = 0.02*
Tsai 2007 117/124 (94.4) 120/126 (95.2) 0.10, P = 0.75
Tsukahara 2010 14/16 (87.5) 14/16 (87.5) 0, P = 1
Tønnesen 2013 54/69 (78.3) 61/70 (87.1) 1.92, P = 0.17
Walker 2014 473/655 (72.2)
[cytisine]
482/655 (73.6) 0.31, P = 0.58
Wang 2009 161/168 (95.8) 158/165 (95.8) 0.001, P = 0.97
Westergaard 2015 14/26 (53.8%) 19/26 (73.1%) 2.07, P = 0.15
Williams 2007 59/126 (46.8) 135/251 (53.8) 1.63, P = 0.20
Williams 2012 40/43 (93.0) 75/85 (88.2) 0.72, P = 0.40
Wong 2012 119/135 (88.1) 134/151 (88.7) 0.02, P = 0.88
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Analysis 13.1. Comparison 13 Sensitivity analysis, Outcome 1 ITT treatment vs per protocol control.
Review: Nicotine receptor partial agonists for smoking cessation
Comparison: 13 Sensitivity analysis
Outcome: 1 ITT treatment vs per protocol control
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Anthenelli 2013 52/254 28/179 4.0 % 1.31 [ 0.86, 1.99 ]
Bolliger 2011 155/394 26/198 4.2 % 3.00 [ 2.05, 4.37 ]
Carson 2014 61/190 42/160 5.6 % 1.22 [ 0.88, 1.70 ]
Chengappa 2014 6/31 2/20 0.3 % 1.94 [ 0.43, 8.66 ]
Cinciripini 2013 24/86 15/76 1.9 % 1.41 [ 0.80, 2.49 ]
De Dios 2012 3/10 0/7 0.1 % 5.09 [ 0.30, 85.39 ]
EAGLES 2016 444/2037 191/1552 26.4 % 1.77 [ 1.51, 2.07 ]
Ebbert 2015 182/760 45/516 6.5 % 2.75 [ 2.02, 3.73 ]
Eisenberg 2016 53/148 39/112 5.4 % 1.03 [ 0.74, 1.43 ]
Evins 2014 16/40 5/26 0.7 % 2.08 [ 0.87, 4.99 ]
Gonzales 2006 77/352 29/187 4.6 % 1.41 [ 0.96, 2.08 ]
Gonzales 2014 50/249 8/144 1.2 % 3.61 [ 1.76, 7.41 ]
Heydari 2012 (1) 29/89 6/91 0.7 % 4.94 [ 2.16, 11.32 ]
Jorenby 2006 79/344 35/204 5.4 % 1.34 [ 0.94, 1.92 ]
Nahvi 2014a 3/37 0/43 0.1 % 8.11 [ 0.43, 151.98 ]
Nakamura 2007 56/155 35/132 4.6 % 1.36 [ 0.96, 1.94 ]
NCT00828113 10/50 11/34 1.6 % 0.62 [ 0.30, 1.29 ]
NCT01347112 4/16 0/5 0.1 % 3.18 [ 0.20, 50.67 ]
Niaura 2008 35/160 12/155 1.5 % 2.83 [ 1.52, 5.24 ]
Nides 2006 18/127 6/68 1.0 % 1.61 [ 0.67, 3.86 ]
Oncken 2006 58/259 5/40 1.1 % 1.79 [ 0.77, 4.19 ]
Rennard 2012 171/493 21/132 4.0 % 2.18 [ 1.45, 3.29 ]
Rigotti 2010 68/355 26/289 3.5 % 2.13 [ 1.39, 3.25 ]
Stein 2013 2/137 0/35 0.1 % 1.30 [ 0.06, 26.57 ]
Tashkin 2011 46/248 14/157 2.1 % 2.08 [ 1.18, 3.66 ]
Tsai 2007 59/126 27/117 3.4 % 2.03 [ 1.39, 2.97 ]
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Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Wang 2009 63/165 42/161 5.2 % 1.46 [ 1.06, 2.02 ]
Wong 2012 55/151 34/119 4.6 % 1.27 [ 0.90, 1.82 ]
Total (95% CI) 7463 4959 100.0 % 1.79 [ 1.65, 1.94 ]
Total events: 1879 (Treatment), 704 (Control)
Heterogeneity: Chi2 = 68.07, df = 27 (P = 0.00002); I2 =60%
Test for overall effect: Z = 14.40 (P < 0.00001)
Test for subgroup differences: Not applicable
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(1) per protocol and ITT denominators identical (no losses to follow-up reported)
Analysis 13.2. Comparison 13 Sensitivity analysis, Outcome 2 Continuous abstinence at 9 - 12 weeks.
Review: Nicotine receptor partial agonists for smoking cessation
Comparison: 13 Sensitivity analysis
Outcome: 2 Continuous abstinence at 9 - 12 weeks
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Anthenelli 2013 92/256 42/269 4.0 % 2.30 [ 1.67, 3.18 ]
Bolliger 2011 209/390 37/199 4.8 % 2.88 [ 2.12, 3.91 ]
Carson 2014 95/190 71/194 6.9 % 1.37 [ 1.08, 1.73 ]
Chengappa 2014 15/31 3/29 0.3 % 4.68 [ 1.51, 14.50 ]
Cinciripini 2013 37/86 18/106 1.6 % 2.53 [ 1.56, 4.12 ]
De Dios 2012 (1) 3/10 0/11 0.0 % 7.64 [ 0.44, 131.75 ]
EAGLES 2016 682/2037 254/2035 25.1 % 2.68 [ 2.35, 3.06 ]
Eisenberg 2016 67/151 45/151 4.4 % 1.49 [ 1.10, 2.02 ]
Gonzales 2006 155/352 61/344 6.1 % 2.48 [ 1.92, 3.21 ]
Gonzales 2014 112/249 29/245 2.9 % 3.80 [ 2.63, 5.49 ]
Hajek 2015 26/100 23/100 2.3 % 1.13 [ 0.69, 1.84 ]
Jorenby 2006 151/344 60/341 6.0 % 2.49 [ 1.93, 3.23 ]
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Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Nakamura 2007 104/155 60/154 5.9 % 1.72 [ 1.37, 2.16 ]
NCT01347112 6/16 1/17 0.1 % 6.38 [ 0.86, 47.29 ]
Niaura 2008 63/160 18/160 1.8 % 3.50 [ 2.17, 5.63 ]
Nides 2006 36/127 13/127 1.3 % 2.77 [ 1.54, 4.97 ]
Oncken 2006 128/259 15/129 2.0 % 4.25 [ 2.60, 6.95 ]
Rennard 2012 262/493 32/166 4.7 % 2.76 [ 2.00, 3.80 ]
Rigotti 2010 167/353 26/354 2.6 % 6.44 [ 4.38, 9.48 ]
Steinberg 2011 12/40 13/39 1.3 % 0.90 [ 0.47, 1.72 ]
Tashkin 2011 105/248 22/253 2.2 % 4.87 [ 3.18, 7.45 ]
Tsai 2007 75/126 40/124 4.0 % 1.85 [ 1.38, 2.47 ]
Wang 2009 83/165 53/168 5.2 % 1.59 [ 1.22, 2.09 ]
Wong 2012 (2) 71/151 43/135 4.5 % 1.48 [ 1.09, 1.99 ]
Total (95% CI) 6489 5850 100.0 % 2.49 [ 2.33, 2.65 ]
Total events: 2756 (Treatment), 979 (Control)
Heterogeneity: Chi2 = 142.05, df = 23 (P<0.00001); I2 =84%
Test for overall effect: Z = 27.82 (P < 0.00001)
Test for subgroup differences: Not applicable
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(1) 7-day PPA result
(2) 7-day PPA at 12 wks
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Analysis 13.3. Comparison 13 Sensitivity analysis, Outcome 3 Continuous abstinence at 24 weeks.
Review: Nicotine receptor partial agonists for smoking cessation
Comparison: 13 Sensitivity analysis
Outcome: 3 Continuous abstinence at 24 weeks
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Anthenelli 2013 64/256 33/269 4.0 % 2.04 [ 1.39, 2.99 ]
Bolliger 2011 155/394 26/199 4.3 % 3.01 [ 2.06, 4.40 ]
Carson 2014 78/191 54/194 6.6 % 1.47 [ 1.10, 1.95 ]
Chengappa 2014 6/31 2/29 0.3 % 2.81 [ 0.61, 12.81 ]
Cinciripini 2013 24/86 15/106 1.7 % 1.97 [ 1.11, 3.52 ]
De Dios 2012 (1) 3/10 0/11 0.1 % 7.64 [ 0.44, 131.75 ]
EAGLES 2016 444/2037 191/2035 23.6 % 2.32 [ 1.98, 2.72 ]
Ebbert 2015 244/760 52/750 6.5 % 4.63 [ 3.49, 6.14 ]
Eisenberg 2016 54/151 39/151 4.8 % 1.38 [ 0.98, 1.95 ]
Gonzales 2006 104/352 36/344 4.5 % 2.82 [ 1.99, 4.00 ]
Gonzales 2014 72/249 19/245 2.4 % 3.73 [ 2.32, 5.99 ]
Heydari 2012 52/89 12/91 1.5 % 4.43 [ 2.54, 7.72 ]
Jorenby 2006 102/344 45/341 5.6 % 2.25 [ 1.64, 3.09 ]
Nakamura 2007 63/155 44/154 5.5 % 1.42 [ 1.04, 1.95 ]
NCT01347112 4/16 0/17 0.1 % 9.53 [ 0.55, 164.01 ]
Niaura 2008 44/160 14/160 1.7 % 3.14 [ 1.80, 5.50 ]
Nides 2006 26/127 9/127 1.1 % 2.89 [ 1.41, 5.92 ]
Oncken 2006 75/259 7/129 1.2 % 5.34 [ 2.53, 11.24 ]
Rennard 2012 171/493 21/166 3.9 % 2.74 [ 1.81, 4.16 ]
Rigotti 2010 100/353 34/354 4.2 % 2.95 [ 2.06, 4.23 ]
Stein 2013 2/137 0/45 0.1 % 1.67 [ 0.08, 34.08 ]
Steinberg 2011 8/40 11/39 1.4 % 0.71 [ 0.32, 1.57 ]
Tashkin 2011 64/248 18/253 2.2 % 3.63 [ 2.22, 5.94 ]
Tsai 2007 59/126 27/124 3.4 % 2.15 [ 1.47, 3.15 ]
Wang 2009 63/165 42/168 5.1 % 1.53 [ 1.10, 2.12 ]
Wong 2012 (2) 54/151 35/135 4.6 % 1.38 [ 0.97, 1.97 ]
0.01 0.1 1 10 100
Favours placebo Favours varenicline
(Continued . . . )
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(. . . Continued)
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Total (95% CI) 7380 6636 100.0 % 2.44 [ 2.26, 2.63 ]
Total events: 2135 (Treatment), 786 (Control)
Heterogeneity: Chi2 = 103.35, df = 25 (P<0.00001); I2 =76%
Test for overall effect: Z = 23.28 (P < 0.00001)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours placebo Favours varenicline
(1) 7-day PPA result
(2) 7-day PPA at 6m
A P P E N D I C E S
Appendix 1. Glossary of tobacco-related terms
Term Definition
Abstinence A period of being quit, i.e. stopping the use of cigarettes or other tobacco products.
May be defined in various ways; see also:
point prevalence abstinence; prolonged abstinence; continuous/sustained abstinence
Biochemical verification Also called ’biochemical validation’ or ’biochemical confirmation’:
A procedure for checking a tobacco user’s report that he or she has not smoked or used
tobacco. It can be measured by testing levels of nicotine or cotinine or other chemicals
in blood, urine, or saliva, or by measuring levels of carbon monoxide in exhaled breath
or in blood
Bupropion A pharmaceutical drug originally developed as an antidepressant, but now also licensed
for smoking cessation; trade names Zyban, Wellbutrin (when prescribed as an antide-
pressant)
Carbon monoxide (CO) A colourless, odourless highly poisonous gas found in tobacco smoke and in the lungs
of people who have recently smoked, or (in smaller amounts) in people who have been
exposed to tobacco smoke. May be used for biochemical verification of abstinence
Cessation Also called ’quitting’
The goal of treatment to help people achieve abstinence from smoking or other tobacco
use, also used to describe the process of changing the behaviour
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Continuous abstinence Also called ’sustained abstinence’
A measure of cessation often used in clinical trials involving avoidance of all tobacco
use since the quit day until the time the assessment is made. The definition occasionally
allows for lapses. This is the most rigorous measure of abstinence
’Cold Turkey’ Quitting abruptly, and/or quitting without behavioural or pharmaceutical support
Craving A very intense urge or desire [to smoke].
See: Shiffman et al ’Recommendations for the assessment of tobacco craving and with-
drawal in smoking cessation trials’
Nicotine & Tobacco Research 2004: 6(4): 599-614
Dopamine A neurotransmitter in the brain which regulates mood, attention, pleasure, reward,
motivation and movement
Efficacy Also called ’treatment effect’ or ’effect size’:
The difference in outcome between the experimental and control groups
Harm reduction Strategies to reduce harm caused by continued tobacco/nicotine use, such as reducing
the number of cigarettes smoked, or switching to different brands or products, e.g.
potentially reduced exposure products (PREPs), smokeless tobacco
Lapse/slip Terms sometimes used for a return to tobacco use after a period of abstinence. A
lapse or slip might be defined as a puff or two on a cigarette. This may proceed to
relapse, or abstinence may be regained. Some definitions of continuous, sustained or
prolonged abstinence require complete abstinence, but some allow for a limited number
or duration of slips. People who lapse are very likely to relapse, but some treatments
may have their effect by helping people recover from a lapse
nAChR [neural nicotinic acetylcholine receptors]: Areas in the brain which are thought to
respond to nicotine, forming the basis of nicotine addiction by stimulating the overflow
of dopamine
Nicotine An alkaloid derived from tobacco, responsible for the psychoactive and addictive effects
of smoking
Nicotine Replacement Therapy (NRT) A smoking cessation treatment in which nicotine from tobacco is replaced for a limited
period by pharmaceutical nicotine. This reduces the craving and withdrawal experi-
enced during the initial period of abstinence while users are learning to be tobacco-free.
The nicotine dose can be taken through the skin, using patches, by inhaling a spray, or
by mouth using gum or lozenges
Outcome Often used to describe the result being measured in trials that is of relevance to the
review. For example smoking cessation is the outcome used in reviews of ways to help
smokers quit. The exact outcome in terms of the definition of abstinence and the length
of time that has elapsed since the quit attempt was made may vary from trial to trial
Pharmacotherapy A treatment using pharmaceutical drugs, e.g. NRT, bupropion
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Point prevalence abstinence (PPA) A measure of cessation based on behaviour at a particular point in time, or during a
relatively brief specified period, e.g. 24 hours, 7 days. It may include a mixture of recent
and long-term quitters. cf. prolonged abstinence, continuous abstinence
Prolonged abstinence A measure of cessation which typically allows a ’grace period’ following the quit date
(usually of about two weeks), to allow for slips/lapses during the first few days when
the effect of treatment may still be emerging.
See:Hughes et al ’Measures of abstinence in clinical trials: issues and recommendations’;
Nicotine & Tobacco Research, 2003: 5 (1); 13-25
Relapse A return to regular smoking after a period of abstinence
Secondhand smoke Also called passive smoking or environmental tobacco smoke [ETS]
A mixture of smoke exhaled by smokers and smoke released from smouldering
cigarettes, cigars, pipes, bidis, etc. The smoke mixture contains gases and particulates,
including nicotine, carcinogens and toxins
Self efficacy The belief that one will be able to change one’s behaviour, e.g. to quit smoking
SPC [Summary of Product Characteristics] Advice from the manufacturers of a drug, agreed with the relevant licensing authority,
to enable health professionals to prescribe and use the treatment safely and effectively
Tapering A gradual decrease in dose at the end of treatment, as an alternative to abruptly stopping
treatment
Titration A technique of dosing at low levels at the beginning of treatment, and gradually in-
creasing to full dose over a few days, to allow the body to get used to the drug. It is
designed to limit side effects
Withdrawal A variety of behavioural, affective, cognitive and physiological symptoms, usually tran-
sient, which occur after use of an addictive drug is reduced or stopped.
See: Shiffman et al ’Recommendations for the assessment of tobacco craving and with-
drawal in smoking cessation trials’
Nicotine & Tobacco Research 2004: 6(4): 599-614
Appendix 2. Participant numbers in varenicline trials
Study Varenicline Placebo Bupropion NRT TOTAL
Anthenelli 2013 256 269 525
Aubin 2008 378 379 757
Baker 2016 424 662
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Bolliger 2011 394 199 593
Carson 2014 196 196 392
Chengappa 2014 31 29 60
Cinciripini 2013 86 106 102 294
De Dios 2012 10 11 11 32
EAGLES 2016 Psych 1032
Non-psych 1005
Psych 1026
Non-psych 1009
Psych 1033
Non-psych 1001
Psych 1025
Non-psych 1013
4116
4028
Ebbert 2015 760 750 1510
Eisenberg 2016 151 151 302
Evins 2014 40 47 87
Gonzales 2006 352 344 329 1025
Gonzales 2014 249 245 494
Hajek 2015 100 100 200
Heydari 2012 89 91 92 272
Jorenby 2006 344 341 342 1027
Nahvi 2014a 57 55 112
Nides 2006 128 (0.3 x 1)
128 (1.0 x 1)
127 (1.0 x 2)*
127 128 638
NCT00828113 50 (Extended)
51 (Standard)
101
NCT01347112 16 17 33
Oncken 2006 129 (0.5NT)
130 (0.5T)
129 (1.0NT)*
130 (1.0T)*
129 647
Williams 2012 85 43 128
Rennard 2012 493 166 659
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Stein 2013 137 45 133 315
Tønnesen 2013 70 69 139
Tonstad 2006 1927 Phase 1
[603] Phase 2* [607] Phase 2
1927
Nakamura 2007 153 (0.25x2)
156 (0.5x2)
156 (1.0x2)*
154 619
Tsai 2007 126 124 250
Williams 2007 251 126 377
Niaura 2008 160 160 320
Wang 2009 165 168 333
Rigotti 2010 355 359 714
Rose 2013 112 114 226
Steinberg 2011 40 39 79
Tsukahara 2010 16 16 32
Tashkin 2011 250 254 504
Westergaard 2015 26 25 52
Wong 2012 151 135 286
TOTALS 11,801
* used in primary
MA
7109 2935 3445 25,290
Appendix 3. Measures of craving, withdrawal and reinforcement
Study MNWS or WSWS QSU-B Total Craving score mCEQ (for smokers)
Carson 2014
(wk 1)
1.0 mg bid vs placebo
At week 1, Likert scale:
Craving: V: 3.36; placebo: 4.45
Anxiety: V: 3.19; placebo: 4.25
Confidence: V: 7.95; placebo:
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7.02
Motivation:V: 8.22; placebo: 7.
50
Gonzales 2006
(wks 1 - 7)
1.0 mg bid vs placebo
Urge to smoke: -0.54 (P< .001)
ES: -0.57*N
Negative affect: -0.19 (P < .
001) ES: -0.30
Restlessness: -0.14 (P< .01) ES:
-0.16
Increased appetite: +0.12 (P = .
04) ES: 0.15
Insomnia: +0.05 (P = .36) ES:
0.06
-0.45 (1.69 V, 2.13 P); P < 0.
001; ES: -0.33
Baseline to wk 1: diff in changes
between V&P:
Smoking satisfaction: -0.60 (P
< .001) ES: -0.47
Psych Reward: -0.50 (P < .001)
ES: -0.37
Enjoy resp tract: -0.34 (P < .
001) ES: -0.21
Craving reduction: -0.52 (P < .
001) ES: -0.33
Aversion: -0.18 (P = .053) ES: -
0.19
Jorenby 2006
(wks 1 - 7)
1.0 mg bid vs placebo
Diff in mean change in:
Urge to smoke: -0.48 (P< .001)
Negative affect: -0.13 (P = 0.
001)
Restlessness:-0.10(P = 0.05) In-
creased appetite: +0.07 (P = 0.
22)
Insomnia: +0.10 (P = 0.07)
-0.44 ; (P < .001)
[Factor 1 (pleasure) -0.56; (P <
.001)
Factor 2 (negative affect relief )
-0.27 (P < .001)]
Baseline to wk 1: diff in changes
between V&P:
Smoking satisfaction: -0.44 (P
< .001)
Psych Reward: -0.32 (P < .001)
Enjoy resp tract: -0.22 (P = 0.
01)
Craving reduction: -0.25 (P =
0.04)
Aversion: 0 (P = 0.96)
Nides 2006
(wks 1 - 7)
1.0 mg bid vs placebo
Diff in mean change in:
Urge to smoke: wk 1 -1.14; wk
2 -1.19; wk 3 -1.57; wk 4 -1.81;
wk 5 -1.88; wk 6 -2.04; wk 7 -
1.61(P < .001 for wks 1 - 6, P <
.01 wk 7)
Total score: wk 1 -7.00; wk 2 -
10.71; wk 3 -12.72; wk 4 -14.
08; wk 5 -13.24; wk 6 -14.94;
wk 7 -14.38 (wks 1, 3, 5 P < .
001, wks 2, 4, 6, 7 P < .01)
Baseline to wk 1: diff in changes
between V&P:
Smoking satisfaction: -1.62
Psych Reward: -0.35
Enjoy resp tract: -0.29
Craving reduction: -0.13
Aversion:-0.79
Oncken 2006
(MNWS: wks 1 - 12; mCEQ
wks 1 - 7)
1.0 mg bid vs placebo
Diff in mean change in Urge to
Smoke score (extrapolated from
graph):
Wk 7: -0.2, Wk 12 -0.5; (P < .
001 for both)
Baseline to wk 7: diff in changes
between V&P:
(extrapolated from graph)
Smoking satisfaction: -1.3 (P <
0.01)
Psych reward: -2.2 (P < 0.001)
Enjoy resp tract: -0.6 (P < 0.
001)
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Tonstad 2006
1.0 mg bid vs placebo
Diff in mean change in Urge to
Smoke score (extrapolated from
graph):
All participants: Wk 13: -0.35,
Wk 25 -0.25;
Abstainers only: Wk 13: -0.30,
Wk 25 +0.02
Tsai 2007
(wks 1 - 6)
1.0 mg bid vs placebo
Diff in mean change in Urge to
Smoke:
Wks 1 - 6: -0.40 (P < 0.001)
Mean total score, wks 1 - 6: -0.
39 (P < 0.001)
Mean diff wks 1 - 6: V vs P:
Smoking satisfaction: -0.39 (P
< 0.008)
Nakamura 2007
(wks 1 - 7)
1.0 mg bid vs placebo
(Nicotine-dependent group
only)
Diff in mean change in:
Urge to Smoke score: -0.51 (P
< 0.001)
Negative Affect score: -0.28 (P
< 0.001)
Restlessness score: -0.38 (P < 0.
001)
Appetite+ score: -0.09 (P = 0.
481)
Insomnia score: 0.56 (P = 0.
380)
Mean total score: -0.51 (P < 0.
001)
Factor 1 [pleasure] mean diff: -
0.60 (P < 0.001)
Factor 2 [negative affect] mean
diff: -0.38 (P < 0.001)
Mean diff wks 1 - 7: V vs P:
Smoking satisfaction: -0.74 (P
< 0.001)
Psych reward: -0.53 (P < 0.001)
Enjoy resp tract: -1.00 (P < 0.
001)
Craving reduction: -0.45 (P <
0.001)
Aversion:-0.38 (P < 0.0007)
Steinberg 2011
1.0 mg bid vs placebo
At 4 wks, Varenicline group had
score of -1.45, placebo +0.11
Aubin 2008
(wks 1 - 7)
1.0 mg bid vs NRT
Diff in mean change in:
Urge to Smoke score: -0.32 (P
< 0.001); E.S. -0.37
Negative Affect score: -0.16 (P
< 0.001); E.S. -0.21
Restlessness score: -0.20 (P < 0.
001); E.S. -0.21
Appetite + score: 0.09 (P = 0.
116); E.S. 0.12
Insomnia score: -0.07 (P = 0.
207); E.S. -0.07
Mean diff wks 1 - 7: V vs NRT:
Smoking satisfaction: -0.54 (P
< 0.001); E.S. -0.43
Psych reward: -0.32 (P = 0.001)
E.S. -0.26
Enjoy resp tract: -0.39 (P < 0.
001); E.S. -0.25
Craving reduction: -0.52 (P <
0.001); E.S. -0.32
Aversion: -0.07 (P = 0.436); E.
S. 0.08
Niaura 2008
1 - 4 x 0.5 mg ad lib
Diff in Urge to smoke, all pts:
Wk 1: -0.4; Wk 2: -0.4; Wk 3 -
0.6; Wk 4 -0.5; Wk 5 -0.6; Wk
Diff in changes between V&P:
Smoking satisfaction:
Enjoy resp tract:Wk1 -0.1;Wk
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6 -0.5; Wk 7 -0.4; Wk 12 -0.6
Diff in withdrawal, all pts: Wk
1: -0.4; Wk 2: -0.7; Wk 3 -0.7;
Wk 4 -1.1; Wk 5 -0.3; Wk 6 -
0.4; Wk 7 -0.2; Wk 12 -0.9
2 -0.3; Wk 3 -0.4; Wk 4 -0.5;
Wk 5 -0.5; Wk 6 -0.5; Wk 7 -
0.4
Tsukahara 2010
1.0 mg bid vs NRT
Diff in withdrawal score (all
symptoms), V vs NRT:Wk 2 2.
36; Wk 4 0.64; Wk 8 0.78; Wk
12 0.08
Cinciripini 2013 Significantly higher reward
score ( 3.8) in placebo relapsers
than in varenicline relapsers ( 2.
7; P = 0.01)
(extrapolated from graph)
Evins 2014 WSWS measured over 12 wks
open-label varenicline:
Total score: Baseline:59.9 - wk
12: 50.77
Urge to smoke: Baseline: 11.85
- wk12: 8.2
Irritability: Baseline: 5.62 - wk
12: 4.46
Depression: Baseline: 6.61 - wk
12: 5.8
Increased appetite: Baseline: 11.
79 - wk 12: 11.88
Difficulty concentrating: Base-
line: 5.86 - wk 12: 5.15
Insomnia: Baseline: 8.52 - wk
12: 8.25
Anxiety: Baseline: 8.84 - wk 12:
7.04
Tønnesen 2013 For V vs placebo at 12 wks:
Craving: -0.26 for V (P < 0.
0001)
Appetite: -0.14 for V (P = 0.
001)
Total symptoms score: -0.16 (P
= 0.002)
Hajek 2015 Smoking enjoyment ratings up
to TQD:
Baseline/pre-randomizarion:V:
2.5, placebo: 2.5
Day 15 (≤ 3 mg/day): V: 1.8,
placebo: 2.1
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Day 18 (≤ 4 mg/day): V: 1.7,
placebo: 2.1
TQD (day 21;≤ 5 mg/day): V:
1.6, placebo: 2.0
Appendix 4. Serious Adverse Events and deaths
Study ID Period Placebo Varenicline Bupropion NRT
VARENICLINE trials
Anthenelli 2013 During treatment or
within 30 days of last
dose
Intentional self in-
jury;
Depression with
suicidal ideation;
Agitation;
Depression
Psychotic disorder
and depression;
Suicidal ideation
Post-treatment to
week 52
Intentional self in-
jury
2 other SAEs
2 deaths: overdose
of clonazepam and
morphine sulfate;
Accidental fall
3 other SAEs
Aubin 2008
During treatment or
within 30 days
of last dose
Depression*;
Constipation
Bile duct ca, sepsis;
Gastrointestinal
bleed;
MI (2);
Chest pain (2);
Salivary gland tu-
mour;
Aggravation of old
knee trauma
Acute ethanol in-
toxication;
Suicidal ideation*;
No deaths reported
Abdominal cyst;
No deaths reported
Baker 2016 Post-treatment to
week 52
Hospitalised due to
allergic reaction to
varenicline
None reported
Bolliger 2011 During treatment or
within 30 days
of last dose
Thyroid neoplasm;
Appendicitis, peri-
tonitis, diverticuli-
Abortion (possibly
*);
Hypersensitivity;
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tis;
No deaths reported
Overdose;
Bronchitis and
asthma;
Nasal septum devia-
tion;
Suicidal ideation +
depressed mood;
Suicidal ideation*;
Tachycardia, brady-
chardia +dyspnoea;
Panic attack;
Injury;
Appendicitis
No deaths reported
Carson 2014 During treatment (active control: coun-
selling):
Depressive episodes
x 2;
Agitation;
4 N-STEMI (died);
2 lung ca (died)
1 stroke (died)
Atrial fibrillation;
Depressive episodes
x 3;
Aggression;
1 arrhythmia (died)
1 bradycardia (died)
2 respiratory/
COPD (died)
2 N-STEMI (died)
Post-treatment to 52
weeks
Depressive episode
Chengappa 2014 During treatment Alcohol
intoxication;
Exacerbation of
asthma;
Pregnancy;
Exacerbation of
anxiety;
Rash;
Agitation, hostility,
alcohol abuse, drug
abuse*;
Hypoxia, asthma
with COPD;
Tremulousness,
grogginess, left-arm
weakness;
Post-treatment to 52
weeks
Chest pain, left-
hand numbness
Pneuomonia
Cincripini 2013 Diabetes;
Chest pain*
Chest pain;
Psychiatric hospital-
isation
Bilateral
mammoplasty;
Facial paralysis;
Syncope*
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EAGLES 2016 During treatment or
within 30 days of last
dose
(De-
tail of SAES given
in ClinicalTrials.gov
posted results)
16 (non-psych)
25 (psych)
2 deaths (suicide,
non-psych; pul-
monary embolism,
psych)
16 (non-psych)
23 (psych)
2 deaths (heroin
OD non-psych; CV
event, psych)
19 (non-psych)
29 (psych)
21 (non-psych)
24 (psych)
> 30 days after last
dose
2 deaths (RTA, non-
psych; MI, non-
psych)
1 death (lung can-
cer, psych)
3 deaths (prostate
can-
cer, non-psych; oe-
sophageal adenoma,
psych; sepsis, psych)
Ebbert 2015 During treatment or
within 30 days of last
dose
10 x suicidal
ideation
6 x suicidal ideation
Post-treatment to
week 52
18 other SAEs 10 other SAEs
Eisenberg 2016 Within 30 days of
treatment
3 MIs
5 unstable anginas
Ischaemic
cardiomyopathy
Sick sinus syndrome
Ruptured pseudoa-
neurysm
Bowel obstruction
COPD
Rheumatoid arthri-
tis
Road traffic acci-
dent
Melena
Non-cardiac chest
pain
Allergic reaction
2 deaths (1 cardiac,
1 sudden death un-
defined)
3 MIs
Unstable angina
Depression
Pulmonary
embolism
TIA
Arrythmia and ICD
implant
2 gastric bleeds
2 suspected unstable
anginas (ruled out)
Peroneal embolus
with septic cellulitis
Bowel surgery
Dehydration
Syncope
Wound infection
Evins 2014 Randomization
phase
Sepsis (died);
MI;
Depressed mod and
discontinuation of
meds;
Suicidal ideation;
Worsened
Pancreatitis;
Hyperglycaemia;
Depressed mood;
Worsened psychotic
symptoms
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psychosis;
Worsened psychosis
and MJ intoxica-
tion;
Manic symptoms
Gonzales 2006
During treatment or
within 7 days
of last dose
Lung cancer;
Acute MI;
Acute exacerbation
of
schizophrenia;
Chest pain (2);
UTI
Atrial fibrillation
Abdominal pain;
Atrial fibrillation*;
Pneumonia;
Possible stroke
Cholecystitis, septic
shock;
Headache;
Grand mal seizure*
Post-treatment to
week 52
Mediastinal mass;
Fall, fractured el-
bow, collapsed lung,
death unexplained;
I death (as above)
Non-cardiac chest
pain;
Acute appendicitis;
No deaths reported
Appendicitis;
UTI;
No deaths reported
Gonzales 2014 During treatment or
within 30 days of last
dose
Acute coronary syn-
drome;
Ligament rupture;
Hyperventilation;
Drug sensitivity
Knee arthroplasty;
pyelonephritis;
Intervertebral disc
protrusion;
Ankle fracture;
Chest pain*;
Drug sensitivity to
amoxicillin;
Drug sensitivity to
hair dye
Post-treatment to
week 52
Acute on chronic al-
coholism (died)
Jorenby 2006
During treatment or
within 7 days
of last dose
Ruptured ovarian
cyst;
Ischaemic heart
disease;
Ruptured appendix;
Pneumonia;
Allergic reaction
Lung or brain can-
cer;
Acute coronary syn-
drome;
Chest pain;
Dehydration, peri-
orbital cellulitis;
Acute psychosis,
emotional lability;
Vertigo, raised BP,
chest pain*
Ectopic pregnancy;
Angiodoema*;
Gunshot wound;
Post-op bleeding;
Lower Leg pain;
Breast cancer (fe-
male)
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Post-treatment to
week 52
Appendicitis;
No deaths reported
Staphylococcal cel-
lulitis;
Acute psychosis;
No deaths reported
Occlusion coronary
artery;
Miscarriage;
1 death (RTA)
Nahvi 2014a During treatment Chest pain;
Alcohol detoxifica-
tion
Hypoglycaemia;
Alcohol and cocaine
rehab;
Knee replacement
Post-treatment to 24
weeks
Total hip
relacement
Alcohol rehab, acute
cholecystitis;
Asthma
exacerbation
Nakamura 2007
During treatment Subarachnoid
haemorrhage;
Contusion;
Foot fracture
0.25 mg bid:
Gastroenteritis;
Cholecystitis*;
Gastric cancer;
Cholecystitis, peri-
tonitis;
Herpes Zoster
0.5mg bid:
Haemorrhoids, in-
testinal prolapse;
Pituitary
haemorrhage;
1 mg bid:
Neurosensory deaf-
ness;
Angina pectoris*,
intervertebral disc
protrusion, MS;
1 death (RTA)
NCT00828113 During treatment Road traffic acci-
dent
More than 30 days
after treatment
Bladder surgery
Niaura 2008
Post-treatment
or within 30 days of
last dose
None reported
No deaths reported
MI;
Ventricular fibrilla-
tion;
Spontaneous abor-
tion;
No deaths reported
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Nides 2006
During treatment None reported
No deaths reported
Transient ischaemic
attack*,
transient loss of vi-
sion*;
No deaths reported
Syncope, possible
seizure*;
Grand mal convul-
sion*;
Bloody diarrhoea*;
No deaths reported
Oncken 2006
During treatment Syncope Syncope;
Duodenal ulcer;
Cholesteatoma;
Generalised tonic-
clonic seizure;
Unstable angina;
Parox-
ysmal supraventric-
ular tachycardia;
Cholelithiasis;
Aseptic meningitis;
Relapsing MS
None reported
Post-treatment Suicide attempt;
No deaths reported
Carcinoid colon
cancer;
Diabetes (> 30d
post-treat);
No deaths reported
None reported
No deaths reported
Rennard 2011 During treat-
ment and within 30
days of last dose
Suicidal ideation Intervertebral disc
protrusion x 2;
Carotid artery
stenosis;
Syncope;
PAOD;
Ureteric calculus
Rigotti 2010
During treatment Atrial fibrillation*;
Congestive cardiac
failure*;
Chest pain*;
Acute coronary
syndrome*;
+ 17 others
1 death (unrelated)
Chest pain*;
MI*;
Gingival bleeding*;
CVA*;
+ 19 others
Post-treatment to
week 52
4 deaths (unrelated) 2 deaths (unrelated)
Stein 2013 During and post-
treatment
Rashes x 2 Heart attack
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Steinberg 2011 During and post-
treatment to week 24
5 events (no detail)
No deaths
6 events (no detail)
No deaths
Tashkin 2010
During treatment or
within 28 days of last
dose
Bronchitis;
CVA;
Cholelithiasis;
Lung cancer;
Pneumonia;
Musculoskeletal
pain;
Acute MI;
Appendicitis;
COPD;
Chest pain;
Anxiety
Acute MI;
Vocal cord polyp;
Hyperkeratosis;
Back pain;
Angina pectoris;
CVA;
Cellulitis;
Post-treatment COPD;
Pneumonia;
Palpitations;
Chest pain;
1
death (amyotrophic
lateral sclerosis)
L Ventricular dys-
function;
Aortic valve steno-
sis;
COPD;
Chest pain;
Laryngeal cancer;
2 deaths (1 cardiac,
I RTA)
Tønnesen 2013 Post-treatment Rectal cancer with
ileostomy, peritoni-
tis;
Gall stone;
Malignant
melanoma;
Exacerbation of
COPD
Stroke;
Severe constipation;
Bradycardia;
Cardiac arrest;
Probable dengue
fever
Tonstad 2006
Open-label phase
(during treatment)
R Breast indetermi-
nate path;
Suicidal ideation;
Menorrhagia;
Glandular
adenocarcinoma;
Diminshed vision;
Accidental injury;
Headache;
Abdominal pain*;
Acute psychosis*;
Acute pancreatitis;
Neopharyngeal car-
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cinoma;
Raised AST, ALT,
LDH, CPK;
Grand mal convul-
sion;
Atrial fibrillation;
Ureteral stones;
Persistent epistaxis;
Worsening kidney
stones;
Loss of teeth, dislo-
cated shoulder
Open-label phase
(post-treatment)
MI;
Miscarriage
Double-blind phase
(during treatment)
Increased dysmen-
orrhoea;
Appendicitis;
Spinal cord com-
pression;
Abdominal pain
Injury to tibial
artery;
Uterine & bladder
prolapse,
suspected MI;
Alcohol poisoning,
costal fracture;
Transient vision
loss*;
MI
Double-blind phase
(post- treatment)
Acute cholecystitis;
No deaths reported
Colon cancer;
Tumour;
Ovarian tumour;
Cerebral in-
farct, deep cerebral
vein thrombosis;
Supraventricular
tachycardia;
3 deaths (unrelated)
Tsai 2007 During treatment or
within 28 days of last
dose
3 RTAs;
No deaths reported
Unstable angina*;
Acute pyelonephri-
tis;
Peritonitis, acute
appendicitis;
No deaths reported
Tsukahara 2010 None reported None reported
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Wang 2009
During treatment or
within 7 days of last
dose
Intestinal ulcer;
1 not described;
No deaths reported
None reported
No deaths reported
Williams 2007
Up to week 52 Vertebral compres-
sion fracture;
DVT, pulmonary
embolism;
Worsening coro-
nary artery disease;
No deaths reported
Coronary artery dis-
ease;
Herniated disc;
Bilateral subcapsu-
lar cataracts*
Chest pain, hypo-
glycaemia;
Sinus
bradycardia, hy-
potension, ventricu-
lar bigeminy, coro-
nary angioplasty;
Stroke;
Cardiac catheteriza-
tion;
Tachycardia;
Suspected GI bleed;
Saphenous vein oc-
clusion, ischaemia;
MI, DVT;
Ileus;
Chest wall pain;
Non-cardiac chest
pain, chronic bron-
chitis, pneumonia,
chest pain;
Spinal stenosis;
No deaths reported
Williams 2012 During treat-
ment and within 30
days of last dose
Hyperglycaemia;
Breast cancer;
Aggression;
Suicidal ideation;
No deaths
Chest pain;
Convulsion;
“Psychiatric symp-
tom”;
Suicidal ideation;
Suicidal attempt;
Asthma;
1 death
CYTISINE trials
Scharfenberg 1971 CYTISINE Not reported Not reported
Vinnikov 2008 CYTISINE None reported None reported
204Nicotine receptor partial agonists for smoking cessation (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
Walker 2014 56 events in 45 peo-
ple
(see Table S5 in
NEJM supplemen-
tary data)
45 events in 39 peo-
ple
(see Table S5 in
NEJM supplemen-
tary data)
West 2011 CYTISINE COPD (died);
Stroke (died);
Lung cancer (died)
Stroke;
Tracheal cancer;
Cardiac arrest (died)
;
Lung cancer (died);
DIANICLINE trial
Tonstad 2011 DIANICLINE Subileus;
Thrombophlebitis;
SVT;
No deaths reported
Appendicitis;
Severe asthma;
MI;
No deaths reported
* Possibly, probably or definitely attributable to study medication
Abbreviations: ALT: Alanine transaminase; AST: Aspartate transaminase; BP: blood pressure; COPD: Chronic Obstructive Pul-
monary Disease; CPK:Creatine phosphokinase; CVA: cerebrovascular accident; DVT: deep vein thrombosis; LDH: Lactate dehydro-
genase; MI: myocardial infarction; MS: Multiple Sclerosis; N/STEMI: non-ST-elevation myocardial infarction; PAOD: peripheral
arterial occlusive disease; RTA: road traffic accident; SVT: supraventricular tachycardia; UTI: urinary tract infection
WH A T ’ S N E W
Last assessed as up-to-date: 12 May 2015.
Date Event Description
31 January 2016 New citation required and conclusions have changed Additional comparisons. Analyses expanded and restruc-
ture. SAE information updated
31 January 2016 New search has been performed 39 trials of varenicline now included
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H I S T O R Y
Protocol first published: Issue 3, 2006
Review first published: Issue 1, 2007
Date Event Description
16 May 2013 Amended Minor change made to labelling on forest plot.
14 March 2012 New citation required and conclusions have changed Safety profile modified, as new possible cardiovascular
and psychiatric adverse events information incorpo-
rated. Efficacy findings unchanged but confirmed
14 March 2012 New search has been performed Seven new included studies (5 varenicline, 1 cytisine,
1 dianicline) and 14 new excluded studies added, plus
safety data
13 January 2011 Amended Vinnikov trial of cytisine added to Studies awaiting
Classification, for inclusion in next update
8 November 2010 New search has been performed Six new RCTs added; sources of funding added for all
trials. Ongoing trials section expanded
8 November 2010 New citation required and conclusions have changed Surveillance data and secondary analyses do not sup-
port fears about safety. Efficacy conclusions strength-
ened but unchanged
17 July 2008 Amended Date of last search amended (2007 corrected to 2008)
; Source of support added
12 May 2008 New citation required and conclusions have changed Three new included trials, switch in the MA metric
fromOR to RR, updated background section and new
safety information
15 March 2008 New search has been performed New search conducted.
30 August 2007 Amended Converted to new review format.
15 November 2006 New citation required and conclusions have changed Substantive amendment.
206Nicotine receptor partial agonists for smoking cessation (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
C O N T R I B U T I O N S O F A U T H O R S
KC: Performed clinical trials register searching, extracted data, conducted the analyses and wrote the review.
NL-H: Extracted data, contributed to the writing and updating process.
TF: Conducted the neuropsychiatric adverse event meta-analyses and advised on statistical interpretation.
KT: Contributed data and advice on neuropsychiatric adverse event data.
TL: Gave editorial and conceptual support.
All authors contributed to text and findings, and approved the final version.
D E C L A R A T I O N S O F I N T E R E S T
Kate Cahill : None known
Nicola Lindson-Hawley: NLH is a co-applicant on the Preloading Trial, which is funded by the NIHR HTA. The study treatment is
nicotine patches which are provided free of charge by GlaxoSmithKline.
Tom Fanshawe: None known
Kyla Thomas: None known
Tim Lancaster: None known
Robert West, who is an editor for the Tobacco Addiction Group, has ruled himself out of participating in the editorial process for this
review, as he is a member of the varenicline advisory board for Pfizer Inc.
S O U R C E S O F S U P P O R T
Internal sources
• Department of Primary Care Health Sciences, University of Oxford, UK.
• National School for Health Research School for Primary Care Research, UK.
External sources
• NHS Research and Development Fund, UK.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
For this 2016 update, we have restructured the analyses to accommodate increasing variation in the settings, populations, comparisons
and regimens of trials that have been conducted.
For this 2016 update we include ’Summary of findings’ tables for the main comparisons.
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I N D E X T E R M S
Medical Subject Headings (MeSH)
Alkaloids [∗therapeutic use]; Azepines [∗therapeutic use]; Azocines [therapeutic use]; Benzazepines [∗therapeutic use]; Bupropion
[therapeutic use]; Counseling [methods]; Heterocyclic Compounds with 4 or More Rings [∗therapeutic use]; Nicotine [adverse ef-
fects; antagonists & inhibitors]; Nicotinic Agonists [adverse effects; ∗therapeutic use]; Quinolizines [therapeutic use]; Quinoxalines
[∗therapeutic use]; Randomized Controlled Trials as Topic; Smoking [drug therapy]; Smoking Cessation [∗methods]; Substance With-
drawal Syndrome [prevention & control]; Varenicline
MeSH check words
Humans
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